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General Introduction and Outline
1.1 Iminosugars: Structures, Activities and Applications
Alkaloids are nitrogen containing molecules which are widely distributed in na-
ture. They are produced by a wide variety of organisms such as plants, fungi, bac-
teria, marine animals, amphibians, some birds and a few mammals. 1–7 Over the
years the group of polyhydroxylated alkaloids has gained considerable interest as
potential therapeutic agents and as tools to gain a better insight in biological pro-
cesses. This specific group of alkaloids can be considered as carbohydrate mim-
ics in which the endocyclic oxygen is replaced by a nitrogen. This alteration in
combination with their structural resemblance to normal sugars makes that they
are often evaluated as inhibitors of glycosidases 8 and glycosyltransferases. 9 These
enzymes in turn, both play an essential role in various biological processes includ-
ing carbohydrate catabolism, maturation, transport and secretion of glycoproteins
and cell recognition processes. 10,11 Polyhydroxylated alkaloids, often referred to
as iminosugars, can be divided in several different classes depending on their ring
structures (Figure 1.1). 12
Nojirimycin 1 (NJ) is the first iminosugar isolated from natural sources (S. roseo.
R-468 and S. laven. SF-425), and shows remarkable biological activity. In subse-
quent studies NJ was shown to be a good inhibitor of various α- and β -glycosi-
dases. 13,14 Nojirimycin contains a hemiaminal function, which renders it rather
unstable under neutral and acidic conditions at room temperature, therefore it
is usually stored as bisulphite adduct or reduced to the more stable 1-deoxyno-
jirimycin 2 (DNJ). 13,15 Over the years a wide range of iminosugar and related al-
kaloids were isolated from the leaves, root bark and fruits of the mulberry tree
1
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(Morus spp.). Prominent examples are DNJ 2, 16 fagomine 4, N-methyl-DNJ 3 and















































































Figure 1.1: Five classes of iminosugars with some examples.
Nojirimycin (NJ, 1); 1-Deoxynojirimycin (DNJ, 2); N-methyl-DNJ (3); Fagomine (4);
α-Homonojirimycin (α-HNJ, 5); 7-O-β -D-glucopyranosyl-α-HNJ (6); 1,4-Dideoxy-1,4-
imino-D-arabinitol (DAB, 7); Broussonetin B (8); Lentiginosine (9); Swainsonine (10);
Hyacinthacine C1 (11); Australine (12); Calystegine B4 (13); Calystegine B1-3-O-β -D-
glucopyranosyide (14).
In the field of iminosugar research many N-alkylated derivatives of DNJ have
been synthesized. Miglitol (15, Figure 1.2) is the firstα-glucosidase inhibitor based
on DNJ 2 and is used as drug for diabetes mellitus type 2. 20,21 By inhibition of α-
glucosidase, 15 slows down the rate by which large carbohydrates (poly- and oligo-
mers) are processed in the gut. 21,22 Fleet et al. 23 synthesized N-butyl-1-deoxyno-
jirimycin 16 (NB-DNJ or Miglustat) which was found to be an inhibitor of glu-
cosylceramide synthase (GCS). 24,25 GCS plays an essential role in the biosynthe-
sis of glucosylceramide, the precursor for more complex glycosphingolipids (Fig-
ure 1.2C). Inhibitory properties of NB-DNJ 16 are used to the full extent in the
so called substrate reduction therapy (SRT) 26–28 to prevent the accumulation of
glucosylceramide (GC) in cells (Figure 1.2B). NB-DNJ is the first orally adminis-
tered drug to be active in the treatment of type 1 Gaucher disease. 29 Gaucher dis-
ease is a rare lysosomal storage disorder in which GC is inefficiently hydrolyzed
by mutant glucocerebrosidase (GBA1, Figure 1.2B). This causes accumulation of
GC-laden macrophages which results in enlargement of organs (spleen and liver)
and inflammation. The first therapy developed for the treatment of Gaucher dis-
2
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ease was enzyme replacement therapy (ERT), in which recombinant GBA1 (called
cerezyme) is intravenously administrated to patients. 30 This functional GBA1 en-
zyme ends up in the Gaucher cells where it temporarily restores the efflux of GC
(Figure 1.2B). The disadvantages of ERT are the intravenous administration and
the high costs of enzyme production. Substrate reduction therapy offers a useful
alternative. Inhibition of GCS alters the influx of GC thereby restoring the influx/-
























































Figure 1.2: A: Structures of Miglitol (15), NB-DNJ (16), AMP-DNJ (17); B: Schematic
overview of Gaucher disease and currently used therapies; C : Anabolism and catabolism
of glucosylceramide.
Compound 17, also known as AMP-DNJ, bears a N-5-(adamantan-1-yl-meth-
oxy)-pentyl (AMP) chain on the ring nitrogen and has been found to be a better in-
hibitor of GCS as compared to NB-DNJ. 34 AMP-DNJ has great potential as a novel
drug for Gaucher disease and other sphingolipidoses 25,35 and shows promising
results regarding treatment of daibetes mellitus type 2, 36 hepatosteatosis and in-
flammatory bowel disease. 37 Oral adminstration of AMP-DNJ has also been found
to result in prevention of atherosclerosis 38 and neurodegenenration in Sandhoff
disease. 39
Next to decorating iminosugars by alkylation of its endocyclic nitrogen to gain
better or more selective inhibitors, iminosugars can also be glycosylated to yield a
new class of potential inhibitors. Glycosylated iminosugars may be closer mimics
of the natural substrates for the enzyme of interest, thereby making them poten-
tially more selective inhibitors than the non-glycosylated iminosugars. Glycosyla-
ted iminosugars can also give a better insight in the mechanism of action of gly-
cosidases, as well as potentially being prodrugs or slow-releasing agents that have
to undergo an enzymatic transformation to liberate the active inhibitor. There
are several examples of naturally occurring glycosylated iminosugars, which are
mostly found in iminosugar producing plants. Isolation is often done by extrac-
3
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tion of leaves, bark or roots with aqueous MeOH or EtOH, after which the extracts
are purified by a variety of ion-exchange chromatography steps. After isolation
and purification careful characterization, is done by Nuclear Magnetic Resonance
Spectroscopy (NMR), High Resolution Mass Spectroscopy (HRMS) and enzymatic
assays to confirm their structure. Glycosylated iminosugars have been found to
contain, amongst others, α- and β -glucosides, α-galactosides, apiosides, β -xylo-
sides, β -mannosides and β -fructofuranosyl glycosides. Some examples are given
in Figure 1.1 and Figure 1.3. 8,12,17,40–44 Biological evaluation show that most glyco-
sylated iminosugars are selective inhibitors, probably due tot their close resem-

















































































Figure 1.3: Structures of natural occuring glycosylated iminosugars.
2-O-α-D-glucopyranosyl-1-deoxynorjirimycin (18), 1-epi-australine-2-O-β -D-glucopyr-
anoside (19), 4-O-α-D-galactopyranosyl-calystegine B2 (20), 4-O-β -D-mannopyranosyl-
6-deoxy-homoDMDP (21), homoDMDP-7-O-apioside (22), homoDMDP-7-O-β -D-
xylopyranoside (23); DMDP-7-O-β -D-fructofuranoside (24).
1.2 Synthesis of O-Glycosylated Iminosugars
1.2.1 Chemical Synthesis
The natural abundance of O-glycosylated iminosugars is extremely low and most
of them are potent inhibitors of several glycosidases. 19 To fully explore the poten-
tial of O-glycosylated iminosugars larger quantities are needed. This goal can be
achieved through chemical or enzymatic synthesis.
One of the first syntheses of glycosylated iminosugars was reported by Ganem
et al. 45 who prepared a cellulase inhibitor. Using the trichloroacetimidate met-
hod 46 a glucose mono-, di- or trimer was coupled in aβ -1,4 fashion to an iminosu-
gar (Scheme 1.1). Biological evaluation of the resulting glycosylated iminosugars
32, 33 and 34 showed potent inhibitory effects towards different endo-cellulases
from T. fusca. 47,48
4
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R1 = H; R2 = Ac; R3 = Bn
R1 = β-D-glucopyranosyl; R2 = Ac; R3 = Bn




R1 = H; R2 = H; R3 = H
R1 = β-D-glucopyranosyl; R2 = H; R3 = H















Reagents and conditions: a) BF3 ·OEt2, DCM, 0
◦C; b) (1) KOH, MeOH; (2) Pd/C, H2, EtOH:HCl, 32
(50% overall), 33 (38% overall), 34 (40% overall).
To get a better insight in the processing of cross-linked polysaccharides Blat-
ter and co-workers 49 O-glycosylated DNJ at various positions (Scheme 1.2) and
evaluated several β -1,3, β -1,4 and β -1,6 linked DNJ oligo-glucosides as potential
fungicides. For the synthesis several O-acetylated glycosyl trichloroacetimidate
donors were condensed with a protected DNJ derivative. A regioselective coupling
was achieved in the synthesis of β -1,6 linked disaccharide 46. 50 All compounds
were tested, after deprotection, on a wide variety of fungi and small organisms of
which only the brine shrimp (Artemia salina) showed to be vulnerable to most of
compounds.
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Reagents and conditions: a) TMSOTf, DCM, 0◦C.
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Reagents and conditions: a) NIS, TMSOTf, DCM:Et2O, -50
◦C, 72%; b) DMTST, DCM:Et2O, 59%; c)
Me2S2−Tf2O, DCM:Et2O, 80%.
Glycosylated iminosugars have also been used as inhibitors for heparanase, as
a potential antimetastatic cancer drug. 54,55 The groups of Nakajima 51 and
Fügedi 52,53 independently synthesized a set of iminosugar containing heparanase
inhibitors using 2-azido-2-deoxy-D-glucopyranosyl donors 49 and 50. Condens-
ing 49 with iminosugar 51, having the D-glucuronic acid configuration, 51 afforded,
after deprotection, inhibitor 53. Compound 53 showed to inhibit heparanase,
thereby preventing the degradation of heparan sulfate. 56,57 Fügedi and co-workers 52,53
based their design on the use of iminosugars having the L-ido configuration. Con-
densation of the iminosugars having a L-idose (54) or L-iduronic acid configura-
tion (57) with donor 50 using DMTST or Me2S2−Tf2O led to the pseudo disaccha-
rides 55 and 58 which were transformed into 56 and 60. No biological data were
reported on these compounds.
To assess if iminosugars can act as a ceramide mimic in β -glucocerebrosidase
(GBA1), Martin and Compain 58 developed two GBA1 inhibitors, featuring a N-
alkylated DNJ derivative bearing two alkyl chains (65) and a glucose, to fully mimic
the natural substrate of GBA1. Condensation of 2,3,4,6-tetra-O-acetyl-α-D-gluco-
pyranosyl bromide donor 61 with DNJ acceptor 62 or 65 under Koenings-Knorr
conditions afforded, after deprotection, inhibitors 64 and 67. Biological results
show improved affinity of 67 towards GBA1 (IC50 56µM) as compared to the mono-
alkylated 64 (no inhibition) and even as compared to DNJ 2 (IC270 56 µM).
6
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R1 = Ac, R2 = Bn, R3 = TBDMS
R1, R2,R3  = H
b
R1 = Ac, R2 = Bn









Reagents and conditions: a) AgOTf, DCM, -78◦C, 34%; b) (1) nBu4NF, THF, 0
◦C, 70%, (2) NaOMe,
MeOH, 86%, (3) Pd/C, H2, iPrOH/AcOH, (4) Dowex
TM OH– , 44%; c) AgOTf, DCM, -78◦C, 55%; d) (1)
NaOMe, MeOH, quant., (2) Pd/C, H2, iPrOH/AcOH, (3) Dowex
TM OH– , quant.






























R1, R2 = benzylidene






























































Reagents and conditions: a) DMTST, benzene, 7◦C, 92%; b) NaCNBH4, Et2O, 81%; c) NIS, TfOH,
DCM, 70%; d) NIS, TfOH, DCM, 61%; ∗ protected forms of Lewisx and sialyl-Lewisx iminosugar
analogs.
Next to iminosugars that are glycosylated on one position, various iminosu-
gars have been synthesized that bear more than one carbohydrate. Furui and
7
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co-workers 59 reported the synthesis of Lewisx 73 and sialyl-Lewisx 75 iminosu-
gar analogs in which DNJ is di-glycosylated (Scheme 1.5). Coupling of L-fucose 68
to the 3-position of DNJ 69 followed by selective opening of the benzylidene in 70
gave acceptor 71. Mono glycosylated DNJ acceptor 71 was then condensed with
D-galactose 72 under influence of NIS and TfOH to yield trimer 73, which after
deprotection gave the DNJ derivative of Lewisx . By coupling of thio donor 74 to
DNJ acceptor 71, using similar conditions as in the assembly of 73, tetramer 75
was gained, which after deprotection afforded DNJ analog of sialyl-Lewisx .




















































Reagents and conditions: a) NaOMe, MeOH; b) Pd(OH)2, H2, NH4OH, H2O, 24% over two steps.
A different approach for the synthesis of glycosylated iminosugars is to first
synthesize a carbohydrate oligomer, after which the reducing end sugar is con-
verted in the corresponding iminosugar. By using naturally occurring oligomers
as starting material, this approach circumvents the use of a glycosylation steps
and lengthy protective group manipulations. The group of Stütz reported three
syntheses in which they use cellobiose, maltose or maltulose as starting materials
for the synthesis of glucosylated iminosugars (Scheme 1.6 and Scheme 1.7). 60,61
Conversion of cellobiose and maltose into their 1,6-anhydrosugar derivatives (β -
77 and α-77), followed by deprotection of the acetyl functions and concomitant
ring opening afforded di-carbonyl β -78 and α-78 (Scheme 1.6). Double reduc-
tive amination using Pearlmans catalyst in aqueous ammonia under a hydrogen
atmosphere yielded target compounds β -79 and α-79.
The maltulose derivative was synthesized via open-chain bromide 80 62
(Scheme 1.7), which cyclized under Zemplén conditions to give 81, which was sub-
sequently reacted with NaN3 in DMF to gain compound 82. Conventional catalytic
hydrogenation of azidodeoxysugar 82 in dry methanol using Pd(OH)2 furnished ti-
tle compound 83.
The group of Piancatelli 63 used glycosyl glycals (D-lactal 84a, D-cellobial 84b,
D-maltal 84c and D-melibial 84d) for the synthesis of glycosylated L-fagomine
8
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Reagents and conditions: a) NaOMe, MeOH; b) NaN3, DMF; c) Pd(OH)2, H2, MeOH, 26% over 3
steps.
derivatives. Opening of the glycals 84a-d by mercury(II) acetate/sodium boro-
hydride, 64,65 gave compounds 85a-d which were converted in N-heterocyclized
compounds 88a-d in a three-step sequence: 1) formation of the 2,6-di-O-mesyla-
tes (86a-d), 2) regioselective azidation by treatment with NaN3 in DMF (87a-d), 3)
cyclization by reduction of the azide (88a-d).
Scheme 1.8: Synthesis of glycosylated imonosugars via D-lactal (84a), D-cellobial (84b),


























a: R1 = Bn, R2 = 2´, 3´,4´,6´-tetra-O-benzyl-β-D-galactopyranosyl
b: R1 = Bn, R2 = 2´, 3´,4´,6´-tetra-O-benzyl-β-D-glucopyranosyl
c: R1 = Bn, R2 = 2´, 3´,4´,6´-tetra-O-benzyl-α-D-glucopyranosyl









































Reagents and conditions: a) Hg(OAc)2, NaBH4, DCM, 85 a-d ∼90%; b) Et3N, MsCl, DCM, 86 a-d
∼80%; c) NaN3, DMF, 70
◦C, 87 a-d ∼80%; d) P(Ph)3, THF:H2O; e) Et3N, 40
◦C 88 a-d ∼70%.
1.2.2 Enzymatic Synthesis
Enzymatic synthesis using glycosidases and glycosyltransferases can be a useful
alternative for the synthesis of iminosugar containing oligomers. There are a few
examples in which DNJ or N-protected DNJ is used as acceptor for enzymatic syn-
theses of glycosylated DNJs.
9
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For the syntheses of the DNJ derivatives of sialyl Lewisx and Lewisa on a large
scale, Kojima et al. 66 used a β -galactosidase to gain a large amount of the galac-
tosylated DNJ building block. Mixing of lactose (50 kg), DNJ (5 kg) and β -galac-
tosidase (250 mL) in H2O (250 L) for 18 hours gave 8.2 kg of product as a mixture
of galactosyl-DNJ derivatives. Purification by strong base anion-exchange resin
yielded 300 grams of different galactosyl-DNJ in the following ratio; unreacted DNJ
2 (32%), 1,2-linked 89 (6%), 1,3-linked 90 (20%), 1,4-linked 91 (25%), 1,6-linked 92











R1 = Cbz, R2 = α-Glc, R3 = H, R4 = H
R1 = Cbz, R2 = H, R3 = α-Glc, R4 = H
R1 = Cbz, R2 = Η, R3 = H, R4 = α-Glc
R1 = Cbz, R2 = β-Glc, R3 = H, R4 = H
























































Figure 1.4: Structures of glycosylated iminosugars described in section 1.2.2.
By using α- and β -glucosidases and N-benzyloxycarbonyl protected DNJ, A-
sano and co-workers 67 made a series of α- and β -linked glucosylated DNJ deriva-
tives. Maltose and DNJ were stirred with rice α-glucosidase yielding 1,4-linked
(95), 1,3-linked (94) and 1,2-linked (93) α-glucosyl DNJ in yields of 40, 13 and 2%
respectively (Figure 1.4). No 1,6-linked coupling was observed, probably due to
steric hindrance of the N-benzyloxycarbonyl group. Cellobiose was used as glu-
cose donor in the coupling effected by yeast β -glucosidase to give 1,2-linked (96)
and 1,4-linked (97) β -glucosylated DNJ in yields of 69% and 3% respectively (Fig-
ure 1.4). After deprotection the glucosylated iminosugars were tested for their bi-
ological activity showing that α-1,2-linked (93) and α-1,3-linked (94) were more
effective than DNJ against trehalases and rice α-glucosidase, respectively.
To elucidate the mechanism of hydrolysis of cellulase, the group of Arai 68 syn-
thesized cellulase inhibitors by condensing cellobiose and DNJ using a transglyco-
sylase. They synthesized three inhibitors, two bearing a disaccharide either on the
4- (98) or the 6-position (100) of DNJ and one bearing a glucose on the 4-position
of DNJ (99) (Figure 1.4). Trimer 98 (1,4) was found to be the best inhibitor for sev-
eral fungal and bacterial cellulases as it best resembles natural cellulose. 69
10
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1.3 Synthesis of Different Linked Glycosylated Iminosugars
Aside from the O-glycosylated iminosugars there a few examples in which the en-
docyclic nitrogen of an iminosugar is linked to a carbohydrate by a non-hydro-
lyzable bond. The group of Merrer reported 70,71 the synthesis of DNJ which bears
D-glucitol on the ring nitrogen. First bis-epoxide 101 was reacted with NaN3 and
SiO2, directly followed by an O-cyclization according to a 5-exo-tet process giving
D-glucitol 102. 72 71



















R1 = N3, R2 = H
R1 = N3, R2 = TBDMS




R1 = Bn, R2 = TBDMSe
R1,R2 = H








Reagents and conditions: a) NaN3, SiO2, ACN, ∆, 95%; b) TBDMSCl, imidazole, DMF, 95%; c) Pd
black, H2, EtOAc, 95%; d) 101, EtOH, 105 40%, 107 30%; e) (1) nBuN4F, THF, 85%, (2) Pd black, H2,
AcOH, 70%; f) (1) nBuN4F, THF, 80%, (2) Pd black, H2, AcOH, 75%.
Next the primary hydroxyl was protected to give 103, followed by reduction
of the azide moiety in 103 to give 104. The free amine in 104 was subsequently
reacted with another equivalent of bis-epoxide 101 to form azepane derivative 105
and DNJ derivative 107, via an N-cyclyzation in 40% and 30% yield respectively.




































Reagents and conditions: a) DMF,∆, 80%; b) Pd/C, H2, EtOH, 79%.
11
CHAPTER 1
Another example of a N-glycosylated iminosugar is N-[6-deoxy-1-O-methyl-
6-α-glucopyranosyl]-1-deoxynojirimycin or MDL 7395 (112 Scheme 1.10), which
was synthesized by the pharmaceutical company Merrel Dow (Strasbourg, Fra-
nce). 73 Coupling using an excess glucosyl halide (109) with DNJ acceptor (110)
yielded, after deprotection, 112. 73 Biological evaluation of MDL 7395 (112) showed
that it reduced the glycemic response, by inhibition of the intestinalα-glucohydro-
lase, which makes it a potential diabetes mellitus drug. 74
Vasella and co-workers 75 used anomeric oximes such as 113 to link monosac-
charides to iminosugars, gaining selective α- and β -glycosidase inhibitors
(Scheme 1.11). They used two approaches to synthesize methyl β -cellobioside
analog 119: one by alkylation of the hydroximolactam 113 76 with trifate 114 77 and
the other by condensation of the thiogluconolactam 115 78 with hydroxylamine
116. By use of the latter method compounds 120 and 121 were also synthesized.
It was found that compounds 119, 120 and 121 were strong inhibitors of several
different β -glucosidases. 75






































































Reagents and conditions: a) NaOH, Et4NBr, Tol, 59%; b) Hg(OAc)2, Et(iPr)2N, THF, 72%; c) (1) Li,































Figure 1.5: Examples of C-glycosylated iminosugars.122 79, 123 80, 124. 81
A different class of iminosugars with promising biological and therapeutic
properties are iminosugars bearing C-glycosides. An overview of the synthesis and
12
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strategical design of this class of stable iminosugar analogs is given in several re-
views. 82–84
1.4 Thesis Outline
The ongoing research in the field of lysosomal storage diseases (LSD), and more
specific Gaucher disease is the basis for the research described in this thesis. The
progress of Gaucher disease and the effect of therapeutic intervention is correlated
to the level of chitotriosidase (CHIT1), the first identified human chitinase. Mea-
surement of plasma CHIT1 activity in man is done by an assays using fluorogenic
substrate 125. The ability of CHIT1 to transglycosylate can complicate the enzyme
assay, however compound 125 is not prone to be transglycosylated. And gives a
proportional fluorophore to active enzyme ratio read-out. Because of this umbel-
liferone 4’-deoxychitobioside 125 has become a popular fluorogenic substrate for
the measurement of human chitinases, an improved scalable route towards 125 is
described in Chapter 2.
Chapter 3 describes the synthesis and biological evaluation of three novel flu-









































R1 = OH, R2 = AMP
*






























Figure 1.6: Overview of the compounds described in this thesis.
∗ AMP = N-5-(adamantan-1-yl-methoxy)-pentyl
The locally elevated activity of CHIT1 allows site-specific drug delivery via the
prodrug approach. Chapter 4 describes the design and synthesis of novel pro-
drugs in which a chitobiose core, the substrate for CHIT1, is coupled to known in-
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hibitors of GCS which are able to restore the influx/efflux balance of GC in Gaucher
cells.
It is known that some iminosugars and N-alkylated derivatives thereof have
a taste bitter. In Chapter 5 attempts are made to palliated this bitter taste by ap-
pending a galactosyl moiety to DNJ. Aside from potentially masking the bitter taste
this modification will also help to direct the inhibitors to the colon were they will
be processed by lactase.
Cholesteryl-α-glucoside and cholesteryl-β -glucoside, the synthesis of which
is described in Chapter 6, will be used as as internal standards to get a better in-
sight in the biosynthesis of the potentially neurotoxic steryl-glucosides, which are
potentially linked to a high level of glycosylceramide. Chapter 7 summarizes the
research described in chapters 2 to 6 and future prospects based on these results
are presented.
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A Preparative Synthesis of Human
Chitinase Fluorogenic Substrate⋆
2.1 Introduction
Chitinases are a class of enzymes capable of cleaving natural chitin (a linear poly-
mer of β -1,4-linked-N-acetylglucosamine) and a wide variety of artificial chitin-
like substrates. The existence of endogenous chitinases in mammals was discov-
ered at the end of the last century. 1 First to be identified was chitotriosidase
(CHIT1), a human chitinase that is strongly expressed and secreted by lipid-laden
tissue macrophages that are found in patients suffering from Gaucher disease. 2–4
Gaucher disease is a rare lysosomal storage disease in which the influx/efflux bal-
ance of glucosylceramide (GC) is disturbed by the inefficient hydrolysis, of GC,
by mutant β -glucocerebrosidase (GBA1). A second mammalian chitinase, named
AMCase (Acidic Mammalian Chitinase), was identified some years later 5,6 and its
role in the etiology of asthma has been proposed. 7
The CHIT1 activity in plasma of Gaucher patients correlates to the progres-
sion of the disease and the effect of therapeutic intervention. 1,8 Chitotriosidase
activity thus is an ideal marker by which Gaucher patients are identified and by
which their susceptibility towards therapeutic agents is monitored. 9 Currently two
⋆ Duivenvoorden, B. A.; Dinkelaar, J.; Wennekes, T.; Overkleeft, H. S.; Boot, R. G.; Aerts, J. M. F. G.;
Codée, J. D. C.; van der Marel, G. A. Eur. J. Org. Chem., 2010, 13, 2565-2570.
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therapies for the treatment of Gaucher patients are applied, namely enzyme re-
placement therapy (ERT) and substrate reduction therapy (SRT) (see also chap-
ter 1). 10–15 Both therapies are expensive and monitoring their effect (i.e. optimal
dosage and treatment regimen) through measuring of serum CHIT1 activity has a
considerable clinical value.
In the years immediately following the discovery of CHIT1 activity as mar-
ker for Gaucher, umbelliferyl chitobioside 126 (Figure 2.1) was used as a fluoro-
genic substrate in biological assays to give a fluorescent read-out. 1 However, it was
found that human CHIT1 possesses intrinsic transglycosylase activity, 16 in that
higher oligomers are formed through hydrolysis of 126 followed by coupling to the
4-position of the non-reducing end carbohydrate of another substrate. This side
reaction complicates interpretation of the kinetics of the enzyme-mediated gen-
eration of the fluorescent 4-methylumbelliferyl anion (4-MU). To circumvent the
possibility of CHIT1 mediated transglycosylation a modified fluorogenic substrate
125 (Figure 2.1) was synthesized, in which the 4’-OH is removed. 16 This modifica-
tion gave a superior CHIT1 and AMCase substrate as compared to 126. 8 Given the
growing interest to monitor CHIT1 activity and given the present interest of AM-
Case in relation to asthma, umbelliferone 4’-deoxychitobioside 125 has become a
























Figure 2.1: Umbelliferyl chitobioside fluorogenic substrates 126 and 125.
In the original paper 16 the synthesis of 125 started from chitobiose, a disac-
charide, forming the target compound 125 in nine consecutive synthetic steps.
Although sufficiently effective for the preparation of several milligrams, the route
falls short when aiming for larger quantities. The nine-step sequence is quite in-
efficient (3% overall yield) and furthermore the starting disaccharide (chitobiose)
is rather expensive. This chapter describes a more efficient and reliable route to-
wards the superior substrate 125.
2.2 Results and Discussion
4-Methylumbelliferyl deoxychitobioside 125 was synthesized as outlined in Fig-
ure 2.2. The linkage between the chitobiose and the 4-methylumbelliferyl fluo-
rophore could best be achieved via a SN 2-displacement of the anomericα-chloride
in 127 by the umbelliferyl phenolate anion. This procedure was selected as aro-
matic hydroxyl functions are substantially less nucleophilic than the correspond-
ing aliphatic hydroxyls. In addition, Lewis acid mediated glycosylation of phe-
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nols can give rise to an unwanted Fries rearrangement. 17 For the construction of
the chitobiose-core a thiophenyl glycoside building block was used because the
anomeric thiophenyl group can be introduced early in the synthesis, is stable to
the reaction conditions employed and can be selectively activated with a variety of
soft electrophiles to provide glycosylating species. Furthermore thiophenyl glyco-
sides are shelf stable and often crystalline, which for the large-scale preparation of
building blocks is a valuable asset. To maximize the efficiency in the construction
of 4’-deoxychitobiosyl umbelliferone 125 a route was designed, in which a single
thioglycoside (130) serves as an advanced precursor for both the non-reducing
and reducing end glucosamine building blocks. To protect the glucosamine nitro-
gen function the phthaloyl group was selected because it is cheap, robust under
both basic and acidic conditions, and can be readily introduced on glucosamine
on a large scale using well-established chemistry. 18,19 The phthalimide group re-
liably provides anchimeric assistance in the coupling of the two glucosamines to
give the 1,2-trans glycosidic bond and does not give rise to oxazoline side prod-













































Figure 2.2: Outline for the large-scale synthesis of umbelliferyl chitobioside fluorogenic
substrate 125.
Scheme 2.1 depicts the synthesis of 4’-deoxychitobiosyl umbelliferone which
started with the synthesis of thioglycoside 130. Thioglucosamine 131 was ob-
tained from D-glucosamine in 40% yield over 8 steps on a 147 g scale. 18,19 Only
a single chromatographic purification was required in this sequence of reactions.
Reductive opening of the benzylidene acetal in the next step was affected by treat-
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ment of 131 with TFA and TES to selectively provide key thioglycoside 130 in 85%
yield. 20 The formation of the regioisomeric C-4 benzyl ether was not observed. To
provide the non-reducing end glucosamine building block, alcohol 130 was sub-
jected to a Barton-McCombie deoxygenation by treatment with NaH and CS2 fol-
lowed by MeI to provide the methyl dithiocarbonate. Radical fragmentation using
Bu3SnH and AIBN as initiator in refluxing toluene then led to the deoxygenated
glucosamine 128 in 87% yield. 21 For the construction of the reducing end glu-
cosamine building block 129, partly protected thioglycoside 130 was condensed
with benzyl alcohol employing N-iodosuccinimide (NIS) and a catalytic amount of
TMSOTf as activator cocktail. 22 The use of a large excess of BnOH (5 equivalents),
and the high nucleophilicity of this alcohol as compared to the glucosamine 4-OH,
completely prevented self-condensation of 130. Glucosamine 129 was obtained in
75% yield. In the ensuing NIS/TMSOTf mediated glycosylation deoxy glucosamine
128 and benzyl glucosamine 129 were reacted in a 1 : 1 ratio to provide chitiobio-
side derivative 132 in excellent yield.
To introduce the umbelliferyl chromophore, disaccharide 132 was transformed
into the disaccharide α-chloride 127. To this end, both N-phthaloyl groups in 132
were removed by transamidation with ethylenediamine in refluxing n-butanol.
Subsequent acetylation of the resulting free amines then provided the crystalline
dimer 133. Removal of all benzyl groups from this disaccharide proved to be more
troublesome than expected due to the low solubility of the partly debenzylated-
N-acetyl chitobioside intermediates. The best results were obtained when disac-
charide 133 was treated under 5 bar hydrogen pressure using 5 mol% of Pearlman’s
catalyst in a 1:1 THF/MeOH solvent mixture in the presence of 5 equivalents of
AcOH. The fully deprotected 4’-deoxychitobioside was then acetylated to give the
penta-O-acetate 134 in 65% yield as an amorphous white solid over two steps.
The final stages of the synthesis followed procedures slightly adapted from lit-
erature. 23 Chlorination of the reducing end glucosamine derivative required care-
ful tuning of the reaction conditions. The anomeric acetate 134 was treated with
dry HCl in a mixture of AcOH and Ac2O at 5
◦C for 42 hours to afford 4’-deoxychito-
biosyl chloride 127 in 74%. Shorter reaction times led to incomplete chlorination
and higher reaction temperatures gave interglycosidic bond cleavage. Previously
it has been reported that the anomeric chlorination of chitobiosyl acetate can be
readily accomplished at room temperature. 23 Presumably the absence of the hy-
droxyl function on the 4-position of the non-reducing end GlcNAc in 134 makes
the glycosidic linkage more labile towards acidic cleavage. Introduction of the 4-
methylumbelliferyl chromophore was accomplished by SN 2 displacement of the
anomeric α-chloride by the tetrabutyl ammonium salt of 4-methylumbelliferone,
generated under phase transfer conditions (PTC). 24 The protected umbelliferyl
derivative was obtained in 62% as a white amorphous solid. Saponification of the
acetyl esters with NaOMe and HPLC purification completed the synthesis of target
compound 125, yielding 227 mg (28%) of product.
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Reagents and conditions: a) DCM, BnOH, NIS, 0◦C , TMSOTf (75%) b) (1) THF, imidazole, CS2, 0
◦C,
NaH, 1h, then rT, MeI (93%); (2) Tol, Bn3SnH, AIBN, ∆ (87%); c) DCM, NIS, 0
◦C , TMSOTf (86%);
d) (1) nBuOH, ethylenediamine, ∆ ; (2) MeOH, Ac2O, Et3N (82% over two steps); e) (1) THF, MeOH,
AcOH, Pd(OH)2, H2; (2) pyr., Ac2O (65% over two steps); f) AcOH, Ac2O, HCl, 0
◦C to 5◦C (74%); g)
CHCl3, H2O, NaHCO3, umbelliferone sodium salt, TBAHS (62%); h) MeOH, NaOMe (28% after HPLC
purification).
2.3 Conclusion
This chapter describes an efficient, reliable and scalable route for the synthesis
of 4’-deoxychitobiosyl umbelliferone 125. The synthesis is based on the use of a
partially protected thiophenyl glucosamine derivative 130 as main building block,
which is readily transformed into both the reducing and non-reducing end build-
ing blocks for the construction of 4’-deoxychitobiose core. This carbohydrate core
is then converted to an α-chloride donor, which was then coupled, under PTC,
with 4-methylumbelliferone salt to yield, after deprotection, target compound 125.
2.4 Experimental section
All reagent were of commercial grade and used as received (Acros, Fluka, Merck, Schleicher
& Schuell) unless stated otherwise. Diethyl ether (Et2O), light petroleum ether (PE 40-60),
en toluene (Tol) were purchased from Riedel-de Haën. Dichloromethane (DCM), N,N-
dimethylformamide (DMF), methanol (MeOH), pyridine (pyr) and tetrahydrofuran (THF)
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were obtained from Biosolve. THF was distilled over LiAlH4 before use. Dichloromethane
was boiled under reflux over P2O5 for 2 h and distilled prior to use. Molecular sieves 3Å
were flame dried under vacuum before use. All reactions sensitive to moisture or oxygen
were performed under an inert atmosphere of argon unless stated otherwise. Solvents
used for flash chromatography were of pro analysis quality. Flash chromatography was
performed on Screening Devices silica gel 60 (0.004 - 0.063 mm). TLC-analysis was con-
ducted on DC-alufolien (Merck, Kieselgel60, F245) with detection by UV-absorption (254
nm) for UV-active compounds and by spraying with 20% H2SO4 in ethanol or with a so-
lution of (NH4)6Mo7O24 ·4 H2O 25 g/L, (NH4)4Ce(SO4)4 ·2 H2O 10 g/L, 10% H2SO4 in H2O
followed by charring at∼150 ◦C. 1H and 13C NMR spectra were recorded on a Bruker DMX-
400 (400/100 MHz), a Bruker AV 400 (400/100 MHz), a Bruker AV 500 (500/125 MHz) or a
Bruker DMX-600 (600/150 MHz) spectrometer. Chemical shifts (δ) are given in ppm rel-
ative to the chloroform residual solvent peak or tetramethylsilane as internal standard.
Coupling constants are given in Hz. All given 13C spectra are proton decoupled. High
resolution mass spectra were recorded on a LTQ-Orbitrap (Thermo Finnigan) Mass spec-
trometer. LC/MS analysis was performed on a Jasco HPLC-system (detection simultane-
ous at 214 nm and 245 nm) equipped with an analytical Alltima C18 column (Alltech, 4.6
mmD x 50 mmL, 3µ particle size) in combination with buffers A: H2O, B: MeCN and C:
0.5% aq. TFA and coupled to a Perkin Almer Sciex API 165 mass spectrometer. Optical
rotations were measured on a Propol automatic polarimeter. IR spectra were recorded on








Glycoside 130 (25.4 g, 43.8 mmol) was coevaperated thrice with diox-
ane, then taken up in THF (220 mL). Imidazole (0.298 g, 4.38 mmol) and
CS2 (7.9 mL, 131 mmol) were added after which the mixture was cooled
to 0◦C. NaH (2.63 g, 60% dispersion in oil, 65.7 mmol) was added and
the reaction was kept at 0◦C for one hour then allowed to warm to rT. At rT MeI (4.82 mL,
77.5 mmol) was added. After 30 min. the mixture was quenched by addition of AcOH and
subsequently diluted with EtOAc (250 mL). The mixture was then washed with NaHCO3.
The layers were separated and the organic layer was dried over MgSO4 and concentrated
in vacuo. Purification by column chromatography (Tol-EA 100-0→95-5) yielded the thio-
carbamate intermediate as the yellow oil (27.4 g, 93%). The thiocarbonate (27.4 g, 40.8
mmol) was coevaporated three times with toluene, dissolved in toluene (800 mL) and de-
gassed with sonication under argon flow for 5 min. Bu3SnH (16.4 mL, 61.2 mmol) and
AIBN (0.33 g, 2.04 mmol) were added and the mixture was warmed to 120◦C . After 1h
when TLC analysis showed complete consumption of starting material the reaction was
cooled to rT and concentrated in vacuo. The residue was taken up in ACN and washed
twice with hexane, the ACN layer was concentrated in vacuo. Column chromatography
(EtOAc/PE 30%) afforded 128 as an oil (20.1 g, 87%). TLC: EtOAc/PE 45%; 1H NMR (400
MHz, CDCl3)δ 7.66-7.83 (m, 4H, Harom), 7.28-7.39 (m, 7H, Harom), 7.16-7.17 (m, 3H, Harom),
6.98-7.02 (m, 5H, Harom), 5.57 (d, 1H, J = 10.4 Hz, H-1), 4.55-4.57 (m, 3H, CH2 Bn), 4.19-
4.34 (m, 3H, H-2, H-3, CH2 Bn), 3.84 (m, 1H, H-5), 3.65-3.69 (m, 1H, H-6), 3.54-3.58 (m,
1H, C-6), 2.31 (dd, 1H, J = 3.6 Hz, 12.8 Hz), 1.59 (q, 1H, J = 11.6 Hz, H-4); 13C NMR (100
MHz, CDCl3) δ 167.7, 168.0 (C=O Phth), 137.7, 138.0 (Cq), 133.7 (CHarom), 132.5 (Cq), 132.0
(CHarom), 131.5 (Cq), 127.3-128.6 (CHarom), 123.3, 123.1, 83.6 (C-1), 75.4 (C-5), 73.5 (C-3),
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73.3 (CH2 Bn), 72.3 (C-6), 70.6 (CH2 Bn), 55.5 (C-2)34.0 (C-4); HRMS: C34H31NO5S+Na
+
requires 588.18151, found 588.18115.







Glycoside 130 (23.6 g, 40.5 mmol) was coevaperated thrice with tol-
uene. DCM (810 mL), BnOH (21 mL, 202 mmol) and NIS (10.9 g,
48.6 mmol) were added. The mixture was stirred over activated 3Å
molsieves for 30 min. After cooling to 0◦C a catalytic amount of TM-
SOTf (0.81 mL, 4.5 mmol) was added. After 1h the mixture was allowed to warm to rT
when TLC analyses showed complete consumption of starting material the reaction was
quenched by addition of Et3N (5.6 mL, 40.5 mmol). The reaction mixture was diluted
with DCM and washed with Na2S2O3. The water layer was extracted twice with DCM, the
collected organic layers were dried over MgSO4 and concentrated in vacuo. Purification
by column chromatography (EtOAc/PE 20%) yielded 129 as a colorless oil (17.6 g, 75%).
TLC: EtOAc/PE 50%; 1H NMR (400 MHz, CDCl3) δ , 7.76 (bs, 1H, Harom), 7.62-7.63 (m, 2H,
Harom), 7.53 (bs, 1H, Harom), 7.28-7.36 (m, 5H, Harom), 7.02-7.07 (m, 7H, Harom), 6.89-6.93
(m, 3H, Harom), 5.15-5.17 (m, 1H, H-1), 4.78 (d, 1H, J = 12.4 Hz, CH2 Bn), 4.74 (d, 1H, J
= 12.4 Hz, CH2 Bn), 4.64 (d, 1H, J = 12.0 Hz, CH2 Bn), 4.58 (d, 1H, J = 12.0 Hz, CH2 Bn),
4.51 (d, 1H, J = 12.4 Hz, CH2 Bn), 4.47 (d, 1H, J = 12.4 Hz, CH2 Bn), 4.23-4.25 (m, 2H, H-2,
H-3), 3.82 (m, 3H, H-4, H-6, H-6), 3.62-3.65 (m, 1H, H-5),3.20 (d, 1H, J = 2.4 Hz, OH); 13C
NMR (100 MHz, CDCl3) δ 168.0 (C=O Phth), 168.1 (C=O Phth), 136.9, 137.6, 138.0 (Cq),
131.4 (Cq), 133.5 (CHarom), 127.2-128.3 (CHarom), 97.2 (C-1), 123 (CHarom), 78.4 (C-3), 74.1
(CH2 Bn), 73.8 (C-4), 73.7 (C-5), 73.5 (CH2 Bn), 70.6 (CH2 Bn), 70.3 (C-6), 55.3 (C-2); HRMS:
C35H33NO7+Na
+ requires 602.21492, found 602.21471.
Phenyl 3,6-di-O-benzyl-2-deoxy-2-phthalimido-4-O-(3,6-di-O-benzyl-2,4-di-deoxy-2-











A mixture of donor 128 (20.1 g, 35.4 mmol) and acceptor 129
(20.6 g, 35.4 mmol) were coevaperated three times with tolu-
ene. DCM (350 mL) and NIS (9.56 g, 42.5 mmol) were added
and the mixture was stirred over activated 3Å molsieves for 30
min. The mixture was cooled to 0◦C before a catalytic amount of TMSOTf (0.32 mL, 1.77
mmol) was added. After TLC analysis showed complete consumption of starting material
(3 h) at 0◦C , the reaction was quenched with Et3N (5.0 mL, 35 mmol). The reaction mixture
was diluted with DCM and washed with Na2S2O3. The water layer was extracted twice with
DCM, the collected organic layers were dried over MgSO4 and concentrated in vacuo. Pu-
rification by column chromatography (EtOAc/PE 30%) yielded 132 as a colorless oil (31.7
g, 86%). TLC : EtOAc/PE 30%; 1H NMR (400 MHz, CDCl3)δ = 7.88-7.89 (m, 2H, Harom),
7.67-7.71 (m, 4H, Harom), 7.58-7.59 (m, 2H, Harom), 7.20-7.37 (m, 10 H, Harom), 6.96-7.02 (m,
12H, Harom), 6.82 (bs, 3H, Harom), 5.29 (d, 1H, J = 8.0 Hz, H-1’), 4.98 (d, 1H, J = 6.4 Hz, H-1),
4.84 (d, 1H, J = 12.4 Hz, CH2 Bn), 4.68 (d, 1H, J = 12.4 Hz, CH2 Bn), 4.44-4.58 (m, 6H, CH2
Bn), 4.11-4.39 (m, 7H), 3.34-3.58 (m, 6H), 2.28 (dd, 1H, J = 4.8 Hz, 12.8 Hz, H-4’), 1.52 (q,
1H, J = 12.0 Hz, H-4’); 13C NMR (100 MHz, CDCl3) δ 167.5-168.1 (C=O Phth), 136.9-138.6
(Cq), 133.4-133.7 (CHarom), 131.5 (Cq), 126.7-128.3 (CHarom), 122.9-123.5 (CHarom), 97.2 (C-
1’), 97.0 (C-1), 76.5, 75.5, 74.5, 74.0, 73.2, 72.5, 72.4, 71.9, 71.1, 70.6, 70.3, 68.1, 57.7 (C-2’),
55.6 (C-2), 34.2 (C-4’); HRMS: C63H58N2O12+Na















Disaccharide 132 (31.7 g, 30.6 mmol) was dissolved in n-
BuOH (275 mL) and ethylene diamine (30 mL). This mix-
ture was refluxed overnight and subsequently concentrated in
vacuo. The reaction was then coevaporated thrice with tolu-
ene and taken up in MeOH (300 mL). At 0◦C Ac2O (30 mL, 300
mmol) and Et3N (8.5 mL, 61.2 mmol) were added and the mixture was allowed to warm to
rT. The resulting mixture was concentrated in vacuo and taken up in CHCl3 and washed
with H2O. The collected organic layer was stirred over activated carbon and filtered over
hyflo-gel concentrated in vacuo. Crystallization PE-EA yielded 133 (26.6 g, 82%) as slightly
yellow crystals. TLC: EtOAc/PE 25%; 1H NMR (400 MHz, CDCl3 /CD3OD, 1/1): δ 7.21-7.35
(m, 25H, Harom), 4.86 (d, 1H, J = 12.4 Hz, CH2 Bn), 4.75 (d, 1H, J = 11.6 Hz, CH2 Bn), 4.54-
4.69 (m, 5H, CH2 Bn, H1’), 4.38-4.49 (m, 5H, CH2 Bn, H1), 4.12 (t, 1H, J = 6.8 Hz), 3.97 (t,
1H, J = 6.4 Hz), 3.63-3.79 (m, 5H), 3.44-3.51 (m, 3H), 3.37-3.38 (m, 1H), 2.20 (dd, 1H, J =
4.8 Hz, 12.8 Hz, H-4’), 1.94 (s, 6H, CH3 NHAc), 1.45 (q, 1H, J = 12.0 Hz, H-4’);
13C NMR
(100 MHz, CDCl3/CD3OD, 1/1): δ 171.4 (Cq NHAc), 170.8, 137.1-138.3 (Cq), 126.8-128.0
(CHarom), 100.2 (C-1, C-1’), 99.6, 78.4, 75.4, 74.4, 74.1, 73.1, 73.0, 72.3, 71.8, 70.5, 70.2, 69.8,
68.9, 55.5 (C-2’), 51.8 (C-2), 33.1 (C-4’), 22.5 (CH3 NHAc),22.2; HRMS: C51H58N2O10+Na
+













Disaccharide 133 (22.9 g, 26.6 mmol) was disolved in THF
(250 mL) then MeOH (250 mL), AcOH (9 mL, 106 mmol)
and Pd(OH)2 (1 g, 20% on activated carbon, 1.33 mmol)
were added. The mixture was shaken overnight on a Parr
apparatus R© under 5 bar hydrogen pressure. The resulting mixture was filtered over
Whatmann R© filter paper, concentrated in vacuo and taken up in pyridine (180 mL). At
0◦C, Ac2O (55 mL) was added, after 1h the mixture was allowed to warm to rT and stirred
o.n.. The reaction was quenched by addition of MeOH at 0◦C then concentrated in vacuo.
The residue was taken up in CHCl3 and washed with 1M HCl:NaHCO3 and brine. The
organic layer was dried over MgSO4 and concentrated in vacuo. Purification by column
chromatography (MeOH/DCM 3%) yielded 134 as a white amorphous solid (10.6 g, 65%).
TLC: MeOH/DCM 5% ; 1H NMR of α acetate (400 MHz, CD3OD): δ 5.99 (d, 1H, J = 3.6
Hz, H-1), 5.24 (t, 1H, J = 10.0 Hz), 5.04 (dt, 1H, J = 5.2 Hz, 10.8 Hz), 4.56 (d, 1H, J = 8.0
Hz, H-1’), 4.44 (d, 1H, J = 12.0 Hz), 4.30 (dd, 1H, J = 3.6 Hz, 10.8 Hz), 4.23 (dd, 1H, J =
5.6 Hz, 11.6 Hz), 4.04-4.12 (m, 2H), 3.88 (t, 1H, J = 9.6 Hz), 3.98 (m, 1H), 3.79 (m, 1H), 3.61
(t, 1H, J = 9.2 Hz), 1.86-2.14 (22H, CH3 Ac, H-4’), 1.51 (q, 1H, J = 11.6 Hz, H-4’);
13C NMR
of α-acetate (100 MHz, CD3OD): δ 171.9-172.4 (C=O Ac), 102.6 (C-1’), 91.5 (C-1), 76.9,
72.4, 72.0, 71.6, 70.7, 66.7 (C-6, C-6’), 63.5, 56.4 (C-2, C-2’), 52.2, 33.8 (C-4’),20.8-23.0 (CH3
Ac);HRMS: C26H38N2O15+Na















Disaccharide 134 (1.61 g, 2.59 mmol) was dis-
solved in AcOH (13 mL) and Ac2O (3.2 mL).
At 0◦C dry HClg was bubbled through (liber-
ated under Kipp conditions) for 3h. The re-
action mixture was then placed at 5◦C for 42
h at which TLC analysis (DCM-acetone 60-40)
showed complete consumption of starting material. The reaction diluted with CHCl3 (50
mL, 0◦C) and washed twice with H2O (25 mL, 0
◦C) and twice with NaHCO3 (25 mL, 0
◦C).
The organic layer was dried over MgSO4 and concentrated in vacuo yielding an amor-
phous solid 127 (1.14 g) and purity was evaluated by 1H NMR (400 MHz, CDCl3): δ 1.55
(q, 1H, J = 11.6 Hz, H-4’), 1.86-2.14 (22H, CH3 Ac, H-4’), 3.73-3.83 (m, 4H), 4.03 (dd, 1H, J
= 4.0 Hz, 11.6 Hz), 4.20-4.25 (m, 2H), 4.36-4.54 (m, 3H), 4.48 (d, 1H, J = 8.0 Hz, H-1’), 5.02
(dt, 1H, J = 5.2 Hz, 11.2 Hz), 5.30 (t, 1H, J = 10.0 Hz), 5.94 (d, 2H, J = 8.0 Hz, NHAc), 5.96
(d, 2H, J = 8.0 Hz, NHAc), 6.12 (d, 1H, J = 3.6 Hz, H-1). The resulting solid was dissolved
in CHCl3 (76 mL) and added to a solution of H2O (76 mL), NaHCO3 (1.29 g, 15 mmol), 4-
methylumbelliferyl sodium salt 25 (1.9 g, 9.59 mmol) and TBAHS (1.3 g, 3.84 mmol). The
biphasic mixture was stirred overnight under exclusion of light. The phases were sepa-
rated and the organic layer was washed twice with NaHCO3 (0.2 M) and twice with H2O.
The organic layer was dried over MgSO4 and concentrated in vacuo. Purification by col-
umn chromatography (MeOH/CHCl3 3%) yielded 135 (0.88 g, 62%) as a white amorphous
solid. TLC: MeOH/DCM 5%; 1H NMR (400 MHz, CDCl3 / CD3OD, 1/1): δ 7.44 (d, 1H, J =
10.4 Hz), 6.86 (m, 2H), 6.72 (d, 1H, J = 9.2 Hz, NHAc), 6.54 (d, 1H, J = 9.2 Hz, NHAc), 6.09
(s, 1H), 5.46-5.49 (m, 2H), 5.23-5.26 (m, 3H), 5.14 (t, 1H, J = 8.1 Hz), 4.04-4.29 (m, 7H), 2.38
(s, 3H, CH3 4-methylumbelliferyl), 1.86-2.14 (19H, CH3 Ac, H-4’), 1.71 (q, 1H, J = 12.4 Hz,
H-4’); 13C NMR of (100 MHz, CDCl3/CD3OD, 1/1): δ 171.9-172.4 (Cq Ac), 160.1 (Cq), 159.9,
154.4, 153.3, 125.5 (CHarom), 114.7 (Cq), 133.3 (CHarom), 112.4, 103.5 (CHarom), 102.9 (C-1’),
98.7 (C-1), 72.1, 72.0, 70.0, 69.9, 68.5, 65.2 (C-6, C-6’), 62.0, 54.4 (C-2, C-2’), 54.2, 32.5 (C-4’),















To a suspension of 135 (0.878 g, 1.195 mmol)
in MeOH (60 mL) was added NaOMe (44 µL,
30 wt% in MeOH, 0.24 mmol). The reaction
was stirred under exclusion of light. When
LCMS (gradient 0 to 50% MeOH) showed com-
plete conversion to the product, the mixture
was quenched with AcOH (70 µL, 1.2 mmol). The reaction was diluted with H2O (60
mL), the MeOH was evaporated in vacuo and the remaining H2O was lyophilized. Pu-
rification by HPLC (gradient H2O-MeOH+ 0.1% TFA 80-20→60-40) evaporation of MeOH
and lyophilizing H2O yielded 125 (227 mg, 28%) as white fluffy solid.
1H NMR (400 MHz,
(D6) DMSO): δ 7.90 (d, 1H, J = 8.8 Hz, NH), 7.67-7.71 (m, 2H, 4-methylumbelliferyl, NH),
7.02 (d, 1H, J = 1.6 Hz), 6.94 (d, 1H, J = 8.8 Hz, 4-methylumbelliferyl), 6.25 (s, 1H, 4-
methylumbelliferyl), 5.17 (d, 1H, J = 8.4 Hz, H-1), 4.84-4.90 (m, 3H, OH), 4.69 (bs, 1H, OH),
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4.30 (d, 1H, J = 8.4 Hz, H-1’), 3.78 (q, 1H, J = 9.2 Hz, C-2 or C-2’), 3.36-3.68 (m, 10 H), 2.39
(s, 3H, CH3 4-methylumbelliferyl), 1.84 (s, 4H, CH3 NHAc, H-4’), 1.80 (s, 3H, CH3 NHAc),
1.21 (q, 1H, J = 11.6 Hz, H-4’); 13C NMR (100 MHz, (D6) DMSO): δ 169.2, 169.4 (C=O Ac),
160.1 (Cq), 159.9, 154.4, 153.3, 126.5 (CHarom), 114.3 (Cq), 113.5 (CHarom), 111.9 (CHarom),
103.2 (CHarom), 102.5 (C-1’), 98.3 (C-1), 80.9, 75.1, 72.9, 72.3, 68.2 (C-3, C-4, C-5, C-3’, C-5’),
59.7, 63.5 (C-6 and C-6’), 54.4, 57.0 (C-2 and C-2’), 35.8 (C-4’), 23.1 (CH3 NHAc), 23.0 (CH3
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Until the end of the last century it was believed that man lacked the ability to
process chitin, a linear polymer of β -1,4-linked N-acetyl-D-glucosamines which is
found on cell walls and coating of many organisms. The first mammalian chitinase
was serendipitously discovered in the search for elevated serum glycosidase activ-
ity in patients suffering from Gaucher disease, a rare lysosomal storage disease
in which glucosylceramide (GC) is inefficiently processed by mutant β -glucocere-
brosidase (GBA1). 1–4
This enzyme, identified as human chitotriosidase (CHIT1), is nowadays used
as marker to reflect the total body burden on Gaucher cells. 5 A drawback in the
marker assays is the disproportional fluorophore to enzyme ratio (Figure 3.1 A),
which is found when using high concentrations of 4-methylumbelliferyl-chitobiose
126 (Figure 2.1) as substrate. 6 This is caused by the transglycosylase activity of
CHIT1 forming larger chito-oligomers as substrates, resulting in inefficient release
⋆ Duivenvoorden, B. A.; Ghauharali, K.; Bussink, A. P.; Codée, J. D. C.; van der Marel, G. A.; Scheij,




of 4-methylumbelliferyl (4-MU), the fluorophore. To circumvent the possibility of
CHIT1 mediated transglycosylation a modified fluorogenic substrate 125 was syn-
thesized (Chapter 2), in which the 4’-OH is removed. 6 This derivative follows
Michaelis-Menten kinetics giving rise to a proportional 4-MU to enzyme ratio (Fig-
ure 3.1 A). 6,7 More recent studies 8 showed that 125 is also the substrate of choice
when dealing with Gaucher patients having the common polymorphism (G102S)
in CHIT1, which shows a slightly impaired catalytic activity toward 4-MU-chito-
bioside substrate 126 as compared to the wild type CHIT1. However, G102S-CHIT1
activity is normal when using 4-methylumbelliferyl 4’-deoxychitobioside 125 as
substrate. It should further be mentioned that increased plasma chitotriosidase
activity is not unique for Gaucher patients. Plasma chitotriosidase activity is in-
creased, albeit much more modestly, in several lysosomal and nonlysosomal dis-
eases, such as sarcoidosis, visceral leishmaniasis, leprosy, arthritis, multiple scle-
rosis, thalassemia, chronic obstructive pulmonary disease (COPD), malaria, and
atherosclerosis. 2,9–17
To gain a bigger pool of effective CHIT1 fluorescent substrates, this chapter de-
scribes the synthesis of three novel human chitinase substrates 136,137 and 138
bearing an anomeric 4-MU for fluorometric read-out. The three substrates have a
different modification on the 4’-OH of the non-reducing sugar, going from the rel-
ative small O-methyl group (OMe) to the more sterically demanding O-isopropyl
(iOPr) and O-methyl cyclohexane group (OMCH). A 1,6-anhydro building block is
used as a common precursor for the synthesis of the donors and acceptors which
after condensation and further modifications, will be evaluated as substrates for
CHIT1.
3.2 Results and discusion
The use of an 1,6-anhydro building block for the synthesis of the donors and ac-
ceptors helps to overcome the low reactivity of the 4-OH function of N-acetyl-
glucosamine, which is well recognized. 18 These constrained 1,6-anhydro sugars
are know to exhibit enhanced reactivity of the 4-OH function over there uncon-
strained counterparts. 19 Further enhancement of the reactivity of the 4-OH can
be gained by the use of an azide group on the 2-position of glucosamine, result-
ing in a 10 fold increase of reactivity as compared to N-acetyl or N-phthalimido-
protected acceptors, as shown by the group of Crich. 18 By using 1,6-anhydro glu-
cosamine 148 as the key building block a route was developed for the synthesis
of three novel fluorogenic 4-methylumbelliferyl chiotobiose substrates, bearing a
modification on the 4’-OH of the non-reducing end the retrosyntheis of which is
outlined in Scheme 3.1.
First acceptor 148 was synthesized via a modified literature procedure. 20–22
Deacetylation of tri-O-acetyl-D-glucal and treatment with bis(tributyltin)oxide in
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refluxing acetonitrile, followed by 1,6-iodocyclization 21,23,24 gave compound 150
(Scheme 3.2). Compound 150 was then heated in a DMF:H2O mixture and treated
with a mild base (NaHCO3) to yield 1,6:2,3-bis-anhydro-β -D-glucopyranose 151.
Cerny epoxide 151 was carefully purified to prevent the formation of the unwanted
regio-isomer in the next step. This side reaction was attributed to the presence of
trace amounts of tin. Opening of the epoxide of 151 with sodium azide, followed by
benzylation of the diol and subsequently regioselective debenzylation using TiCl4
gave acceptor 148. 25












R1 = R2 = OH
R1 = R2 = OBn













Reagents and conditions: a) MeOH/H2O/Et3N; b) (1) (Bu3Sn)2O, ∆, ACN; (2) I2, DCM, 4
◦C; c)
NaHCO3, DMF/H2O, 98% over three steps; d) NaN3, DMF/H2O, 120
◦C, 52%; e) BnBr, NaH, DMF,
0 ◦C, 80%; f) TiCl4, DCM, 75%.
Alkylation of the 4-position of anhydro sugar 148 using sodium hydride and
MeI in DMF yielded compound 154 (Scheme 3.3) in a good yield. Under similar
conditions the application of IiPr and BrMCH (bromomethyl cyclohexane) gave
rise to compounds 155 and 156 in slightly reduced yields. Subsequently all three
1,6-anhydro sugars were opened under acidic conditions followed by in situ acety-
lation, using Ac2O and TFA. Selective deprotection of anomeric position and treat-
ment with trichloroacenitrile and DBU led to the isolation of anomeric mixture of
33
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imidates 145, 146 and 147 with α as the major isomer.
































































Reagents and conditions: a) MeI, NaH, DMF, 91%; b) IiPr, NaH, DMF, 60%; c) BrMCH, NaH, DMF,
75%; d) Ac2O, TFA (10% v/v), 157: 90%, 158: 86%, 159: 72%; e)THF, piperidine (6%v/v), 160: 71%,
161: quant., 162: 98%; f) CCl3CN, DBU, DCM, 145: 83%, 146: 70%, 147: 71%.
Couplings of the imidates (145, 146, 147) with acceptor 148 (Scheme 3.4) were
performed at -80 ◦C, in dry toluene under influence of BF3 ·OEt2 yielding dimers
142, 143 and 144 in high yield and high β -selectivity. 26 After deacetylation, pure
β -anomers (163, 164, 165) were obtained by silica gel chromatography. Trifluo-
roacetic acid and Ac2O mediated opening of the 1,6-anhydro sugar in 163, 164,
165 resulted in the formation of dimers 166, 167 and 168. The final steps towards
the target substrates involved several protective group manipulations. Starting off
with a Staudinger reduction of the azides, the released amines were acetylated us-
ing Ac2O and pyridine. The benzyl groups were removed by hydrogenolysis using
Pearlman’s catalyst in MeOH:2,2,2-trifluoroethanol (TFE). Preceding the introduc-
tion of the fluorophore at the anomeric center the free hydroxyls were protected
with acetyl groups yielding intermediate 139, 140 and 141.
Fluorophore 4-MU was selected by virtue of its easy quantification in fluoro-
metric assays. Introduction of 4-MU can be attained by phase transfer conditions
(PTC) which involves a halide donor in combination with a phenolate also known
as the Michael procedure. 27,28 Conversion of the anomeric acetate in 139, 140
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and 141 into the corresponding α-chloride was found to be troublesome. Sev-
eral methods were explored including ZnCl2 and α,α-2,2-dichloromethyl methyl
ether (DCMME) 29, AcCl and HCl 30 however, these did not give satisfactory results.
A combination of AcOH and Ac2O at 0
◦C and dry HCl gas, produced using Kipp
conditions (HCl and H2SO4), gave the highest yields and most reproducible re-
sults. 31,32 The obtained chlorides were coupled with fluorophore 4-MU via a opti-
mized Michael procedure using NaHCO3 as a base, an excess of 4-MU sodium salt
and TBAHS gave the best results to yield compounds 169, 170 and 171. Deacetyla-
tion under Zemplén conditions and HPLC purification yielded the final products
136, 137 and 138 as white powders.
























































































































Reagents and conditions: a) BF3 ·Et2O, Tol, -80
◦C, 142: 83%, 143: 81 %, 144: 65%; b) NaOMe, MeOH,
163: 65%, 164: 50%, 165: 52%; c) Ac2O, TFA (15% v/v), 166: 90%, 167: 80%, 168: 87%; d) (1) PMe3,
Tol:H2O:dioxane; (2) Ac2O, Pyr. (3) Pd(OH)2, H2, MeOH, TFE; (4) Ac2O, Pyr., 139: 48%, 140: 40%, 141:
38%; e) (1) AcOH, Ac2O, HClg , 0
◦C; (2) Na 4-MU, TBHS, NaHCO3 0.2M, CHCl3, 169: 25%, 170: 17%,
171: 50%; f) NaOMe, MeOH, 136: 37%, 137: 60%, 138: 22%.
The three human chitinase substrates (136, 137 and 138) were tested for their
ability to be processed by human chitinase CHIT1. CHIT1 is able to degrade 4-
MU-chitotriose and 4-MU-chitobiose by removal of the oligosaccharide moiety
and concomitant release of fluorescent 4-MU. However, the ongoing transglycosy-
lation of the substrates, results in a reduced 4-MU release at higher substrate con-
centrations (Figure 3.1 A). As described in Chapter 2 4-MU-deoxychitobiose 125
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is an improved fluorogenic substrate, which indeed allows a superior fluoromet-
ric assay of chitinase activity since the interfering transglycosylation of substrate
does not occur (Figure 3.1 A). Compounds 136, 137 and 138 all showed Michaelis-
Menten kinetics like the parent 4’-deoxy substrate 125 (Figure 3.1 B).
















































Figure 3.1: (A) Michaelis-Menten kinetics of 4-MU-deoxychitobiose; ◦:125, •:4-MU-
chitobiose 126, ⊡:4-MU-chitotriose; (B) Michaelis-Menten kinetics chitinase substrates
bearing a modification at the 4-position of the non-reducing end; ◦:125, Í:136, È:137,
⋆:138.
Km values of the new 4-MU-substrates become higher with a more bulky sub-
stituent: 37, 50, 88, and 200 µM for 125, 136, 137 and 138, respectively. Vm a x
values are quite similar for 125, 136 and 137: 5.0, 4.7 and 4.4 mmol/mg CHIT1/h,
respectively. The Vm a x value for 138, (1.7 mmol/mg chitotriosidase/h) is clearly
lower. Nevertheless none of the three novel compounds was superior to the 4-
deoxy derivative 125.
In plasma or tissue extracts a stepwise degradation of chitinase substrates can
occur. This reaction is catalyzed by β -hexosaminidase which slowly and step-
wise removes a GluNAc moiety from the non-reducing end, resulting in undesired
background release of 4-MU. 33 Therefore, the ability of jack bean (Canavalia) β -
hexosaminidase to sequentially hydrolyze the modified 4-MU-chitobioses was ex-
amined, its enzymatic activity towards 4-MU-GlcNAc (0.135 mM) was first deter-
mined at the optimal pH of 4.0. The assay showed to be linear in time over 60
minutes (Figure 3.2 A).
An identical amount of enzyme was incubated with 0.135 mM of 4-MU-chi-
tobioses with different modifications at 4-position of the non-reducing end (136,
137 and 138) as well as the 4’-deoxy derivative 125 and the unmodified substrate.
Both the unmodified 4-MU-chitobiose substrate and 125 are relatively good sub-
strates, resulting in gradual release of the fluorescent leaving group (Figure 3.2 B).
After 1 hour incubation with 4-MU-chitbiose the amount of 4-MU released by jack
bean β -hexosaminidase was about 4% of that released from 4-MU-GlcNac un-
der similar conditions. In contrast, in the case of 125 this was about 2%. Fig-
ure 3.2 B shows that substrates bearing a modification at the 4-position of the
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Figure 3.2: (A) Hydrolysis of 4-MU-GlcNAc (0.135 mM) over 60 minutes by jack bean β -
hexosaminidase; :4-MU-GlcNAc; (B) Hydrolysis of chitobiose and derivatives bearing a
modification at the 4-position of the non-reducing end; •:4-MU-chitobiose 126, ◦:125,
Í:136, È:137, ⋆:138.
non-reducing end, particularly 4’-isopropyloxychitobiosyl umbelliferone 137 and
4’-cyclohexylmethoxychitobiosyl umbelliferone 138, are much more resistant to-
wards jack bean β -hexosaminidase mediated hydrolysis, most likely due to the
steric bulk which precludes binding of a other sugar to the active site of this β -he-
xosaminidase.
3.3 Conclusion
This chapter describes the synthesis of three novel human chitinase fluorogenic
substrates, using 1,6-anhydrosugar 148 as a common building block. Anhydro
sugar 148 was not only transformed into a glycosyl acceptor but was also used
as precursor in the synthesis of the three different imidate donors (145, 146, 147).
Key step entailed the coupling under phase transfer conditions of the fluorophore
and the dimeric α-chlorides.
The newly designed compounds 136, 137 and 138 do not act as acceptors in
transglycosylation and offer substrates for CHIT1 that are hydrolysed according
to Michaelis-Menten kinetics. An additional advantage is that the novel com-
pounds are lesser substrates for β -hexosaminidases. In situations where signifi-
cant β -hexosaminidase activity is suspected in a sample, next to chitinase activity,
and where one aims to monitor specifically chitinase activity, the latter two sub-
strates (4’-isopropyloxychitobiosyl umbelliferone 137 and 4’-cyclohexylmethoxy-
chitobiosyl umbelliferone 138) may be the reagents of choice.
3.4 Experimental section
All reagent were of commercial grade and used as received (Acros, Fluka, Merck, Schleicher
& Schuell) unless stated otherwise. Diethyl ether (Et2O), light petroleum ether (PE 40-60),
en toluene (Tol) were purchased from Riedel-de Haën. Dichloromethane (DCM), N,N-
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dimethylformamide (DMF), methanol (MeOH), pyridine (pyr) and tetrahydrofuran (THF)
were obtained from Biosolve. THF was distilled over LiAlH4 before use. Dichloromethane
was boiled under reflux over P2O5 for 2 h and distilled prior to use. Molecular sieves 3Å
were flame dried under vacuum before use. All reactions sensitive to moisture or oxygen
were performed under an inert atmosphere of argon unless stated otherwise. Solvents
used for flash chromatography were of pro analysis quality. Flash chromatography was
performed on Screening Devices silica gel 60 (0.004 - 0.063 mm). TLC-analysis was con-
ducted on DC-alufolien (Merck, Kieselgel60, F245) with detection by UV-absorption (254
nm) for UV-active compounds and by spraying with 20% H2SO4 in ethanol or with a so-
lution of (NH4)6Mo7O24 ·4 H2O 25 g/L, (NH4)4Ce(SO4)4 ·2 H2O 10 g/L, 10% H2SO4 in H2O
followed by charring at∼150 ◦C. 1H and 13C NMR spectra were recorded on a Bruker DMX-
400 (400/100 MHz), a Bruker AV 400 (400/100 MHz), a Bruker AV 500 (500/125 MHz) or a
Bruker DMX-600 (600/150 MHz) spectrometer. Chemical shifts (δ) are given in ppm rel-
ative to the chloroform residual solvent peak or tetramethylsilane as internal standard.
Coupling constants are given in Hz. All given 13C spectra are proton decoupled. High
resolution mass spectra were recorded on a LTQ-Orbitrap (Thermo Finnigan) Mass spec-
trometer. LC/MS analysis was performed on a Jasco HPLC-system (detection simultane-
ous at 214 nm and 245 nm) equipped with an analytical Alltima C18 column (Alltech, 4.6
mmD x 50 mmL, 3µ particle size) in combination with buffers A: H2O, B: MeCN and C:
0.5% aq. TFA and coupled to a Perkin Almer Sciex API 165 mass spectrometer. Optical
rotations were measured on a Propol automatic polarimeter. IR spectra were recorded on






A solution of the commercial available tri-O-acetyl-D-glucal (2.72 g, 10
mmol) was dissolved in MeOH:H2O:Et3N (10:10:1, 125 mL) was stirred for
1 h at ambient temperature, then concentrated. The residue was dried by
coevaporation with dioxane (3x 50 mL). The clear oil was use further with-
out any purifications. Crude deprotected D-glucal (1.46 g, 10 mmol) was
dissolved in 100 mL MeCN. The solution was boiled under reflux with 4.08 mL bis(tributyl
stannyl) oxide (4.77g, 8 mmol) and molsieves 4Å for 2.5 h. Subsequently the reaction was
cooled to 0 ◦C, followed by portion wise addition of 3.8 g I2 (15 mmol, 1.5 equiv). The dark
brown mixture was stirred overnight at 4 ◦C. TLC showed complete conversion of D-glucal
into 150. The mixture was filtered through Celite and concentrated. To the residue were
added Na2S2O3 (50 mL) and PE (50 mL), and the biphasic mixture was vigorously stirred
for several h until the mixture became colorless. The aqueous phase was than washed
several times with EtOAc(4x 40 mL). The combined organic layers were dried (Na2SO4)







A heterogeneous solution of compound 150 (2.71 g, 10 mmol) and
NaHCO3 (2.5 g, 25 mmol, 2.5 equiv) in DMF:H2O (10:1) 25 mL was heated
to 120 ◦C. After 4 h, the reaction mixture was cooled, concentrated (in
vacuo) and silica gel purification (MeOH/EtOAc 10%) yielded 1.42 g (9.85
mmol, 98% over 3 steps) of the title compound 151 as light yellow oil. TLC:
EtOAc/PE 50%; 1H NMR (200 MHz, CDCl3) δ 3.15 (d, J = 3.7 Hz, 1H, CH, C’-2), 3.25 (d, J =
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8.8 Hz, 1H, CH, C’-4), 3.44 (t, J = 2.9, 1H, CH, C’-3), 3.69-3.95 (m, 2H, CH2, C’-6), 5.70 (d, J
= 2.9 Hz, CH, C’-1), 13C NMR (50 MHz, CDCl3) δ 48.49 (CH, C’-2), 53.23 (CH, C’-3), 64.69






The bis-anhydro sugar 151 (1.15 g, 8 mmol) was heated to reflux temper-
ature in a 10:1 MeOH:H2O (40 mL) solution containing 5.20 g NaN3 (80
mmol, 10 equiv), and 4.24 g NH4Cl (80 mmol, 10 equiv). After
1H NMR
showed complete conversion to compound 152 (4.5 days), the solution
was cooled, filtered through Celite and concentrated under reduced pres-
sure. Silica gel purification (EtOAc/PE 80%) yielded 0.99 g (5.32 mmol, 66.5%) of the title
compound 152 as off-white solid. TLC: EtOAc/PE 50%; 1H NMR (200 MHz, CDCl3) δ 3.17
(s, 1H, CH, C’-2), 3.53 (s, 1H, CH, C’-4), 3.32-3.69 (m, 2H, CH, CH2, C’-3, C’-6), 4.03 (d, J =
7.3 Hz, 1H, CH2, C’-6), 4.46 (d, J = 4.3 Hz, 1H, CH, C’-5), 5.36 (s, 1H, CH, C’-1);
13C NMR
(50 MHz, CDCl3) δ 64.07 (CH, C’-2), 66.55 (CH2, C’-6), 72.92 (CH, C’-3, C’-4), 77.99 (CH,






The anhydro sugar 152 (9.35 g, 50 mmol) was dissolved in DMF and
cooled to 0 ◦C. Benzyl bromide (15 mL, 125 mmol, 2.5 equiv) was added
followed by portion wise addition of NaH (6 g, 150 mmol, 3 equiv). The re-
action was stirred for 3 h, allowing the mixture to warm to rT, after which
it was cooled (0 ◦C) and quenched by addition of MeOH. The mixture was
concentrated in vacuo and the oily residue was taken up in Et2O and washed with 1M HCl.
The organic layer was dried, filtered and concentrated under reduced pressure. Purifica-
tion by silica gel chromatography (EtOAc/PE 20%) yielded compound 153 in 65% (11.93
g, 32.5 mmol). TLC: EtOAc/PE 30%; 1H NMR (400 MHz, CDCl3) δ 7.42 - 7.22 (m, 12H),
5.51 - 5.43 (s, 1H), 4.65 - 4.44 (m, 5H), 4.03 - 3.96 (d, J = 7.3 Hz, 1H), 3.73 - 3.68 (m, 1H),
3.67 - 3.62 (s, 1H), 3.38 - 3.34 (s, 1H), 3.29 - 3.25 (s, 1H).; 13C NMR (100 MHz, d4), MeOD)







Compound 153 (10.28 g, 28 mmol) was coevaporated thrice with Tol, af-
ter which it was dissolved in dry DCM (450 mL). Next TiCl4 (3.2 mL, 29.4
mmol, 1.05 equiv) was carefully added, the mixture was stirred for 1.5 h
at rT. The reaction mixture was than poured into cooled (0 ◦C) H2O af-
ter which the layers were separated. The organic layer was washed with
NaHCO3 and H2O and dried using MgSO4. Concentration and purification by silicagel
chromatography (EtOAc/PE 25%) gave 148 in 75% yield (5.9 g, 21.3 mmol). TLC: EtOAc/PE
40%; 1H NMR (400 MHz, CDCl3)δ 7.43 - 7.26 (m, 5H), 5.47 - 5.43 (s, 1H), 4.71 - 4.57 (m, 2H),
4.56 - 4.50 (d, J = 5.6 Hz, 1H), 4.32 - 4.15 (d, J = 7.3 Hz, 1H), 3.83 - 3.72 (m, 1H), 3.70 - 3.63
(d, J = 7.3 Hz, 1H), 3.62 - 3.58 (m, 1H), 3.55 - 3.50 (s, 1H), 2.70 - 2.57 (d, J = 9.8 Hz, 1H).; 13C









Compound 148 (8.15 mmol, 2.26 g) was dissolved in DMF (25 mL) and
cooled using an ice-bath, after stirring for 15 minutes NaH (60% dis-
persion in mineral oil) (0.49 g, 12 mmol, 1.5 equiv) was added portion
wise. After 30 minutes the gas development stopped and MeI (0.61 mL,
9.8 mmol 1.2 equiv) was added dropwise. After 1.5 h the reaction was
quenched with MeOH. The reaction mixture was concentrated in vacuo and purified us-
ing a short silica column (EtOAc/PE 20%) which gave product 154 as clear oil (91%, 2.16 g,
7.42 mmol). TLC: EtOAc/PE 40%; 1H NMR (400 MHz, CDCl3) δ 7.41-7.27 (m, 5H, CHarom
Bn), 5.48 (s, 1H, H-1, 4.64 (m, 3H, CH2 Bn, H-5), 4.08 (d, J = 7.2 Hz, 1H, H-6), 3.76 (d, J =
6.4 Hz, 1H, H-6), 3.59 (s, 1H, H-4), 3.39 (s, 3H, CH3), 3.29 (s, 1H, H-3), 3.20 (s, 1H, H-2);
13C
NMR (100 MHz, CDCl3) δ 137.4 (Cq), 128.7-127.9 (CHarom Bn), 100.6 (C-1), 78.8 (C-2), 75.9
(C-3), 73.8 (C-4), 72.5 (C-6), 65.3 (CH2 Bn), 59.9 (C-5), 57.2 (CH3 Me); IR (neat) ν 2096.5,












Anhydro compound 154 (2.16 g, 7.42 mmol) was taken up in Ac2O (37
mL) and cooled with an ice bath. To this cooled solution TFA (3.7 mL,
10% v/v) was added and the reaction was stirred overnight at room
temperature. After complete conversion of the starting material the
reaction was diluted with toluene and coevaporated. The resulting oil was purified using a
short silica column (EtOAc/PE 30%) yielding 157 (2.62 g, 6.66 mmol, 90%) as a white solid.
TLC: EtOAc/PE 50%; 1H NMR (400 MHz, CDCl3) δ 7.43-7.23 (m, 5H, CHarom Bnα/β ), 6.22
(d, J = 3.6 Hz, 1H, H-1α), 5.45 (d, J = 8.1 Hz, 1H, H-1β ), 4.88-4.81 (m, 2H, CH2 Bnα/β ),
4.30-4.21 (m, 2H, CH2, H-6α/β ), 3.87-3.78 (m, 2H, H-5α/β H-4α/β ), 3.55-3.45 (m, 4H, CH3
Me, H-3α/β ), 3.30 (m, 1H, H-2α/β ), 2.09 (s, 3H, CH3, OAc), 2.04 (s, 3H CH3, OAc);
13C NMR
(100 MHz, CDCl3) δ 170.1 (Cq, Ac), 168.3 (Cq, Ac), 137.4 (Cq), 128.2-127.7 (CHarom Bn), 92.2
(C-1β ), 90.0 (C-1α), 82.4 (C-4β ), 79.9 (C-4α), 79.5 (C-3α), 79.1 (C-3β ), 75.1 (CH2 Bn), 73.5
(C-5β ), 71.0 (C-5α), 64.5 (CH3 Meβ ), 62.1 (C-6α/β ), 62.1 (CH3 Meα), 60.6 (C-2α), 60.4 (C-2β ),
20.4 (CH3 OAc), 20.3 (CH3 OAc); IR (neat) ν 2106.1, 1753.2, 1733.9, 1373.2, 1136.0, 1109.0,
1004.8, 935.4, 906.5, 740.6; HRMS: C18H23N3O7+Na








Compound 157 (2.62 g, 6.66 mmol) was dissolved in THF (30 mL) and
piperidine (1.8 mL, 6% v/v) was added. The clear solution was stirred
overnight at room temperature. After complete conversion to a lower
running spot on TLC the reaction was diluted with EtOAc (100 mL)
and poured in 1M HCl (100 mL). The layers were separated and the organic layer was
washed twice with H2O and once with brine. Subsequently the EtOAc layer was dried
and concentrated in vacuo. Flash silica column purification (EtOAc/PE 20%) yielded com-
pound 160 in 71% as a white foam (1.65 g, 4.70 mmol). TLC: EtOAc/PE 50%; 1H NMR (400
MHz, CDCl3) δ 7.46-7.28 (m, 8H, CHarom Bn α/β ), 5.26 (d, J = 3.4 Hz, 1H, H-1α), 4.90-4.77
(m, 3H, CH2 Bn α/β ), 4.56 (d, J = 7.5 Hz, 1H, H-1β ), 4.37 (m, 2H, CH2, H-6α/β ), 4.25-4.16
(m, 2H, CH2, H-6α/β ), 4.07-4.00 (m, 1H, H-5α), 3.93 (dd, J = 10.1, 8.9 Hz, 1H, H-4α), 3.69 (s,
1H, OH), 3.55 (s, 3H, CH3, Meα), 3.53 (s, 1H, CH3 Meβ ), 3.47-3.41 (m, 1H, H-4β ), 3.40-3.30




NMR (100 MHz, CDCl3) δ 171.2 (Cq, Ac), 171.1 (Cq, Ac), 137.6 (Cq), 137.6 (Cq Bn), 128.4-
127.9 (CHarom Bn), 95.9 (C-1β ), 91.7 (C-1α), 82.6 (C-3,4β ), 80.4 (C-3,4α), 79.6 (C-3,4α/β ), 75.4
(CH2 Bnα/β ), 75.4 (CH2, Bnα/β ), 73.0 (C-5β ), 68.9 (C-5α), 67.1 (C-2β ), 63.6 (C-2α), 62.97 (C-
6α/β ), 62.95 (C-6α/β ), 60.8 (OMeα/β ), 60.7 (OMeα/β ) 20.7 (CH3 Acα/β ), 20.7 (CH3 Acα/β ); IR
(neat) ν 2937.4, 2106.1, 1739.7, 1456.2, 1319.2, 1238.2, 1120.6, 1085.8, 1035.7, 995.2, 746.4,
698.2; HRMS: C16H21N3O6+Na










A solution of compound 160 (1.6 g, 4.6 mmol) and trichloroaceto-
nitrile (1.37 mL, 13.7 mmol, 3 equiv) in dry DCM (25 mL) was
treated with 0.2 equivalents of DBU (0.12 mL, 0.91 mmol) for 18 h at
ambient temperature. The dark brown solution was concentrated
under reduce pressure and directly purified using a silica gel col-
umn (20% EtOAc/PE and 2.5% TEA) to obtain the title compound
145 in a good yield (1.88 g, 3.80 mmol, 83%). TLC: EtOAc/PE 30% + 2.5% TEA; 1H NMR
(400 MHz, CDCl3) δ 8.74 (s, 1H, NH), 7.45-7.29 (m, 5H, CHarom Bn α/β ), 6.37 (d, J = 3.5 Hz,
1H, H-1α), 4.89 (d, J = 10.4 Hz, 2H, CH2 Bn ), 4.37-4.21 (m, 2H, H-6), 4.01-3.90 (m, 2H, H-
4,5), 3.67-3.59 (m, 1H, H-3), 3.56 (s, J = 11.7 Hz, 3H, CH3 Me), 3.36 (dd, J = 18.4, 8.5 Hz, 1H,
H-2), 2.06 (s, J = 5.0 Hz, 3H, CH3 OAc);
13C NMR (100 MHz, CDCl3) δ 170.4 (Cq, C=N)160.6
(Cq, Ac), 137.6 (Cq), 128.6-128.1 (CHarom Bn) 94.6 (C-1) 90.7 (Cq, CCl3) 79.9 (C-3,4,5), 75.6
(CH2 Bn), 71.8 (C-3,4,5), 62.8 (C-3,4,5), 62.4 (C-6), 61.1 (C-2), 20.8 (CH3 Ac); IR (neat) ν
2110.0, 1733.9, 1678.0, 146.2, 1373,2 1228.6, 1016.4, 986.2, 906.5, 789.5, 734.8, 696.3.
1,6-Anhydro-2-azido-3-O-benzyl-2-deoxy-4-O-(6-O-acetyl-2-azido-3-O-benzyl-2-de-











A mixture of imidate 145 (1.8 g, 3.6 mmol) and alcohol 148
(2.0 g, 7.3 mmol, 2 equiv) were coevaporated thrice with tolu-
ene and dissolved in dry toluene (18 mL). To this mixture acti-
vated molecular sieves (4Å) were added and the solution was
cooled to -78 ◦C. After 10 minutes a solution of BF3 ·Et2O (90
µL, 0.72 mmol, 0.2 equiv) in dry toluene (3 mL) was added and
the temperature was allowed to rise to -20 ◦C in 90 minutes. TLC analysis showed complete
conversion of imidate 145 into a lower running spot. The reaction was quenched using
TEA (0.5 mL), filtered and concentrated in vacuo. The excess of acceptor was acetylated,
using an Ac2O-pyridine cocktail (1 mL/3 mL), after which the reaction was quenched using
MeOH and concentrated. The oily residue was directly purified using a silica gel column
(EtOAc/PE 40%). Compound 142 was obtained in 83% in 1:3 α:β ratio (1.84 g, 3.02 mmol).
TLC: EtOAc/Tol 60%; 1H NMR (400 MHz CDCl3) δ 7.44-7.14 (m, 10H, CHarom Bnα/β ), 5.55
(s, 1H, H-1α), 5.47 (s, 1H, H-1β ), 4.83 (dt, J = 18.1, 10.8 Hz, 2H, CH2, Bn), 4.73-4.52 (m, 3H,
CH2, H-6, H-5’), 4.41-4.24 (m, 2H, CH2 Bn, H-1’), 4.16 - 4.01 (m, 2H, CH2 Bn, H-6’), 3.95
(dd, J = 6.4, 5.0 Hz, 1H, H-3’), 3.85-3.69 (m, 2H, CH2 H-6’, H-5), 3.58-3.52 (m, 3H, CH3 Me),
3.46 (dt, J = 18.9, 9.5 Hz, 1H, H-2’), 3.34-3.12 (m, 4H, H-2/3/4/4’), 2.01 (s, 3H, CH3 Acβ );
13C NMR (100 MHz, CDCl3) δ 170.7 (Cq, Ac), 137.8 (Cq), 128.7-127.8 (CHarom Bn), 102.3
(C-1), 100.7 (C-1’), 82.7 (C-4), 79.3 (C-3’), 77.5 (C-5’), 76.6 (C-4’), 75.6 (CH2 Bn), 75.5 (C-3),
74.8 (C-5), 73.4 (C-6’), 72.9 (C-2), 72.5 (C-6), 65.8 (CH2 Bn), 61.1 (CH3 Me), 59.3 (C-2), 20.9
(CH3 Ac); IR (neat) ν 2100.3, 1739.7, 1456.2, 1363.6, 1232.4, 1066.6, 1001.0, 1026.0, 931.6,
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898.8, 738.7, 696.3; HRMS: C29H34N6O9 +Na
+ requires 633.2279, found 633.2279; [α]23
D
+
11.4 ◦(c = 1, CHCl3).
1,6-Anhydro-2-azido-3-O-benzyl-2-deoxy-4-O-(2-azido-3-O-benzyl-2-deoxy-4-O-me-











Disaccharide 142 (1.84 g, 3.02 mmol) was dissolved in
MeOH (15 mL) and a catalytic amount of NaOMe (30% in
MeOH) was added. The reaction mixture was stirred for
1 h at ambient temperature, after which it was neutralized
(pH∼7) using Amberlite R© IR-120 H+ resin. Filtering off the
resin, concentration and purification using a short silica col-
umn (EtOAc/PE ) yielded title compound 163 as a clear oil (1.0 g, 1.8 mmol, 59%). TLC:
EtOAc/PE 35%; 1H NMR (400 MHz, CDCl3) δ 7.48-7.30 (m, 10H, CHarom 2xBn ), 5.52 (s, 1H,
H-1), 4.87 (q, J = 10.9 Hz, 2H, CH2 Bn), 4.73 (m, 2H, CH2, H-6’, H-5), 4.61 (d, J = 12.3 Hz,
1H, CH2 H-6’), 4.26 (d, J = 8.0 Hz, 1H, H-1’), 4.20-4.10 (m, 1H, CH2 H-6), 3.94 (d, J = 1.3 Hz,
1H, H-3), 3.81 (m, 1H, CH2 H-6), 3.75 (s, 1H, H-5), 3.69 (s, 2H, CH2 Bn), 3.58 (s, 3H, CH3,
OMe), 3.49-3.44 (m, 1H, H-2’), 3.36 (s, 1H, H-2), 3.34-3.28 (m, 2H, H-3’, H-4), 3.13-3.03
(m, 1H, H-4); 13C NMR (100 MHz, CDCl3) δ 137.9 (Cq), 137.3 (Cq), 128.7-127.7 (CHarom
2xBn), 102.1 (C-1’), 100.3 (C-1), 82.5 (C-4), 78.9 (C-3’), 77.9 (C-5’), 75.6 (C-4’, C-3), 75.5
(CH2 Bn), 75.3 (C-5), 74.7 (C-6’), 72.2 (C-2’), 65.8 (C-6), 65.0 (CH2 Bn), 61.4 (CH3, OMe),
59.0 (C-2); IR (neat) ν 2108.1, 1454.2, 1261.4, 1141.8, 1074.3, 1006.8, 740.6, 698.2; HRMS:
C27H32N6O8+Na
+ requires 591.2174, found 591.2172; [α]23
D
-16.67 ◦(c = 0.6, CHCl3).
2-Azido-1,6-di-O-acetyl-3-O-benzyl-2-deoxy-4-O-(2-azido-3-O-benzyl-2-deoxy-4-O-












To a solution of compound 163 (1.0 g, 1.7 mmol) in Ac2O
(8.5 mL) TFA (1.28 mL, 15% v/v) was added. The reaction
was stirred for 18 h after which it was diluted with toluene
and concentrated. After purification using silica gel chro-
matograph (EtOAc/PE 30%) disaccharide 166 was obtained
in 90% yield (1.09 g, 1.53 mmol) as transparent foam. TLC: EtOAc/PE 45%; 1H NMR (400
MHz, CDCl3) δ 7.42-7.27 (m, 15H, CHarom Bnα/β ), 6.20 (d,J = 3.7 Hz, 1H, H-1α), 5.49-5.43
(m, 1H, H-1β ), 5.05 (dd, J = 33.7, 11.2 Hz, 1H, CH2 H6′ ), 4.89-4.59 (m, 4H, CH2 Bn, CH2
H-6’), 4.52-4.44 (m, 2H, CH2 Bn), 4.39-4.28 (m, 1H, H-1’), 4.19 (m, 1H, CH2 H-6), 4.15-4.07
(m, 1H, CH2 H-6), 4.00-3.86 (m, 3H, H-3, H-4, H-5), 3.78 (dd, J = 7.2, 6.0 Hz, 1H),3.74-
3.68 (m, 1H), 3.58-3.50 (m, 1H, H-2), 3.49 (s, 3H, CH3, Me), 3.42-3.31 (m, 2H, H-2’, H-4’),
3.31-3.19 (m, 2H, H-3’, H-5’), 2.19-1.90 (m, 13H, CH3,Acα/β );
13C NMR (100 MHz, CDCl3)
δ 170.7-168.9 (3x Cq, Ac), 138.3-127.5 (Bn), 101.5 (C-1’), 90.23(C-1), 83.3 (C-3’), 79.9 (C-5’),
78.6 (C-4, C-5), 77.5 (C-4, C-5), 75.9 (C-6’), 75.1 (CH2 Bn), 73.5 (C-4), 71.1 (C-3), 66.8 (C-2’),
62.9 (C-6), 62.4 (CH2 Bn), 62.2 (C-2), 61.0 (CH3, OMe), 21.1-20.8 (3x CH3 Ac); IR (neat) ν


















Compound 166 (71 mg, 0.1 mmol) was taken up in a mix-
ture of dioxane:toluene:H2O (5/2/1, v/v/v, 2 mL) and cooled
with an ice-bath. After 10 minutes 1M PMe3 (0.5 mL) in tol-
uene was added and the reaction was stirred for 18 h at 4 ◦C.
After TLC analysis showed conversion towards lower run-
ning, ninhydrin positive spot, the reaction was coevaporated thrice with toluene and sub-
sequently acetylated using an Ac2O-pyridine cocktail (0.5 mL/1.5 mL). The mixture was
stirred for 20 h after which it was quenched with MeOH and concentrated under reduced
pressure. The resulting white solid was dissolved in a 1:1 mixture of MeOH and TFE (4 mL)
and purged with argon. A catalytic amount of Pd(OH)2 spiked with Pd-black was added
and the mixture was purged with H2. Reduction of the benzyl-groups was continued for
5 h followed by filtration and concentration. The residue was again taken up in an Ac2O-
pyridine cocktail (0.5 mL/1.5 mL) with a catalytic amount of DMAP and stirred at ambi-
ent temperature for 18 h. After complete acetylation of the disaccharide the mixture was
quenched with MeOH and concentrated under reduced pressure. Silica gel purification
(MeOH/DCM 3%) yielded 31 mg (47 µmol, 48%) of the title compound 139 as an off-white
solid. TLC: MeOH/DCM 5%; 1H NMR (400 MHz, CDCl3) δ 6.31 (d, J = 9.8 Hz, 1H, NH),
6.11 (m, 2H, NH, H-1α), 5.74 (s, 1H), 5.61 (d, J = 7.5 Hz, 1H, H-1β ), 5.26-5.17 (m, 1H, H-
4’), 5.09-5.01 (m, 1H), 5.01-4.93 (m, 1H H-4), 4.45-4.37 (m, 1H, H-6), 4.30 (m, 5H, H-1’α,
H-1’β , H-2’, H-5), 4.25-4.18 (m, 1H, H-6), 4.17-4.07 (m, 1H, H-2), 4.06-3.94 (m, 1H, H-2’),
3.93-3.75 (m, 2H), 3.45 (m, 1H, H-3’), 3.41 (d, J = 3.0 Hz, 4H, CH3, OMe), 3.35 (d, J = 9.2
Hz, 1H, H-3), 2.21-1.90 (m, 33H, CH3 Ac and NHAc);
13C NMR (100 MHz, CDCl3) δ 171.4,
171.2, 170.9, 170.88, 170.81, 170.6, 170.5, 170.47, 170.4, 170.3, 170.2, 169.4, 168.9, 102.0,
100.8, 92.5, 90.5, 77.4, 77.1, 77.0, 76.7, 75.9, 75.2, 74.9, 73.9, 73.7, 73.0, 71.9, 71.0, 70.9, 70.7,
62.9, 62.8, 62.4, 61.6, 60.4, 60.4, 54.2, 54.1, 51.4, 51.2, 29.7, 23.2, 23.1, 23.0, 21.0, 20.97, 20.9,
20.88, 20.77, 20.70, 20.6; IR (neat) ν 3282.6, 1741.6, 1662.5, 1544.9, 1434.9, 1373.2, 1226.6,
1112.9, 1033.8, 943.1, 732.9; HRMS: C27H40N2O16+H















Dimer 139 (100 mg, 154 µmol) was dissolved
in AcOH (2 mL) and Ac2O (1 mL). At 0
◦C dry
HCl(g ) was bubbled through (liberated under
Kipp conditions) for 3h. The reaction mixture
was then placed at 5 ◦C for 42 h at which TLC
analyses (DCM-acetone 60-40) showed com-
plete consumption of starting material. The reaction was diluted with CHCl3 (10 mL, 0
◦C) and washed twice with H2O (15 mL, 0
◦C) and twice with NaHCO3 (15 ml, 0
◦C). The
organic layer was dried over MgSO4 and concentrated in vacuo yielding the anomeric α-
chloride as an amorphous solid of which purity was evaluated by 1H-NMR. The resulting
solid was dissolved in CHCl3 (5 mL) and added to a solution of NaHCO3 0.2M (5 mL), 4-
methylumbelliferyl sodium salt 34,35 (152mg, 770 µmol) and TBAHS (105 mg, 310 µmol).
The biphasic mixture was stirred overnight with the exclusion of light. The phases were
separated and the organic layer was washed twice with NaHCO3 (0.2 M) and twice with
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H2O. The organic layer was dried over MgSO4 and concentrated in vacuo. Purification by
column chromatography (MeOH/CHCl3 3%) yielded 169 (27 mg, 25%) as a white amor-
phous solid. TLC: MeOH/DCM 5%; 1H NMR (600 MHz, (d4), MeOD) δ 8.06 (d, J = 9.2 Hz,
1H, NH), 7.62 (d, J = 8.7 Hz, 1H, CH, 4-methylumbelliferyl), 6.99-6.94 (m, 2H, CHarom 4-
methylumbelliferyl), 6.19 (s, J = 9.6 Hz, 1H, CHarom 4-methylumbelliferyl), 5.27 (d, J = 8.7
Hz, 1H, H-1β ,H-3), 5.15 (t, J = 9.8 Hz, 1H, H-3’), 4.66 (d, J = 8.4 Hz, 2H, H-1’β ), 4.53 (d, J =
10.2 Hz, 1H, H-6’), 4.33 (dt, J = 20.2, 7.2 Hz, 1H, CH2 H-6’), 4.23-4.17 (m, 1H, H-2), 4.14 (dd,
J = 11.8, 7.3 Hz, 2H, CH2 H-6), 3.95 (t, J= 7.7 Hz, 1H, H-5), 3.86 (t, J = 9.2 Hz, 1H, H-4), 3.79-
3.72 (m, 1H, H-2’), 3.59 (dd, J = 8.6, 2.9 Hz, 1H, H-5’), 3.45-3.40 (m, 3H, CH3 Me), 3.37 (dd,
J = 12.4, 6.4 Hz, 1H, H-4’), 2.44 (s, 3H, CH3, 4-methylumbelliferyl), 2.17-2.05 (m, 12H, CH3
4xAc), 1.97-1.92 (m, 6H, CH3 2xAc);
13C NMR (151 MHz, (d4), MeOD)δ 173.3-171.6 (Cq, Ac),
162.9-154.9 (Cq, 4-methylumbelliferyl), 127.01 (Carom, 4-methylumbelliferyl) 116.2 (Cq,
4-methylumbelliferyl),115.1-104.6 (Carom, 4-methylumbelliferyl), 101.9 (C-1’), 98.9 (C-1),
77.4 (C-4’), 75.9 (C-4), 74.1 (C-3), 74.1 (C-5), 73.7 (C-5’), 64.0 (C-6’), 63.7 (C-6), 60.8 (CH3
Me), 55.9 (C-2’), 54.9 (C-2), 23.1-19.0 (CH3 Ac); IR (neat) ν 1739.7, 1660.6, 1612.4, 1612.4,
1371.3, 1222.8, 1066.6, 1033.8, 623.0; HRMS: C35H44N2O17 +H
+ requires 765.2713, found
765.2717; [α]23
D














To a suspension of 169 (12mg, 15.70 µmol)
in MeOH (1 mL) was added NaOMe (30 wt%
in MeOH) (173 µL, 0.40 µmol). The reaction
was stirred with the exclusion of light. When
LCMS (gradient 0 to 50% MeOH) showed
complete conversion to product the mixture
was quenched with AcOH (5 µL, 80 µmol). The reaction was diluted with H2O (2 ml)
the MeOH was evaporated in vacuo and the remaining H2O was lyophilized. Purifica-
tion by HPLC (gradient H2O-MeOH+ 0.1% TFA 80-20→ 60-40) evaporation of MeOH and
lyophilizing H2O yielded 136 (3.5 mg, 5.9 µmol, 37%) as white fluffy solid.
1H NMR (600
MHz, (d6), DMSO) δ 7.90 (d, J = 9.0 Hz, 1H, NH), 7.75 (d, J = 9.1 Hz, 1H, NH), 7.69 (d, J =
8.8 Hz, 1H, CH, 4-methylumbelliferyl), 7.03 (d, J = 2.2 Hz, 1H, CH, 4-methylumbelliferyl),
6.95 (dd, J = 8.8, 2.3 Hz, 1H, CH, 4-methylumbelliferyl), 6.26 (s, 1H, CH, 4-methylumbelli-
feryl), 5.16 (dd, J = 10.8, 7.4 Hz, 2H, H-1, OH), 4.83 (t, J = 5.3 Hz, 1H, OH), 4.74 (d, J = 2.1
Hz, 1H, OH), 4.68 (t, J = 5.9 Hz, 1H, OH), 4.36 (d, J = 8.5 Hz, 1H, H-1’β ), 3.77 (d, J = 9.6
Hz, 1H), 3.70-3.13 (m, 14H), 2.94 (t, J = 9.2 Hz, 1H), 2.40 (s, 3H, CH3 4-methylumbelliferyl),
1.84 (s, 3H, CH3 Ac), 1.80 (s, 3H, CH3 Ac);
13C NMR (151 MHz, (d6), DMSO) δ 169.2, 160.1,
159.9, 154.4, 153.3, 126.5, 114.3, 113.4, 103.1, 101.9, 98.2, 80.7, 80.0, 75.6, 75.1, 73.8, 72.2,
59.8, 55.7, 54.4, 23.0, 18.1; HRMS: C27H36N2O13+H








Compound 148 (1.5 g, 5.3 mmol) was dissolved in 25 mL DMF and cooled
using an ice-bath and after stirring for 5 minutes NaH (60% dispersion
in mineral oil) (234 mg, 5.86 mmol, 1.1 equiv) was added. After 30 min-
utes the gas formation stopped and 2-iodopropane (586 µL, 5.86 mmol,
1.1 equiv) was added dropwise. After 3 h the reaction was quenched with
MeOH. The mixture was concentrated and the residue was taken up in Et2O and washed
twice with 1M HCl(aq ). The organic layer was dried with MgSO4 and concentrated in vacuo.
The oily residue was re-dissolved in 25 mL DMF and cooled using an ice-bath. The alkyla-
tion step was repeated three times. After four cycles the oil compound was purified using a
short silica column (EtOAc/PE 20%) which gave product 155 as yellow oil (1.0 g, 3.1 mmol,
60%). TLC: EtOAc/PE 40%; 1H NMR (400 MHz, CDCl3) δ 7.31 (s, 5H, CHarom Bn), 5.43 (s,
1H, H-1), 4.64-4.44 (m, 3H, CH2 Bn,H-5), 4.02 (d, J = 6.7 Hz, 1H, H-6), 3.67 (s, 1H, H-6),
3.57 (dd, J = 12.9, 9.5 Hz, 2H, CH, iProp, H-3), 3.33 (s, 1H, H-2), 3.16 (s, 1H, H-4), 1.14 (d, J
= 5.3 Hz, 6H, 2xCH3 iProp);
13C NMR (100 MHz, CDCl3) δ 137.2 (Cq), 128.2-127.5 (CHarom
Bn), 100.3 (C-1), 76.8 (C-3), 75.1 (C-5), 74.2 (C-4), 72.1 (CH2 Bn), 70.1 (iProp), 65.1 (C-6),
59.4 (C-2), 22.1 (CH3 iProp), 21.9 (CH3 iProp); IR (neat) ν 2970.2, 2898.8, 2098.4, 1454.2,













The yellow oil 155 (1.0 g, 3.1 mmol) was taken up in 20 mL Ac2O and
cooled with an ice bath. To this cooled solution 2 mL TFA (10% v/v)
was added and the reaction was stirred overnight at room tempera-
ture. After complete conversion of the starting material the reaction
was diluted with toluene and coevaporated to yellow oil. Purification using a short silica
column (EtOAc/PE 30%) yielded compound 158 in a good yield 86% (1.13 g, 2.69 mmol).
TLC: EtOAc/PE 50%; 1H NMR (400 MHz, CDCl3) δ 7.43-7.28 (m, 6H, CHarom Bn), 6.22 (d, J
= 3.7 Hz, 1H, H-1α), 5.47 (d, J = 8.4 Hz, 1H, H-1β ), 4.90-4.80 (m, 2H, CH2 Bn), 4.34-4.16 (m,
2H, CH-2, H-6), 3.98-3.90 (m, 1H, CH, iProp), 3.87-3.81 (m, 2H, H-3, H-5), 3.56 (m, 2H, H-
4, H-2), 2.19-2.13 (m, 4H, CH3 Ac), 2.07 (s, 4H, CH3 Ac), 1.21 (t, J = 5.4 Hz, 3H, CH3 iProp),
1.12 (t, J = 6.3 Hz, 3H, CH3 iProp);
13C NMR (100 MHz, CDCl3) δ 170.7 (Cq, Ac), 168.9
(Cq, Ac), 137.6 (Cq), 128.6-128.1 (CHarom Bn), 92.9 (C-1β ), 90.5 (C-1α), 83.3 (C-3/5β ), 80.8
(C-3/5α), 75.9 (CH2 Bn), 74.4 (C-4β ), 74.2 (C-4α), 73.3 (C-3/5β ), 73.3 (C-3/5α), 71.7 (iProp),
65.3 (C-2β ), 63.0 (C-2α), 62.5 (C-6), 23.2 (Ac), 22.0 (Ac), 21.1 (iProp), 20.9 (iProp); IR (neat)
ν 3423.4, 2358.8, 2343.4, 2102.3, 1745., 1456.2, 1371.3, 1234.4, 1143.7, 1124.4, 1026.1, 968.2,
997.1, 948.9, 740.6, 694.3; HRMS: C20H27N3O7+Na








Compound 158 (1.13 g, 2.69 mmol) was dissolved in 20 mL THF and
1.5 mL piperidine (6% v/v) was added. The clear solution was stirred
overnight at room temperature. After complete conversion to a lower
running spot on TLC the reaction was diluted with 100 mL EtOAc and
poured in 100 mL 1M HCl. The layers were separated and the or-
ganic layer was washed twice with H2O and once with brine. Subsequently the EtOAc
layer was dried and concentrated in vacuo. Flash silica column purification (EtOAc/PE
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CHAPTER 3
30%) yielded compound 161 in quantitative yield (1.02 g, 2.69 mmol) as a white foam.
TLC: EtOAc/PE 40%; 1H NMR (400 MHz, CDCl3) δ 7.43-7.26 (m, 10H, CHarom Bn ), 5.26
(d, J = 2.9 Hz, 1H, H-1α), 4.90-4.75 (m, 4H, CH2 Bn), 4.58-4.53 (m, 1H, H-1β ), 4.42-4.33
(m, 3H, CH2 H-6), 4.14 (m, 1H, CH2 H-6), 4.03 (m, 2H, H-5), 3.98-3.87 (m, 2H, H-3), 3.51-
3.39 (m, 4H, H-4, CH, iProp.), 3.36 (m, 2H, H-2), 2.08 (m, 6H, CH3 Ac), 1.23-1.16 (m, 6H,
CH3 iProp), 1.13 (m, 6H, CH3 iProp);
13C NMR (100 MHz, CDCl3) δ 171.3 (Cq, Ac), 137.7
(Cq), 137.64 (Cq), 128.5-127.9 (CHarom Bn), 96.2 (C-1β ), 91.8 (C-1α), 83.2 (CHβ iProp), 80.3
(CHα iProp), 75.8 (CH2 Bn), 75.7 (CH2 Bn), 75.1 (C-4α, 74.5 (C-4β ), 73.4 (C-3β ), 73.2 (C-
3α), 73.2 (C-5α), 69.2 (C-5β ), 67.6 (C-2β ), 64.1 (C-2α), 63.0 (C-6α/β ), 62.9 (C-6α/β ), 23.1 (CH3
Acα/β ), 23.1 (CH3 Acα/β ), 22.0 (CH3 iProp), 20.9 (CH3 iProp); IR (neat) ν 2922.0, 2108.1,
1739.7, 1363.6, 1224.7, 1026.1, 1010.6, 966.3, 914.2, 740.6, 696.3; HRMS: C18H25N3O6+Na
+










A solution of compound 161 (1.02 g, 2.69 mmol) and trichloro-
acetonitrile (0.809 mL, 8.07 mmol, 3 equiv) in dry 15 mL DCM was
treated with 1,8-diazabicyclo[5.4.0]undec-7-ene 83 µL (0.54 mmol,
0.2 equiv) for 18 h at ambient temperature. The dark brown solu-
tion was concentrated under reduce pressure and directly purified
using a silica gel column (EtOAc/PE 12.5% + 2.5% TEA) to obtain
the title compound 146 as a yellow oil (0.986 g, 1.88 mmol, 70%). TLC: EtOAc/PE 30%; 1H
NMR (400 MHz, (d4), MeOD) δ 8.77 (s, 1H, NH), 7.42-7.25 (m, 5H, CHarom Bn), 6.40 (d, J =
3.5 Hz, 1H, H-1α), 4.89 (q, J = 10.6 Hz, 2H, CH2 Bn), 4.34 (dd, J = 12.1, 2.1 Hz, 1H, H-5, 4.18
(dd, J = 12.1, 4.4 Hz, 1H, H-6), 3.97 (m, 1H, CH, iProp), 3.92 (m, 2H, H-3, H-4), 3.63 (dd, J =
10.2, 3.6 Hz, 1H, H-6), 3.60-3.53 (m, 1H, H-2), 2.03 (s, 3H, CH3 Ac), 1.21 (d, J = 6.1 Hz, 3H,
CH3 iProp), 1.13 (d, J = 6.1 Hz, 3H, CH3 iProp);
13C NMR (100 MHz, (d4), MeOD) δ 170.3
(Cq, C=N), 160.4 (Cq, Ac), 137.4 (Cq), 128.3-127.8 (CHarom Bn), 94.4 (C-1), 90.7 (CCl3), 80.2
(iProp), 75.6 (Cq, CH2 Bn), 74.5 (C-4), 73.2 (C-3), 72.0 (C-5), 63.0 (C-2), 62.2 (C-6), 22.9 (CH3
iProp), 21.9 (CH3 iProp), 20.6 (CH3 Ac); IR (neat) ν 2110.0, 1741.6, 1674.1, 1234.4, 1139.9,
1018.3, 966.3, 908.4, 794.6, 729.0, 644.2.
1,6-Anhydro-2-azido-3-O-benzyl-2-deoxy-4-O-(6-O-acetyl-2-azido-3-O-benzyl-2-











A mixture of imidate 146 (761 mg, 1.45 mmol) and alcohol 148
(803 mg, 2.9 mmol, 2 equiv) was coevaporated thrice with tolu-
ene and dissolved in 7.25 mL of dry toluene. To this mixture ac-
tivated molecular sieves (4Å) were added and the solution was
cooled to -78 ◦C. After 10 minutes a solution of BF3 ·Et2O (37 µL,
0.3 mmol, 0.2 equiv) in dry toluene (0.7 mL) was added and the
temperature was allowed to rise to -20 ◦C in 90 minutes. TLC analysis showed complete
conversion of imidate 146 into a lower running spot. The reaction was quenched using
TEA (0.5 mL), filtered and concentrated in vacuo. The excess of acceptor was acetylated,
using an Ac2O-pyridine cocktail (1 mL/3 mL), after which the reaction was quenched us-
ing MeOH and concentrated. The oily residue was directly purified using a silica gel col-
umn (EtOAc/PE 40%). Compound 143 was obtained in 81% in 1:5 α:β ratio (755 mg, 1.18
mmol). TLC: EtOAc/Tol 40%; 1H NMR (400 MHz, CDCl3) δ 7.39-7.12 (m, 12H, CHarom Bn),
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5.52 (s, 1H, H-1α), 5.49 (s, 1H, H-1β ), 4.87-4.75 (m, 2H, CH2 Bn ), 4.69 (t, J = 5.7 Hz, 1H,
H-5β ), 4.63 (dd, J = 14.8, 7.5 Hz, 2H, CH2 Bn), 4.40-4.32 (m, 2H, CH2, H-6’β , H-1β ), 4.12
(d, J = 7.1 Hz, 2H, CH2, H-6β ), 4.09-4.02 (m, 1H, CH2, H-6’β ), 4.00-3.86 (m, 2H, H-4’β ,
H-3β ), 3.77 (m, 2H, CH2, H-6β , H-4β ), 3.50-3.37 (m, 2H, H-2’β , H-5’β ), 3.33-3.15 (m, 3H,
H-3’β , Hβ , CH, iProp), 2.05 (m, 3H, CH3 Ac), 1.99 (s, 3H, CH3 Ac), 1.18 (m, 3H, CH3 iProp),
1.14-1.07 (m, 3H, CH3 iProp);
13C NMR (100 MHz, CDCl3) δ 170.7 (Ac), 137.8 (Cq), 128.7-
127.7 (CHarom Bn), 102.4 (C-1’), 100.7 (C-1), 83.2 (iProp), 77.3 (C-4) 76.9 (C-4’), 75.9 (CH2
Bn), 74.8 (C-5), 74.2 (C-5’), 73.7 (C-3’), 73.3 (C-3), 72.5 (CH2 Bn), 66.1 (C-2’), 65.1 (C-6),
62.6 (C-6’), 59.3 (C-2), 23.2 (CH3 iProp), 22.1 (CH3 iProp), 20.8 (CH3 Ac); IR (neat) ν 2102.3,
1735.8, 1238.2, 1068.5, 1028.0, 906.5, 727.1, 646.1, 624.9; HRMS: C31H38N6O9+Na
+ requires
661.2592, found 661.2592; [α]23
D
19.4 ◦(c = 1, CHCl3).
1,6-Anhydro-2-azido-3-O-benzyl-2-deoxy-4-O-(2-azido-3-O-benzyl-2-deoxy-4-O-











Disaccharide 143 (755 mg, 1.18 mmol) was dissolved in
MeOH (7 mL) and a catalytic amount of NaOMe (30% in
MeOH) was added. The reaction mixture was stirred for
1 h at ambient temperature, after which it was neutralized
(pH∼7) using Amberlite R© IR-120 H+ resin. Filtering off the
resin, concentration and purification using a short silica col-
umn (EtOAc/PE 25%) yielded title compound 164 as a clear oil (415 mg, 0.70 mmol, 59%).
TLC: EtOAc/Tol 40%; 1H NMR (400 MHz, CDCl3) δ 7.40-7.26 (m, 10H, CHarom Bn ), 5.48 (s,
1H, H-1’β ), 4.86-4.76 (m, 2H, CH2 Bn), 4.73-4.66 (m, 2H, CH2 Bn), 4.57 (d, J = 12.3 Hz, 1H,
H-5), 4.26 (d, J = 8.0 Hz, 1H, H-1), 4.13 (d, J = 7.3 Hz, 1H, H-6), 3.96-3.90 (m, 1H, H-3), 3.89
(s, 1H, H-4’), 3.81-3.75 (m, 1H, H-4), 3.72 (s, 1H, H-6), 3.64 (d, J = 2.9 Hz, 2H, CH2, H6’),
3.47-3.38 (m, 2H, H2, H5′ ), 3.31 (s, 1H, CH, iProp), 3.28-3.21 (m, 1H, H-3’), 3.06 (dt, J = 9.6,
3.2 Hz, 1H, H-2’), 1.28-1.23 (m, 6H, 2x CH3 iProp);
13C NMR (100 MHz, CDCl3)δ 137.9 (Cq),
137.3 (Cq), 128.8-127.8 (CHarom Bn), 102.3 (C-1’), 100.4 (C-1), 83.0 (iProp), 78.0 (C-4), 75.9
(C-4’, C-5), 75.8 (CH2 Bn), 74.8 (C-5), 74.2 (C-3), 73.3 (C-3’), 72.4 (CH2 Bn), 66.3 (C-2’), 65.2
(C-6), 61.4 (C-6), 59.1 (C-2), 23.0 (CH3 iProp), 22.4 (CH3 iProp); IR (neat) ν 2972.1, 212.3,
1454.2, 1259.4, 1070.4, 1026.1, 1004.8, 964.3, 896.8, 867.9, 696.3; HRMS: C29H36N6O8+Na
+
requires 619.2487, found 619.2484; [α]23
D
-10.8 ◦(c = 0.5, CHCl3).
2-Azido-3-O-benzyl-2-deoxy-1,6-di-O-acetyl-4-O-(2-azido-3-O-benzyl-2-deoxy-4-O-













To a solution of compound 164 (0.95 mg, 160 µmol) in
Ac2O (1.5 mL) was treated TFA (0.30 mL, 15% v/v). The
reaction was stirred for 18 h after which it was diluted
with toluene and concentrated. After purification using
silica gel chromatograph (EtOAc/PE 30%) disaccharide
167 was obtained in 96% yield (92 mg, 154 µmol) as transparent foam. TLC: EtOAc/PE
60%; 1H NMR (400 MHz, CDCl3) δ 7.40-7.24 (m, 15H, CHarom Bnα/β ), 6.19 (d,J = 3.7 Hz,
1H, H-1α), 5.45 (d, J = 8.1, Hz, 1H, H-1β ), 5.14-4.98 (m, 1H, CH2 H-6’), 4.90-4.70 (m, 3H,
CH2 Bn, H-6’), 4.54-4.35 (m, 2H, CH2 Bn), 4.35-4.29 (m, 1H, H-1’), 4.26-4.19 (m, 1H, CH2
H-6), 4.10-4.01 (m, 1H, CH2 H-6), 3.95 (dd, J = 9.8, 5.0 Hz, 1H, H-5), 3.94-3.84 (m, 2H,
H-3, H-4), 3.58-3.51 (m, 1H, H-2), 3.47-3.26 (m, 5H, CH, iProp, H-2’/3’/4’/5’), 2.19-2.14
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(m, 3H, CH3 Ac), 2.11 (s, 3H, CH3 Ac), 1.88 (s, 3H, CH3 Ac), 1.17 (d, J = 6.1 Hz, 3H, CH3
iProp), 1.09 (d, J = 6.1 Hz, 3H, CH3 iProp);
13C NMR (100 MHz, CDCl3) δ 170.6 (Cq, Ac),
170.5 (Cq, Ac), 168.8 (Cq, Ac), 138.2 (Cq), 137.6 (Cq), 128.6-127.5 (CHarom Bn), 101.5 (C-1’),
90.2 (C-1), 83.6 (C-3’), 78.4 (C-4/5), 77.1 (C-4/5), 76.0 (C-6’), 75.1 (CH2 Bn), 74.3 (C-5’),
73.7 (C-4’), 73.1 (iProp), 71.1 (C-3), 67.1 (C-2’), 62.8 (C-6), 62.3 (C-2), 62.2 (CH2 Bn), 23.1
(CH3 iProp), 22.1 (CH3 iProp), 21.0 (CH3 Ac), 20.9 (CH3 Ac); IR (neat) ν 2110.0, 1737.7,
















Compound 167 (90 mg, 0.15 mmol) was taken up in a
mixture of dioxane/toluene/H2O (5/2/1, v/v/v, 3 mL)
and cooled with an ice-bath. After 10 minutes 1M PMe3
(0.7 mL) intoluene was added and the reaction was
stirred for 18 h at+4 ◦C. After TLC analysis showed con-
version towards lower running, ninhydrin positive spot, the reaction was coevaporated
thrice with toluene and subsequently acetylated using an Ac2O-pyridine cocktail (1 mL/3
mL). The mixture was stirred for 20 h after which it was quench with MeOH and concen-
trated under reduced pressure. The resulting white solid was dissolved in a 1:1 mixture of
MeOH and TFE (6 mL) and purged with argon. A catalytic amount of Pd(OH)2 spiked with
Pd-black was added and the mixture was purged with H2. Reduction of the benzyl-groups
was continued for 5 h followed by filtration and concentration. The residue was again
taken up in an Ac2O-pyridine cocktail (0.5 mL/1.5 mL) with a catalytic amount of DMAP
and stirred at ambient temperature for 18 h. After complete acetylation of the disaccharide
the mixture was quenched with MeOH and concentrated under reduced pressure. Silica
gel purification (MeOh/DCM 3%) yielded 37 mg (55 µmol, 36%, 71% per step) of the ti-
tle compound 140 as an off-white solid. TLC: MeOH/DCM 5%; 1H NMR (400 MHz,(d4),
MeOD) δ 7.83-7.61 (m, 2H, NH), 6.04 (d, J = 3.6 Hz, 1H, H1′α), 5.65 (d, J = 8.6 Hz, 1H, H1′β ),
5.24 (dd, J = 10.9, 8.9 Hz, 1H), 5.13 (dd, J = 9.9, 8.4 Hz, 1H), 5.04 (dd, J = 10.5, 8.2 Hz,
1H), 4.61-4.54 (m, 2H), 4.47-4.27 (m, 4H), 4.28-4.07 (m, 4H), 3.97 (m, 1H), 3.83 (m, 4H),
3.73-3.65 (m, 2H), 3.57-3.48 (m, 3H), 3.37-3.32 (m, 2H), 2.20 (s, 3H, CH3), 2.17-2.01 (m, 3H,
CH3), 1.95-1.90 (m, 9H, CH3), 1.10 (dd, J = 6.1, 2.1 Hz, 8H, CH3 iProp);
13C NMR (100 MHz,
(d4), MeOD) δ 171.75, 171.61, 171.04, 170.82, 170.53, 170.47, 170.15, 169.32, 169.26, 100.67,
100.29, 91.70, 90.05, 75.26, 74.98, 74.78, 74.65, 73.27, 73.20, 73.14, 72.79, 72.56, 70.71, 70.15,
62.60, 62.12, 61.83, 54.16, 52.20, 50.46, 48.73, 48.52, 48.30, 48.09, 47.88, 47.66, 47.45, 22.17,
21.93, 21.61, 21.51, 20.04, 19.98; IR (neat) ν 1733.9, 1652.9, 1558.4, 1396.4, 1224.7, 1031.8,
1031.8, 908.4, 727.1, 646.1; HRMS: C296H44N2O16+Na


















Dimer 140 (30 mg, 44µmol) was dissolved
in AcOH (2 ml) and Ac2O (1 ml). At 0
◦C
dry HCl(g ) was bubbled through (liberated
under Kipp conditions) for 3h. The reac-
tion mixture was then placed at 5 ◦C for
42 h at which TLC analyses (DCM-acetone
60-40) showed complete consumption of starting material. The reaction diluted with
CHCl3 (10 ml, 0 ◦C) and washed twice with H2O (15 ml, 0
◦C) and twice with NaHCO3
(15 ml, 0 ◦C). The organic layer was dried over MgSO4 and concentrated in vacuo yield-
ing an amorphous solid of which purity was evaluated by 1H-NMR. The resulting solid
α-chloride was dissolved in CHCl3 (2 ml) and added to a solution of NaHCO3 0.2M (1 ml),
4-methylumbelliferyl sodium salt 34,35 (43mg, 220 µmol, 5 equiv) and TBAHS (29 mg, 88
µmol, 2 equiv). The biphasic mixture was stirred overnight with the exclusion of light.
The phases were separated and the organic layer was washed twice with NaHCO3 (0.2 M)
and twice with H2O. The organic layer was dried over MgSO4 and concentrated in vacuo.
Purification by column chromatography (MeOH/CHCl3 3%)yielded 170 (6 mg, 17 %) as
a white amorphous solid. TLC: MeOH/DCM 5%; 1H NMR (400 MHz, (d4), MeOD) δ 7.62
(s, 1H, CH, 4-methylumbelliferyl), 7.01-6.95 (m, 2H, CHarom 4-methylumbelliferyl), 6.21 (s,
1H, CHarom 4-methylumbelliferyl), 5.25 (t, J = 9.3 Hz, 2H, H-11β , H-3), 5.14-5.00 (m, 1H,
H-3’), 4.61 (d, J = 8.4 Hz, 1H, H-1’β ), 4.49 (dd, J = 11.2, 9.5 Hz, 1H, CH2 H-6’), 4.34 (dd,
J = 19.6, 7.1 Hz, 1H, CH2 H-6’), 4.27-4.11 (m, 3H, CH2 H-6, H-2), 3.96-3.90 (m, 1H, H-5),
3.83 (dd, J = 18.6, 9.5 Hz, 2H, H-4, H-2’), 3.71 (dt, J = 12.1, 6.0 Hz, 1H, CH, iProp), 3.54 (t,
J = 7.2 Hz, 2H, H-4’, H-5’), 2.46 (s, 3H, CH3 4-methylumbelliferyl), 2.17-2.03 (m, 12H, CH3
4xAc), 1.94 (d, J = 6.4 Hz, 6H, CH3 2xAc), 1.10 (dt, J = 13.1, 6.5 Hz, 6H, CH3 iProp);
13C NMR
(100 MHz, (d4), MeOD) δ 171.8-170.1 (Cq, 6xAc), 161.5-153.3 (Cq, 4-methylumbelliferyl),
125.5 (CHarom 4-methylumbelliferyl), 114.7 (Cq, 4-methylumbelliferyl), 113.7 (CHarom 4-
methylumbelliferyl), 111.8 (Carom, 4-methylumbelliferyl), 103.2 (C-1’), 100.4 (C-1), 97.4
(C-4’), 75.7 (C-4), 74.6- 72.6 (C-3/3’/5/5’/CH), 62.5 (C-6’), 62.3 (C-6), 54.2 (C-2’), 53.3 (C-
2), 22.0-21.4 (CH3 4xAc), 19.8 (CH3 iProp, Ac), 17.7 (CH3 Ac); IR (neat) ν 2933.5, 1743.5,
















To a suspension of 170 (6mg, 7 µmol) in
MeOH (1 mL) was added NaOMe (30 wt%
in MeOH) (86 µL, 0.4 µmol). The reac-
tion was stirred with the exclusion of light.
When LCMS (gradient 0 to 50 % MeOH)
showed complete conversion to product
the mixture was quenched with AcOH (20 µL, 350 µmol). The reaction was diluted with
H2O (2 mL) the MeOH was evaporated in vacuo and the remaining H2O was lyophilized.
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Purification by HPLC (gradient H2O-MeOH + 0.1% TFA 80-20 → 60-40) evaporation of
MeOH and lyophilizing H2O yielded 137 (2.6 mg, 60%) as white fluffy solid.
1H NMR (600
MHz, (d6) DMSO)δ 7.9 (d, J = 9.1 Hz, 1H, NH), 7.8 (d, J = 9.2 Hz, 1H, NH), 7.7 (d, J = 8.8 Hz,
1H, 4-methylumbelliferyl), 7.0 (d, J = 2.4 Hz, 1H, 4-methylumbelliferyl), 6.9 (dd, J = 8.8,
2.4 Hz, 1H, 4-methylumbelliferyl), 6.3 (d, J = 1.1 Hz, 1H, 4-methylumbelliferyl), 5.2 (d, J =
8.5 Hz, 1H, H1β ), 5.1 (d, J = 6.5 Hz, 1H, OH), 4.8 (s, 1H, OH), 4.8 (d, J = 2.3 Hz, 1H, OH), 4.7
(s, 1H, OH), 4.4 (s, 1H, OH), 3.4 (m, 13H), 2.4 (d, J = 0.9 Hz, 3H, CH3 4-methylumbelliferyl),
1.9 (s, 3H, CH3 Ac), 1.8 (s, 3H, Ac), 1.1 (d, J = 6.1 Hz, 3H, CH3 iProp), 1.1 (d, J = 6.1 Hz,
3H, CH3 iProp);
13C NMR (151 MHz, (d6, DMSO) δ 169.3, 169.3, 160.2, 159.9, 154.5, 153.4,
126.6, 114.4, 113.5, 111.9, 103.2, 102.1, 98.3, 80.9, 76.0, 75.9, 75.1, 74.2, 72.3, 71.9, 55.8, 54.4,
23.2, 23.1, 22.3, 18.2; HRMS: C29H40N2O13+Na







Compound 148 (1.7 g, 6.0 mmol) was dissolved in 30 mL DMF
and cooled using an ice-bath and after stirring for 5 minutes NaH
(60% dispersion in mineral oil) (0.6 g, 15 mmol, 2.5 equiv) was
added. After 30 minutes the gas evolvement stopped and (bro-
momethyl)cyclohexane (4.18 mL, 30 mmol, 5 equiv) was added drop-
wise. The reaction was quenched with MeOH after 3 h. The reaction mixture was concen-
trated. The residue was taken up in Et2O and washed twice with 1M HCl(aq ). The organic
layer was dried with MgSO4 and concentrated in vacuo. The oily residue was re-dissolved
in 25 mL DMF and cooled using an ice-bath. The alkylation step was repeated three times.
After four cycles the oil compound was purified using a short silica column (EtOAc/PE
10%) which gave product 156 as yellow oil (1.7 g, 4.5 mmol, 75%). TLC: EtOAc/PE 30%; 1H
NMR (400 MHz, CDCl3) δ 7.35 (s, J = 29.7 Hz, 5H, CHarom Bn), 5.47 (s, 1H, H-1), 4.64 (q,
J = 12.1 Hz, 3H, CH2 Bn, H-5), 4.04 (d, J = 5.7 Hz, 1H, CH2, H-6), 3.76 (s, 1H, CH2 H-6),
3.60 (s, 1H, H-3), 3.30-3.15 (m, 4H, CH2, MCH, H-2, H-4), 1.66 (t, J = 26.2 Hz, 3H, CH2, CH,
MCH), 1.32-1.08 (m, 2H, CH2, MCH), 0.97-0.87 (m, 2H, CH2, MCH);
13C NMR (100 MHz,
CDCl3) δ 137.5 (Cq, Bn), 128.7-127.9 (CHarom Bn), 100.7 (C-1), 78.0 (C-4), 76.4 (C-3), 75.8
(CH2, MCH), 74.5 (C-5), 72.6 (C-6), 65.6 (C-2), 60.2 (MCH), 38.0 (CH2, MCH), 26.7(CH2,
MCH), 25.9(CH2, MCH); IR (neat) ν 2927.1, 2357.3, 2101.4, 1731.9, 1275.7, 1091.6, 710.4,
316.1; HRMS: C20H27N3O4 +Na
+ requires 396.1894, found 396.1892; [α]23
D










Oil 156 (1.50g, 4 mmol) was taken up in Ac2O (20 mL) and
cooled with an ice bath. To this cooled solution TFA (2mL, 10%
v/v) was added and the reaction was stirred overnight at room
temperature. After complete conversion of the starting material
the reaction was diluted with toluene and coevaporated. Purifi-
cation using a short silica column (EtOAc/PE 7%) gave compound 159 in 72% yield (1.37 g,
2.88 mmol). TLC: EtOAc/PE 25%; 1H NMR (400 MHz,CDCl3) δ 7.46 - 7.28 (m, 6H, CHarom
Bnα/β ), 6.20 (d, J = 3.6 Hz, 1H, H-1α), 5.45 (d, J = 8.2 Hz, 1H, H-1β ), 4.89-4.79 (m, 3H, CH2
Bn), 4.31-4.19 (m, 3H, H-6α/β ), 3.90-3.80 (m, 2H, H-5α/β , H-3α/β , H-4α/β ), 3.72-3.64 (m, 1H,
CH2, MCH), 3.58-3.30 (m, 3H, H-2α/β , H-4α/β , H-3α/β ),3.24 (dt, J = 14.7, 7.4 Hz, 1H, CH2,
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MCH), 2.17 (s, 1H, CH3 OAcβ ), 2.16 (s, 3H, CH3 Acα), 2.08 (s, 4H, Acα/β ), 1.82-0.83 (m, 16H,
CH2, MCH);
13C NMR (100 MHz, CDCl3) δ 170.7 (Cq, Ac), 169.0 (Cq, Ac), 168.9 (Cq, Ac),
137.7(Cq), 137.7 (Cq), 128.6-128.2 (CHarom Bn), 92.8 (C-1β ), 90.5(C-1α), 83.1 (C-4β ), 80.4
(C-4α), 79.5 (CH2, MCH), 79.3 (CH2, OMCH), 78.0 (C-3α), 77.7 (C-3β ), 75.8 (CH2 Bn), 75.7
(CH2 Bn), 74.3 (C-5β ), 71.6 (C-5α), 65.1 (C-2β ), 62.7 (C-2α), 62.7 (C-6β ), 62.6 (C-6α), 38.9
(CH), 38.8 (CH), 30.3-25.9 (CH2, MCH), 21.1 (CH3), 21.1 (CH3 Ac), 21.0 (CH3 Ac), 20.9 (CH3
Ac); IR (neat) ν 2922.0, 2108.1, 1743.5, 1369.4, 1217.0, 1136.0, 1026.1, 1008.7, 931.6, 734.8,
698.2; HRMS: C24H33N3O7+Na









Compound 159 (1.31 g, 2.77 mmol) was dissolved in THF (14 mL)
and piperidine (840 µL, 6% v/v) was added. The clear solution
was stirred overnight at room temperature. After complete con-
version to a lower running spot on TLC the reaction was diluted
with EtOAc (100 mL) and poured in 1M HCl (100 mL). The layers
were separated and the organic layer was washed twice with H2O and once with brine.
Subsequently the EtOAc layer was dried and concentrated in vacuo. Flash silica column
purification (EtOAc/PE 8%) yielded compound 162 in 98% yield (1.23 g, 2.83 mmol) as a
white foam. TLC: EtOAc/PE 25%; 1H NMR (400 MHz, CDCl3) δ 7.44-7.28 (m, 10H, CHarom
Bnα/β ), 5.27 (t, J = 3.1 Hz, 1H, H-1α), 4.89-4.77 (m, 4H, CH2Bnα/β ), 4.57 (d, J = 4.3 Hz, 1H,
H-1β ), 4.38-4.31 (m, 2H, H-6α/β ), 4.25-4.13 (m, 3H, H-6α/β , H-5β ), 4.07 (dtd, J = 6.4, 4.5,
2.3 Hz, 1H, H-5α ), 3.98-3.90 (m, 2H, H-4α/β ), 3.68 (dt, J = 14.4, 6.5 Hz, 2H, CH2), 3.56-3.51
(m, 1H, CH2), 3.47 (m, 1H, CH), 3.41-3.21 (m, 4H, CH2, H-2α/β ), 2.09 (s, 2H, H-3α/β ), 2.08 (s,
3H, CH3 OAc), 1.90-0.77 (m, 3H, CH3 OAc), 1.80-0.83 (m, 22H, CH2, CH, MCH);
13C NMR
(100 MHz, CDCl3) δ 171.0 (Cq, OAc), 137.9 (Cq, OBn), 137.9 (Cq), 128.6- 128.1 (CHarom Bn),
96.2 (C-1β ), 92.1 (C-1α), 83.1 (C-4β ), 80.0 (C-4α), 79.24 (CH2, MCH), 78.71 (C-3α), 78.05 (C-
3β ), 75.67 (CH2 Bn), 75.60 (C-5β ), 73.5 (C-5α), 69.4 (C-2β ), 67.5 (C-2β ), 64.1 (C-6α/β ), 63.2
(CH2), 63.1 (CH2), 47.6 (CH), 42.8- 24.5 (CH2, MCH), 21.4 (CH3 Ac), 21.0 (CH3 Ac): Peak as-
signment based on chemical shift because couplings are inconclusive; IR (neat) ν 2922.0,
2852.5, 2106.1, 1741.6, 1616.2, 1450.4, 1363.6, 1234.4, 1116.7, 1082.0, 1033.8, 910.3, 736.8,
698.2; HRMS: C22H31N3O6+Na










A solution of compound 162 (1.18 g, 2.72 mmol) and trichloro-
acetonitrile (1.03 mL, 8.16 mmol, 3 equiv) in dry DCM (14
mL) was treated with 1,8-diazabicyclo[5.4.0]undec-7-ene 81
µL (0.54 mmol, 0.2 equiv) for 18 h at ambient temperature.
The dark brown solution was concentrated under reduced
pressure and the brown oil was directly purified using a sil-
ica gel column (EtOAc/PE 7.5% + 2.5% TEA) to obtain the title compound 147 as a yellow
oil (1.11 g, 1.93 mmol, 71%). TLC: EtOAc/PE 30%; 1H NMR (400 MHz, CDCl3) δ 8.77 (s, 1H,
NH), 7.43-7.25 (m, 5H, CHarom Bn), 6.38 (d, J = 3.5 Hz, 1H, H-11α), 5.62-5.58 (m, 1H, H-1β ),
4.91-4.82 (m, 2H, CH2 Bn), 4.35-4.19 (m, 2H, CH2 H-6), 4.01-3.90 (m, 2H, CH2, MCH), 3.70
(dt, J = 10.9, 5.5 Hz, 1H, H-4), 3.64-3.57 (m, 1H, H-5), 3.49-3.38 (m, 1H, H-2), 3.25 (dt, J =
12.7, 6.3 Hz, 1H, H-3), 2.08-2.02 (m, 3H, CH3 Ac), 1.82-1.61 (m, 4H, CH2, MCH), 1.60-1.46
51
CHAPTER 3
(m, 1H, CH, MCH), 1.28-1.11 (m, 4H, CH2, MCH), 1.01-0.86 (m, 2H, CH2, MCH);
13C NMR
(100 MHz, CDCl3) δ 170.2 (Cq, C=N), 160.4 (Cq, Ac), 137.5 (Cq), 128.3-127.8 (C-1), 94.5 (Cq,
CCl3), 79.8 (C-3/4/5), 79.2 (CH2, MCH), 77.9 (C-3/4/5), 75.3 (CH2 Bn), 71.8 (C-3/4/5), 62.7
(C-2), 62.2 (C-6), 38.5 (MCH), 30.0-25.6 (CH2, MCH), 20.6 (CH3 Ac); IR (neat) ν 2106.1,
1739.7, 1652.9, 1506.3, 1232.4, 110.9, 1004.8, 904.6, 835.1, 698.2.
1,6-Anhydro-2-azido-3-O-benzyl-2-deoxy-4-O-(6-O-acetyl-2-azido-3-O -benzyl-2-











A mixture of imidate 147 (1.09 g, 1.87 mmol) and alcohol
148 (1.04 g, 3.76 mmol, 2 equiv) was coevaporated thrice
with toluene and dissolved in dry toluene (9.5 mL). To this
mixture activated molecular sieves (4Å) were added and the
solution was cooled to -78 ◦C. After 10 minutes a solution of
BF3 ·Et2O (47 µL, 0.374 mmol, 0.2 equiv) in 0.25 mL dry tol-
uene was added and the temperature was allowed to rise
to -20 ◦C in 90 minutes. TLC analysis showed complete conversion of imidate 147 into a
lower running spot. The reaction was quenched using TEA (0.5 mL), filtered and concen-
trated in vacuo. The excess of acceptor was acetylated, using an Ac2O-pyridine cocktail
(1 mL/3 mL), after which the reaction was quenched using MeOH and concentrated. The
oily residue was directly purified using a silica gel column (EtOAc/PE 10%). Compound
144 was obtained in 65% in 1:8 α:β ratio (0.845 g, 1.22 mmol). TLC: EtOAc/Tol 25%; 1H
NMR (400 MHz, CDCl3) δ 7.42-7.23 (m, 10H, CHarom Bn), 5.55 (s, 1H, H-1α), 5.49 (s, 1H,
H-1β ), 4.87-4.74 (m, 2H, CH2 Bn), 4.72-4.56 (m, 3H, CH2 H-6’, H-5’), 4.37-4.30 (m, 3H, CH2
Bn, H-1), 4.20-3.99 (m, 2H, CH2 Bn, H-6), 3.96 (s, 1H, H-3), 3.80-3.44 (m, 3H, CH2 H-6,
MCH, H-5’), 3.34-3.20 (m, 5H, CH2, MCH, H-2, H-3’, H-4, H-4’), 2.00 (s, 3H, CH3 Ac), 1.78-
1.45 (m, 5H, CH2, CH, MCH), 1.29-1.09 (m, 4H, CH2, MCH), 0.99-0.84 (m, 2H, CH2, MCH);
13C NMR (100 MHz, CDCl3) δ 170.7 (Cq, Ac), 137.9 (Cq), 137.6 (Cq), 128.8-127.8 (CHarom
Bn), 102.3 (C-1’), 100.7 (C-1), 82.9 (C-3’/4’), 80.1 (C-4’/3’), 79.4 (CH2. MCH), 77.6 (C-5’),
77.4 (C-3), 75.7 (CH2 Bn), 75.0, 74.8 (C-5), 73.6 (C-4), 72.6 (C-6’), 65.9 (C-2’), 65.2 (C-6), 62.7
(CH2 Bn), 59.3 (C-2), 38.8 (MCH), 30.3-25.9 (CH2, MCH), 20.9 (CH3 Ac). IR (neat) ν 2922.0,
2100.3, 1739.7, 1454.2, 1363.6, 1236.3, 1070.4, 1026.1, 1006.8, 964.3, 902.6, 736.8, 696.3;
HRMS: C35H44N6O9+Na
+ requires 715.3062, found 715.3064;[α]23
D
5 ◦(c = 0.2, CHCl3).
1,6-Anhydro-2-azido-3-O-benzyl-2-deoxy-4-O-(2-azido-3-O-benzyl-2-deoxy-4-O-me-











Disaccharide 144 (785 mg, 1.13 mmol) was dissolved in
MeOH (5 mL) and a catalytic amount of NaOMe (30% in
MeOH) was added. The reaction mixture was stirred for 1
h at ambient temperature, after which it was neutralized
(pH∼7) using Amberlite R© IR-120 H+ resin. Filtering off
the resin, concentration and purification using a short sil-
ica column (EtOAc/PE 10%) yielded title compound 165 as
a clear oil (377 mg, 580 µmol, 52%). TLC: EtOAc/PE 30%; 1H NMR (400 MHz, d4, MeOD)
δ .43-7.25 (m, 10H, CHarom Bn), 5.46 (s, 1H, H-1), 4.89-4.78 (m, 2H, CH2 Bn), 4.75-4.62
(m, 3H, CH2 Bn, H-5), 4.56 (d, J = 7.4 Hz, 1H, H-1β ), 4.11 (d, J = 7.3 Hz, 1H, CH2 H-6),
3.93 (d, J = 8.3 Hz, 2H, H-5’, H-3), 3.86-3.67 (m, 3H, CH2, H-6’, H-6), 3.62 (dt, J = 14.0,
7.0 Hz, 1H, CH2, MCH), 3.44-3.28 (m, 5H, CH2, MCH, H-2’, H-3’, H-4’, H-4), 3.23 (s, 1H,
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H-2), 1.75 (dd, J = 30.5, 13.3 Hz, 4H, CH2, MCH), 1.53 (s, J = 2.9 Hz, 1H, CH, MCH), 1.33-
1.11 (m, 4H, CH2, MCH), 1.03-0.87 (m, 2H, CH2, MCH);
13C NMR (100 MHz, d4, MeOD) δ
139.7 (Cq), 139.4 (Cq), 129.5-128.8 (CHarom Bn), 102.7 (C-1’), 101.9 (C-1), 84.4 (C-3’/4’/4),
79.9 (CH2, MCH), 78.9 (C-3’/4’/4), 78.7 (C-3’/4’/4), 77.4 (C-5’/3), 77.3 (C-5’/3), 76.4 (CH2
Bn), 76.0 (C-5), 73.4 (CH2 Bn), 67.6 (C-2’), 66.2 (C-2), 62.0 (C-6), 61.0 (C-2), 40.1 (MCH),
31.3-27.0 (CH2, MCH); IR (neat) ν 2927.8, 2356.1, 2106.1, 1733.4, 1278.3, 1113.0, 1069.4,
708.8, 504.4;HRMS: C33H42N6O8 +Na

















To a solution of compound 165 (377 mg, 580 µmol)
in 3 mL Ac2O 0.45 mL (15% v/v) TFA was added. The
reaction was stirred for 18 h after which it was diluted
with toluene and concentrated. After purification us-
ing silica gel chromatograph (EtOAc/PE 10%) disac-
charide 168 was obtained in 87% yield (400 mg, 505 µmol) as transparent foam. TLC:
EtOAc/PE 25%; 1H NMR (400 MHz, CDCl3) δ 7.44-7.19 (m, 10H, CHarom Bn), 6.19 (d, J =
3.7 Hz, 1H, H1α), 5.50-5.41 (m, 1H, H-1β ), 5.17-4.98 (m, 1H, CH2 Bn), 4.87-4.71 (m, 3H,
CH2 Bn), 4.52-4.43 (m, 1H, CH2 H-6), 4.35 (m, 2H, CH2 H-6, H-1), 4.23-4.17 (m, 1H, CH2
H-6’), 4.14-4.07 (m, 2H, CH2 H-6’, H-3’), 4.00-3.85 (m, 2H, H-3, H-4), 3.64 (dd, J = 8.5, 5.8
Hz, 1H, CH2, MCH), 3.57-3.50 (m, 1H, H-2), 3.44-3.27 (m, 4H, H-2’, H-4, H-5, H-5’), 3.20
(dd, J = 8.4, 7.0 Hz, 1H, CH2, MCH), 2.16 (d, J = 2.4 Hz, 3H, CH3 Ac), 2.10 (s, 3H, CH3 Ac),
1.90 (s, 3H, CH3 Ac), 1.75-1.60 (m, 4H, CH2, MCH), 1.54-1.43 (m, 1H, CH, MCH), 1.27-1.09
(m, 4H, CH2, MCH), 0.96-0.83 (m, 2H, MCH);
13C NMR (100 MHz, CDCl3) δ 170.5 (Cq, Ac),
168.8 (Cq, Ac), 138.2 (Cq), 137.6 (Cq), 128.5-127.4 (CHarom Bn), 101.4 (C-1’), 90.1 (C-1), 83.3
(C-4/5/’4), 79.1 (CH2, MCH), 78.4 (C-3), 77.8 (C-4/5/’4), 77.1 (C-4), 7.7 (CH2 Bn), 75.0 (CH2
Bn), 73.5 (C-4/5/’4), 71.0 (C-3’), 66.8 (C-2’), 62.8 (C-6), 62.2 (C-2), 62.1 (C-6’), 38.7 (MCH),
30.1-25.8 (CH2, MCH), 21.0 (CH3 Ac), 20.8 (CH3 Ac), 20.7 (CH3 Ac); IR (neat) ν 2922.0,
2356.9, 2341.4, 2108.1, 1737.7, 1452.3, 1363.6, 1222.8, 1105.1, 1026.1, 1008.7, 931.6, 823.5,
734.8, 696.3; HRMS: C39H50N6O12+Na
+ requires 817.3379, found 817.3382.
2-Acetamido-2-deoxy-1,3,6-tri-O-acetyl-4-O-(2-acetamido-2-deoxy-3,6-O-di-acetyl-4-












Compound 168 (365 mg, 0.46 mmol) was taken up in
a mixture of dioxane:toluene;H2O (5:2:1, v/v/v, 8 mL)
and cooled with an ice-bath. After 10 minutes PMe3
(2.30 mL, 5 equiv) 1M intoluene was added and the
reaction was stirred for 18 h at+4 ◦C. After TLC anal-
ysis showed conversion towards lower running, ninhydrin positive spot, the reaction was
coevaporated thrice with toluene and subsequently acetylated using an Ac2O-pyridine
cocktail (2 mL/6 mL). The mixture was stirred for 20 h after which it was quench with
MeOH and concentrated under reduced pressure. The resulting white solid was dissolved
in a 1:1 mixture of MeOH and TFE (8 mL) and purged with argon. A catalytic amount of
Pd(OH)2 spiked with Pd-black was added and the mixture was purged with H2. Reduc-
tion of the benzyl-groups was continued for 5 h followed by filtration and concentration.
The residue was again taken up in an Ac2O-pyridine cocktail (2 mL:6 mL) with a catalytic
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amount of DMAP and stirred at ambient temperature for 18 h. After complete acetylation
of the disaccharide the mixture was quenched with MeOH and concentrated under re-
duced pressure. Silica gel purification (MeOH/DCM 3%) yielded 122 mg (170 µmol, 39%,
73% per step) of the title compound 141 as an off-white foam. TLC: MeOH/DCM 5%;
1H NMR (400 MHz, CDCl3) δ 7.44-7.19 (m, 14H), 6.19 (d, J = 3.7 Hz, 1H), 5.50-5.41 (m,
1H), 5.17-4.98 (m, 1H), 4.87 - 4.71 (m, 4H), 4.52-4.43 (m, 1H), 4.35 (m, 3H), 4.23-4.17 (m,
1H), 4.14-4.07 (m, 2H), 4.00-3.85 (m, 3H), 3.64 (dd, J = 8.5, 5.8 Hz, 1H), 3.57-3.50 (m, 2H),
3.44-3.27 (m, 5H), 3.20 (dd, J = 8.4, 7.0 Hz, 1H), 2.16 (d, J = 2.4 Hz, 3H), 2.10 (s, 4H),
1.90 (s, 3H), 1.75-1.60 (m, 7H), 1.54-1.43 (m, 2H), 1.27-1.09 (m, 6H), 0.96-0.83 (m, 3H);
13C NMR (100 MHz, CDCl3) δ 171.3, 171.0-169.09, 102.0, 101.9, 100.9, 92.4, 90.4, 90.3,
82.5, 79.0, 78.8, 76.6, 75.8, 75.6, 75.1, 75.0, 74.8, 73.6, 73.4, 73.1, 72.1, 70.9, 70.7, 69.8, 69.7,
63.0, 62.9, 62.2, 61.7, 54.1, 53.6, 51.9, 51.2, 38.4, 29.9, 29.8, 29.7, 29.7, 26.3, 25.7, 25.7, 23.1,
23.1, 22.9, 21.0, 20.9, 20.8, 20.83, 20.79, 20.77, 20.7, 20.6, 20.6; IR (neat) ν 2925.8, 1739.7,
1652.9, 1558.4, 1521.7, 1506.3, 1369.4, 1220.9, 1112.9, 1012.6, 939.3, 906.5, 715.5; HRMS:
C33H50N2O16+Na















Dimer 141 (70 mg, 95 µmol) was dis-
solved in AcOH (2 mL) and Ac2O (1
mL). At 0 ◦C dry HCl(g ) was bubbled
through (liberated under Kipp condi-
tions) for 3h. The reaction mixture
was then placed at 5 ◦C for 42 h at
which TLC analyses (DCM-acetone 60-40) showed complete consumption of starting ma-
terial. The reaction diluted with CHCl3 (10 ml, 0
◦C) and washed twice with H2O (15 ml,
0 ◦C) and twice with NaHCO3 (15 mL, 0
◦C). The organic layer was dried over MgSO4 and
concentrated in vacuo yielding an amorphous solid of which the purity was evaluated by
1H-NMR. The resulting solid was dissolved in CHCl3 (5 ml) and added to a solution of
NaHCO3 0.2M (5 ml), 4-methylumbelliferyl sodium salt
34,35 (94 mg, 480µmol) and TBAHS
(64 mg, 191 µmol). The biphasic mixture was stirred overnight with the exclusion of light.
The phases were separated and the organic layer was washed twice with NaHCO3 (0.2
M) and twice with H2O. The organic layer was dried over MgSO4 and concentrated in
vacuo. Purification by column chromatography (MeOH/CHCl3 3%) yielded 171 (41 mg,
48 µmol, 50%) as a white amorphous solid. TLC: MeOH/DCM 5%; 1H NMR (400 MHz,
d4, MeOD) δ 7.61 (d, J = 8.4 Hz, 1H, CH, 4-methylumbelliferyl), 7.01-6.95 (m, 2H, CHarom
4-methylumbelliferyl), 6.20 (s, 1H, CHarom 4-methylumbelliferyl), 5.25 (t, J = 8.3 Hz, 2H,
H-1β , H-3), 5.17-5.10 (m, 1H, H-3’), 4.63 (d, J = 8.3 Hz, 1H, H-1’β ), 4.51 (d, J = 10.2 Hz,
1H, CH2 H-6), 4.31 (d, J = 2.7 Hz, 2H, CH2 H-6’), 4.24-4.11 (m, 2H, CH2 H-6, H-2), 3.93
(t, J = 8.3 Hz, 1H, H-5), 3.87-3.74 (m, 2H, H-4, H-2), 3.58 (dd, J = 8.0, 4.9 Hz, 1H, H-5’),
3.48-3.25 (m, 3H, CH2, MCH, H-4’), 2.45 (s, 3H, CH3 4-methylumbelliferyl), 2.14 (s, 6H,
CH3 Ac), 2.10-2.04 (m, 6H, CH3 Ac), 1.96 (d, J = 5.8 Hz, 6H, CH3 Ac), 1.68 (t, J = 11.4
Hz, 4H, CH2, MCH), 1.44 (d, J = 11.2 Hz, 1H, CH, MCH), 1.30-1.09 (m, 4H, CH2, MCH),
0.91 (dd, J = 20.8, 11.9 Hz, 2H, CH2, MCH);
13C NMR (100 MHz, d4, MeOD) δ 171.7-170.1
(Cq, Ac), 161.4 (Cq, 4-methylumbelliferyl), 159.4 (Cq, 4-methylumbelliferyl), 154.2 (Cq, 4-
methylumbelliferyl), 153.3 (Cq, 4-methylumbelliferyl), 125.5 (CHarom 4-methylumbellifer-
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yl), 114.7 (Cq, 4-methylumbelliferyl), 113.6 (CHarom 4-methylumbelliferyl), 111.8 (CHarom
4-methylumbelliferyl), 103.3 (CHarom 4-methylumbelliferyl), 100.4 (C-1’), 97.5 (C-1), 78.2
(CH2, MCH), 75.7-75.7 (C-4/4’), 74.4 (C-3’), 72.6-72.4 (C-3/5/5’), 62.6 (C-6’), 62.3 (C-6),
54.3 (C-2’), 53.3 (C-2), 38.0 (MCH), 29.4-25.2 (CH2, MCH), 21.7-17.6 (CH3 Ac); IR (neat) ν
1739.7, 1652.9, 1539.1, 1521.7, 1488.9, 1473.5, 1369.4, 1222.8, 1012.6, 939.3, 902.6, 628.8;
HRMS:C41H54N2O17+Na
+ requires 869.3315, found 869.3317.
2-Acetamido-2-deoxy-4-O-(2-acetamido-2-deoxy-4-O-methyl-cyclohexane-β -D-gluco-












To a suspension of 171 (20 mg, 23
µmol) in MeOH (1 mL) was added
NaOMe (30 wt% in MeOH) (414 µL,
2.30 µmol). The reaction was stirred
with the exclusion of light. When
LCMS (gradient 0 to 50 % MeOH)
showed complete conversion to product the mixture was quenched with AcOH (5 µL, 80
µmol). The reaction was diluted with H2O (2 mL) the MeOH was evaporated in vacuo and
the remaining H2O was lyophilized. Purification by HPLC (gradient H2O-MeOH + 0.1%
TFA 80-20→ 60-40) evaporation of MeOH and lyophilizing H2O yielded 138 (3.5 mg, 5.16
µmol, 22%) as white fluffy solid. 1H NMR (600 MHz, (d6), DMSO) δ 7.90 (d, J = 9.2 Hz,
1H, NH), 7.74 (d, J = 9.0 Hz, 1H, NH), 7.70 (d, J = 8.8 Hz, 1H, CH, 4-methylumbelliferyl),
7.04 (d, J = 2.3 Hz, 1H, CH, 4-methylumbelliferyl), 6.96 (dd, J = 8.8, 2.3 Hz, 1H CH, 4-
methylumbelliferyl), 6.27 (s, 1H, CH, 4-methylumbelliferyl), 5.18 (d, J = 8.4 Hz, 1H, H-1),
5.06 (d, J = 6.3 Hz, 1H, OH), 4.81 (dd, J = 5.7, 5.0 Hz, 1H, OH), 4.77 (d, J = 2.1 Hz, 1H,
OH), 4.69 (t, J = 6.0 Hz, 1H, OH), 4.38 (d, J = 8.4 Hz, 1H, H1′ ), 3.33 (s, 14H), 3.00 (t, J =
9.2 Hz, 1H), 2.41 (s, J = 9.4 Hz, 3H, CH3 4-methylumbelliferyl), 1.85 (s, 3H, CH3 Ac), 1.81
(s, 3H, CH3 Ac), 1.70-1.59 (m, 4H, CH2, MCH), 1.51-1.44 (m, 1H, CH, MCH), 1.24-1.07 (m,
4H, CH2, MCH), 0.89 (d, J = 12.2 Hz, 2H, CH2, MCH);
13C NMR (151 MHz, (d6), DMSO)
δ 169.2, 169.1, 160.0, 159.9, 154.4, 153.3, 126.5, 114.3, 113.4, 111.9, 103.1, 101.9, 98.2, 80.8,
78.6, 77.6, 75.7, 75.0, 74.0, 72.3, 55.8, 54.4, 38.0, 29.7, 29.4, 26.2, 25.4, 25.3, 23.0, 18.1; HRMS:
C33H46N2O13+Na
+ requires 701.2892, found 701.2890
3.5 Biological Evaluation
Enzymes: Human chitotriosidase was expressed in BHK cells and purified from culture
medium as described earlier. 36 Jack bean β -hexosaminidase was purchased from Sigma.
The tissue was homogenized in 4 volumes of 0.1 M potassium phosphate buffer pH 6.5.
The soluble fraction was isolated following ultracentrifugation at 50.000 g for 20 minutes
and next β -hexosamindidase in the supernatant was enriched using Concanavalin. A
chromotagraphy and elution of bound enzyme with 0.1 mM methylmannose 0.1 M potas-
sium phosphate buffer pH 6.5.
Enzyme activity measurements using artificial 4-MU-substrates: For activity measurements
of β -hexosaminidases, 4-MU-GlcNac (Sigma) was used as substrate. Briefly, samples were
incubated for 20 minutes at 37 ◦C with 2 mM 4-MU-GlcNac in McIlvaine buffer (100 mM
citric acid, 200 mM sodium phosphate, pH 4.0). The reactions were stopped by the addi-
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tion of excess 0.3 M glycine-NaOH, pH 10.3. Formed 4-methylumbelliferone was detected
fluorimetrically (excitation at 366 nm; emission at 445 nm). Activity of recombinant chito-
triosidase towards 4-MU-oligosaccharide substrates was determined by incubation at 37
◦C in McIlvaine buffer (100 mM citric acid, 200 mM sodium phosphate, pH 5.2). Substrate
concentrations in various experiments were different as indicated.
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Design and Synthesis of Chitobiose Based
Prodrugs for Gaucher Disease
4.1 Introduction
GBA1 (β -glucocerebrosidase) is a retaining glycosidase (family 30), which plays
an essential role in the catabolisme of glycosphingolipids (GSL). GBA1 hydrolyses
the β -glycosidic bond in glucosylceramide (GC), to give D-glucose and ceramide.
Inefficient degradation of GC occurs when GBA1 is mutated resulting in accumu-
lation of GC in the lysosomes and is the cause of Gaucher disease, a rare lysosomal
storage disorder (LSD). 1 Accumulation of GC leads to lipid-laden macrophages,
which causes enlargement of organs (spleen and liver) and inflammations. Cur-
rently two therapies for the treatment of Gaucher patients are applied, namely
enzyme replacement therapy (ERT) and substrate reduction therapy (SRT) (see
also chapter 1). 2–7 In ERT a recombinant GBA1 (called Cerezyme) is intravenously
administrated to patients. 8 Some of this functional GBA1 enzyme ends up in the
Gaucher cells where it temporarily restores the degradation of GC. A drawback of
ERT is the intravenous delivery and the high costs of enzyme production. Sub-
strate reduction therapy offers a useful alternative, the inhibition of GCS alters the
influx of GC thereby restoring the influx/efflux balance of GC in Gaucher cells. 9–11
However, monitoring of the respective effect (i.e. optimal dosage and treatment
regimen) of both therapies is needed. This can be done by measuring of serum
chitotriosidase activity, which was found to be directly correlated to the progres-
sion of the disease. 10,12 Chitotriosidase (CHIT1) is the first identified human chiti-
nase and is strongly expressed and secreted by the lipid-laden macrophages found
59
CHAPTER 4
in patients suffering from Gaucher disease. 10,13,14 Chitinases are capable to cleave
natural chitin (a linear polymer of β -1,4-linked-N-acetylglucosamine) and a wide
variety of artificial chitin-like substrates such as 4’-methylumbelliferyl chitobiose
(Chapter 2), which is nowadays used to measure CHIT1 activity. 15
The main side effects of SRT using NB-DNJ 16 as inhibitor are associated with
the inhibition of glycosidases in the intestines, resulting in diarrhea, flatulence
and abnormal bloating. 16 By locally activating the GCS inhibitors, these side ef-
fects can be diminished. This can be achieved by the use of a so called prodrug.
The concept of a prodrug was introduced by Albert, 17 who describes it as a sub-
stance that has to be broken down or altered to give the true/active drug. The lo-
cally elevated activity of CHIT1 in Gaucher patients and its direct correlation with
the progression of the disease, makes CHIT1 a perfect target for site-specific drug
delivery via the prodrug approach.
Enzymatic Clevage
by CHIT1
substrate part drug part
Figure 4.1: Schematic representation of an enzymatic prodrug cleavage. ◦: inactive inhib-
itor ; •: active inhibitor.
The designed prodrugs for Gaucher disease will consist of a substrate part, chi-
tobiose (for prodrugs 174 and 172) or 4’-deoxy chitobiose (for prodrug 173) which
are both known to be cleaved by CHIT1 (Figure 4.2). 12,15 As drug part of the pro-
drugs NB-DNJ (16) and AMP-DNJ (17) will be used, which are both known inhibi-
tors of GCS. 18
Recent studies showed that substitution on the 4-OH of AMP-DNJ 17 gives
rise to less active GCS inhibitors, thereby making this position the perfect site for
linkage with the chitobiose core (CHIT1 substrate). 19 Figure 4.1 shows the in vivo
mode of action of the Gaucher prodrug. Upon enzymatic cleavage of the glycosidic
bond, by CHIT1, the active GCS inhibitor will be liberated.
4.2 Results and Discussion
For the synthesis of chitobiose based prodrugs 172, 173 and 174 a sequential gly-
cosylation strategy was selected (Figure 4.2). In the first glycosylation event the
chitobiose core will be formed (175 or 176) which will be used as CHIT1 substrate
part of the prodrugs. Next the iminosugar (177) will be condensed with the chi-
tobiose core, which will later be decorated with a butyl or AMP chain to form the
GCS inhibitor part (drug part) of the Gaucher prodrugs.
For the synthesis of the chitobiose core 176, imidate 179 was used as donor
and thioglycoside 180 20 as acceptor (Scheme 4.1). The phthaloyl group at the 2-
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positions of both donor and acceptor ensure the formation of 1,2-trans glycosidic
bonds in this and the next coupling of the resulting disaccharide 176 with DNJ
acceptor 177 (Scheme 4.3). Chitobiose donor 175 was synthesized under similar
conditions and used to explore the most productive coupling conditions for the














































R1 = OH, R2 = AMP
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Figure 4.2: Retrosynthetic analysis of potential Gaucher prodrugs 172, 173 and 174.

































Reagents and conditions: a) TMSOTf, DCM, 0 ◦C, (175, 73%; 176, 41%.)
DNJ acceptor 177 was synthesized from known benzylated allyl glucopyrano-
side 181. 22 First, the free hydroxyl function in 181 was protected with the 2’-naph-
thylmethylether (NAP) group (Scheme 4.2). This relatively new protective group
can be cleaved under oxidative conditions (e.g. DDQ or CAN) and is more acid
stable than the more commonly used p-methoxybenzyl group. 23–25
Next, the anomeric allyl group in 182 was isomerized using KOtBu in hot
DMSO. The formed vinyl-ether was hydrolyzed using molecular iodine in
THF:H2O, directly followed by LiAlH4 mediated reduction to yield glucitol 183. Cy-
clization to iminosugar 184 was effected by a two step sequence. First lacitol 183
was oxidized under Swern conditions. Subsequently, the crude di-carbonyl was
subjected to a double reductive amination using an excess of ammonium formate
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R1 = ONAP, R2 = H
R1 = ONAP, R2 = Ns
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Reagents and conditions: a) NAP-Br, NaH, DMF, 0 ◦C, 80%; b) (1) KOtBu, DMSO, 100 ◦C, (2) I2,
THF:H2O, (3) LiAlH4, THF, 71% over three steps; c) (1) DMSO, (COCl)2, DCM, -75
◦C, (2) Et3N, -75
◦C
to rT, (3) NaCNBH3, HCOONH4, Na2SO4, MeOH, 0
◦C, 63%; d) NsCl, pyridine, DCM, 87%, e) DDQ,
DCM:MeOH, 90%.
in MeOH at 0 ◦C under the agency of NaCNBH3 and Na2SO4 yielding DNJ deriva-
tive 184. 26 After protection of the endocyclic nitrogen with 2-nitrobenzenesulf-
onyl (nosyl, Ns), the 4-OH was liberated by deprotection of the NAP-group using
DDQ 23 yielding acceptor 177.







































NIS, TMSOTf, DCM 0oC 60%
Ph2SO, Tf2O, DCM 24%
Ph2SO, Tf2O, DCM 0%*
Ph2SO, Tf2O, TTBP, DCM 0%**
Ph2SO, Tf2O, TTBP, DCM 0%*
TMSOTf, DCM 0oC 34%



















Coupling conditions A: Activation at -60 ◦C, addition of acceptor at -60 ◦C, quenching of the reaction
by addition of Et3N at -30
◦C; B: Activation at -60 ◦C, addition of acceptor at -30 ◦C, quenching of the
reaction by addition of Et3N at 0
◦C; ∗ : Hydrolyzed donor and acceptor recovered; ∗∗: Thiodonor and
acceptor recovered.
To investigate an effective glycosylation method for DNJ acceptor 177, several
coupling procedures were explored, using chitobiose donor 175 (Table 4.1). Acti-
vation of 175 with NIS with a catalytic amount of TMSOTf at 0 ◦C, gave a yield of
60% of the desired trimer 187. The activator dimethyl disulfide-triflic anhydride
(Me2S2−Tf2O), developed by the group of Fügedi,
27 gave a lower yield (40%). In




tem was explored. This however, gave disappointing results with a maximum yield
of 24%. Varying the temperature or addition of the non-nucleophilic base 2,4,6-
tri-tert-butylpyrimidine (TTBP) gave either hydrolysed donors (entry 4 and 6) or
recovery of unreacted starting material (entry 5).
Chitobiose imidate donor 186 used in entry 7 was synthesized by first hydroly-
sis of chitobiose thio donor 175 using NBS in wet acetone at -20 ◦C, after which the
hemiacetal was converted into imidate 186 using CCl3CN and DBU in dry DCM.
The chitobiose imidate donor 186 was coupled to DNJ acceptor 177 using TMSOTf
yielding target trimer 187 in an unsatisfactory yield of 34%.
Because of the structure of trimer 187 also allows a sequential glycosylation
strategy it was of special interest to find out whether the assembly of trisaccharide
187 could also be attained in a one-pot procedure (Figure 4.3). To this end, imi-
date 178 was activated using TMSOTf in the presence of acceptor 180 giving rise
to dimer 175. Subsequent coupling of DNJ acceptor 177 under influence of NIS


























Figure 4.3: One-pot procedure for the synthesis of trimer 187.
To obtain compound 188, disaccharide 176 was condensed with protected
DNJ 177 (Scheme 4.2) using the most productive conditions that were found for
the corresponding glycosylation to give 187 (Table 4.1, entry 1).
In the next event, removal of the nosyl protective group from the endocyclic ni-
trogen was accomplished by an aromatic nucleophilic substitution using thiophe-
nol and K2CO3 (Scheme 4.3). The liberated secondary amine in 189 was alkylated
using 1-bromobutane or 5-(adamantan-1-yl-methanol)-1-bromo-pentane 192 un-
der mild basic conditions (K2CO3, DMF). The crude compounds were deprotected,
by removal of the phthalimide with ethylenediamine in refluxing n-butanol fol-
lowed by acetylation of the free amines. Hydrogenation of the benzyl groups and
purification by HPLC gave target prodrugs 172 and 174. Unfortunately, the prod-
ucts were obtained in low yields (3-4%).
Because of the poor yields in the alkylation reaction, attention was directed to
reductive amination using Pd/C (20%), H2 and aldehyde 193 for the synthesis of
prodrug 173. 26 Apart from successful alkylation of the endocyclic nitrogen, this
reduction also conveniently removed all the benzyl-groups. The crude compound
was further deprotected, by removal of the phthalimide with ethylenediamine in
refluxing n-butanol. To facilitate the ensuing purification the resulting product
was fully acetylated to give 191. Saponification of the acetyl esters with NaOMe in
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Reagents and conditions: a) NIS, TMSOTf, DCM, 0 ◦C, 187 73%; 188 70%; b) HSPh, K2CO3, DMF,
189 75%; 190 85%; c) (1) 192, K2CO3, DMF, 85
◦C; (2) (H2NCH2)2, nBuOH, ∆, (3) Ac2O, pyridine; (4)
Pd/C, H2, EtOH:AcOH, 172 3%; d) (1) 193, Pd/C, H2, dioxane:AcOH, (2) (H2NCH2)2, nBuOH, ∆, (3)
Ac2O, pyridine, 191, 36%; e) NaOMe, MeOH, 173 30%; f) (1) 1-bromobutane, K2CO3, DMF, 85
◦C; (2)
(H2NCH2)2, n-Bu,∆, (3) Ac2O, pyridine; (4) Pd/C, H2, EtOH:AcOH, 174 4%.
MeOH and purification by Dowex
TM
H+ column and HPLC completed the synthe-
sis of target prodrug 173 30% yield. It must be mentioned that the use of freshly
oxidized aldehyde 193, in the reductive amination, is crucial to gain a high yield,
which corroborates with the results reported by Wennekes et al. 26
4.3 Conclusion
This chapter describes the synthesis of three Gaucher prodrugs 172, 173 and 174
in which the chitobiose core is used as CHIT1 substrate and NB-DNJ or AMP-DNJ
is used as GCS inhibitor or drug part. The chitobiose core was synthesized via an
imidate coupling with acceptor 180 bearing a thiophenol group on the anomeric
position, which could be immediately used in the next glycosylation step with a
DNJ acceptor 177. It was found that the NIS/TMSOTf activation method, in dry
DCM, gave the highest yield and the most reproducible results (Table 4.1 entry
1). After poor yields for the alkylation of the endocyclic nitrogen of the iminosu-
gar in 189. A different route was used for the synthesis of 173. By reductive ami-
nation, using 5-(adamantan-1-yl-methoxy)-1-pentanal, compound 190 was con-
verted into prodrug 173 in an improved yield. Key in this reductive amination of
the ring nitrogen is the use of freshly oxidized aldehyde 193.
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The synthesized Gaucher prodrugs will be biologically evaluated to gain in-
sights in the ability of CHIT1 to cleave the chitobiose core from the iminosugar,
resulting in the liberation of the active GCS inhibitors 16 or 17.
4.4 Experimental section
All reagent were of commercial grade and used as received (Acros, Fluka, Merck, Schleicher
& Schuell) unless stated otherwise. Diethyl ether (Et2O), light petroleum ether (PE 40-60),
en toluene (Tol) were purchased from Riedel-de Haën. Dichloromethane (DCM), N,N-
dimethylformamide (DMF), methanol (MeOH), pyridine (pyr) and tetrahydrofuran (THF)
were obtained from Biosolve. THF was distilled over LiAlH4 before use. Dichloromethane
was boiled under reflux over P2O5 for 2 h and distilled prior to use. Molecular sieves 3Å
were flame dried under vacuum before use. All reactions sensitive to moisture or oxygen
were performed under an inert atmosphere of argon unless stated otherwise. Solvents
used for flash chromatography were of pro analysis quality. Flash chromatography was
performed on Screening Devices silica gel 60 (0.004 - 0.063 mm). TLC-analysis was con-
ducted on DC-alufolien (Merck, Kieselgel60, F245) with detection by UV-absorption (254
nm) for UV-active compounds and by spraying with 20% H2SO4 in ethanol or with a so-
lution of (NH4)6Mo7O24 ·4 H2O 25 g/L, (NH4)4Ce(SO4)4 ·2 H2O 10 g/L, 10% H2SO4 in H2O
followed by charring at∼150 ◦C. 1H and 13C NMR spectra were recorded on a Bruker DMX-
400 (400/100 MHz), a Bruker AV 400 (400/100 MHz), a Bruker AV 500 (500/125 MHz) or a
Bruker DMX-600 (600/150 MHz) spectrometer. Chemical shifts (δ) are given in ppm rel-
ative to the chloroform residual solvent peak or tetramethylsilane as internal standard.
Coupling constants are given in Hz. All given 13C spectra are proton decoupled. High
resolution mass spectra were recorded on a LTQ-Orbitrap (Thermo Finnigan) Mass spec-
trometer. LC/MS analysis was performed on a Jasco HPLC-system (detection simultane-
ous at 214 nm and 245 nm) equipped with an analytical Alltima C18 column (Alltech, 4.6
mmD x 50 mmL, 3µ particle size) in combination with buffers A: H2O, B: MeCN and C:
0.5% aq. TFA and coupled to a Perkin Almer Sciex API 165 mass spectrometer. Optical
rotations were measured on a Propol automatic polarimeter. IR spectra were recorded on














Known imidate 178 21 (2.98 g, 4.22 mmol, 1.1 equiv) and
acceptor 180 20 (2.23 g, 3.84 mmol) were coevaporated
thrice with toluene and dissolved in dry DCM (40 mL).
Molecular sieves 3Å were added and the reaction was
cooled to -20 ◦C. After 10 minutes the reaction was ac-
tivated by addition of TMSOTf (76 µL, 0.42 mmol, 0.1 equiv) and was stirred for 3 h al-
lowing the mixture to warm to 0 ◦C. Subsequently, the reaction mixture was quenched
with TEA (0.2 mL), filtered and concentrated in vacuo. Purification using a short silica col-
umn (EtOAc/PE 22.5%) gave 175 in 73% yield as a colorless oil (3.20 g, 2.80 mmol). TLC:
EtOAc/PE 40%; 1H NMR (400 MHz, CDCl3) δ 7.87 - 7.41 (m, 7H), 7.36 - 7.19 (m, 17H), 7.16
- 6.67 (m, 13H), 5.39 - 5.33 (d, J = 9.9 Hz, 1H), 5.32 - 5.28 (d, J = 8.3 Hz, 1H), 4.92 - 4.86
(d, J = 12.7 Hz, 1H), 4.84 - 4.74 (m, 2H), 4.73 - 4.62 (d, J = 11.0 Hz, 1H), 4.55 - 4.35 (m,
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8H), 4.27 - 4.15 (m, 4H), 3.91 - 3.79 (dd, J = 9.9, 8.6 Hz, 1H), 3.79 - 3.60 (m, 2H), 3.57 -
3.30 (m, 4H); 13C NMR (100 MHz, CDCl3) δ 168.5 - 167.3, 138.6- 133.9, 133.7, 132.2, 131.7,
131.5, 128.6 - 127.4, 97.1, 83.4, 79.7, 79.1, 78.9, 77.9, 75.6, 75.2, 74.9, 74.8, 74.7, 73.3, 72.7,
68.4, 68.0, 56.8, 54.8; IR (neat) ν 1774, 1710, 1385, 1070, 1025, 737, 719, 696, 612; HRMS:
C69H62N2O12S+Na
+ requires 1165.39157, found 1165.39209; [α]23
D










(3.37 g, 7,12 mmol) was coevaporated thrice with toluene after which
it was dissolved in dry DCM (50 mL). The solution was cooled to 0
◦C and stirred for 10 minutes followed by addition of CCl3CN (7.14
mL, 71.2 mmol, 10 equiv) and DBU (0.27 mL, 1.78 mmol, 0.25 equiv).
The reaction mixture was stirred overnight at 4 ◦C, after which TLC-
analysis showed complete conversion of the starting material in a higher running product.
The reaction mixture was concentrated in vacuo. Purification using a short silica column
(EtOAc/PE 30% + 2.5% TEA) gave 179 in 71% yield (3.12 g, 5.05 mmol). TLC: EtOAc/PE
50%; 1H NMR (400 MHz, CDCl3) δ 8.64 - 8.55 (s, 1H), 7.78 - 7.60 (m, 5H), 7.40 - 7.20 (m,
6H), 7.15 - 6.89 (m, 6H), 6.54 - 6.31 (d, J = 8.3 Hz, 1H), 4.64 - 4.22 (m, 7H), 4.04 - 3.91 (dd,
J = 8.2, 3.6 Hz, 1H), 3.71 - 3.53 (m, 2H), 2.37 - 2.27 (m, 1H), 1.76 - 1.55 (td, J = 12.6, 10.5
Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 160.7, 137.8, 137.7, 134.0, 131.3, 127.6, 127.5, 123.2,













Imidate 179 (3.09 g, 5.00 mmol, 1.1 equiv) and acceptor 180 20
(2.64 g, 4.55 mmol) were coevaporated thrice with toluene
and dissolved in dry DCM (50 mL). Molecular sieves 3Å were
added and the reaction was cooled to -20 ◦C. After 15 minutes
the reaction was activated by addition of TMSOTf (90 µl, 0.50 mmol, 0.1 equiv) and was
stirred for 3 h allowing the mixture to warm to 0 ◦C. Subsequently, the reaction mixture
was quenched with Et3N (0.2 mL), filtered and concentrated in vacuo. Purification using a
short silica column (EtOAc/PE 22.5%) gave 176 in 70% yield as a colorless oil (3.3 g, 3.185
mmol). TLC: EtOAc/PE 40%; 1H NMR (400 MHz, CDCl3) δ 7.91 - 7.45 (m, 8H), 7.39 - 7.18
(m, 16H), 7.14 - 6.94 (m, 13H), 6.87 - 6.76 (m, 4H), 5.49 - 5.39 (d, J = 9.7 Hz, 1H), 5.37 -
5.25 (d, J = 8.2 Hz, 1H), 4.94 - 4.83 (d, J = 12.3 Hz, 1H), 4.65 - 4.09 (m, 14H), 3.63 - 3.34
(m, 6H), 2.36 - 2.18 (m, 1H), 1.58 - 1.41 (q, J = 11.8 Hz, 1H); 13C NMR (100 MHz, CDCl3)
δ 168.2, 167.7, 167.6, 167.0, 138.2 - 137.8, 133.7, 133.6, 132.2, 131.5, 131.3, 128.1 - 126.9,
126.7, 122.9, 74.2, 73.1, 72.4, 71.8, 70.5, 68.2, 34.1; IR (neat) ν 2344, 1709, 1683, 1385, 1274,
1066, 1025, 764, 749, 696, 661, 461; HRMS: C62H56N2O11S+Na
+ requires 1059.34970, found
1059.35039; [α]23
D








Compound 181 22 (19 g, 38.9 mmol) was coevaporated thrice using
toluene, after which it was dissolved in DMF (175 mL) and cooled to
0 ◦C. Sodium hydride (60% in mineral oil) (2.9 g, 76.9 mmol, 2 equiv)
was added portion wise. After 15 minutes the NAP-Br (17 g, 76.9
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mmol, 2 equiv) was added and the reaction was stirred overnight allowing the reaction
mixture to warm to rT. Subsequently, the reaction mixture was cooled to 0 ◦C, quenched
using little MeOH, diluted with Et2O and washed twice with 1M HCl and H2O. The organic
layer was dried using MgSO4 and concentrated under reduced pressure. Purification us-
ing a short silica column (EtOAc/PE 10%) gave 182 in 89% yield (21.56 g, 34.18 mmol).
TLC: EtOAc/PE 30%; 1H NMR (400 MHz, CDCl3) δ 7.88 - 7.70 (m, 3H), 7.59 - 7.42 (m, 3H),
7.38 - 7.22 (m, 19H), 6.05 - 5.84 (m, 1H), 5.41 - 5.25 (m, 1H), 5.24 - 5.15 (m, 1H), 5.06 -
4.91 (m, 3H), 4.87 - 4.58 (m, 5H), 4.56 - 4.39 (m, 2H), 4.21 - 4.10 (dd,J = 12.9, 5.9 Hz, 1H),
3.90 - 3.45 (m, 5H) ; 13C NMR (100 MHz, CDCl3) δ 138.84, 138.62, 138.37, 135.75, 134.23,
133.93, 128.57, 128.51, 128.40, 127.70, 126.78, 126.03, 117.39, 102.89, 84.90, 82.46, 78.04,
75.86, 75.19, 73.67, 70.48, 70.43, 69.14 ; IR (neat) ν 2918, 2864, 1454, 1361,1122, 1070, 1028,
929, 856, 748, 736, 698; HRMS: C41H42O6+Na
+ requires 653.28736, found 653.28750; [α]23
D








A dry solution of 182 (10.72 g, 70 mmol) in DMSO (8.5mL) was
charged with KOtBu (0.95 g, 8.5 mmol, 0.5 equiv) and heated to 100
◦C for 3 h, after which the reaction was quenched by addition of H2O
(5 mL). The reaction mixture was poured in H2O and extracted twice
with Et2O. The organic layers were combined and washed with 1M HCl. The ether frac-
tion was dried using MgSO4 and concentrated in vacuo. The residue was redissolved in
THF:H2O (70:15 mL), followed by addition of molecular iodine (8.63 g, 34 mmol, 2 equiv).
The mixture was stirred overnight after which the reaction was quenched by addition of
Na2S2O3 and washed with EtOAc and brine. The organic layer was dried and concentrated
in vacuo resulting in a yellow solid. The solid was again redissolved in dry THF (120 mL)
and cooled to 0 ◦C followed addition of LiAlH4 (2.26 g, 59.5 mmol, 3.5 equiv) and stirred for
20 h allowing to warm to rT. The excess of LiAlH4 was quenched with water. The mixture
was diluted with EtOAc and washed thrice with NH4Cl. The organic layer was dried and
concentrated in vacuo. Purification using a short silica column (EtOAc/PE 30%) gave 183
in 71% yield (6.96 g, 12.0 mmol). TLC: EtOAc/PE 50%; 1H NMR (400 MHz, CDCl3) δ 7.86
- 7.48 (m, 4H), 7.60 - 6.96 (m, 18H), 4.75 - 4.60 (m, 4H), 4.59 - 4.54 (s, 2H), 4.49 - 4.33 (q,J
= 11.9 Hz, 2H), 4.11 - 4.05 (m, 1H), 3.95 - 3.90 (dd,J = 6.2, 3.7 Hz, 1H), 3.85 - 3.76 (m, 2H),
3.74 - 3.67 (dd,J = 11.8, 4.2 Hz, 1H), 3.65 - 3.54 (m, 3H); 13C NMR (100 MHz, CDCl3) δ 138.1
- 132.7, 128.2 - 125.7, 79.50, 78.89, 77.56, 74.35, 73.14, 72.73, 71.09, 70.59, 61.46; IR (neat) ν
3433, 3032, 2924, 2870, 1713, 1612, 1512, 1458, 1358, 1288, 1250, 1065, 1034, 918, 818, 733;
HRMS: C38H40O6+Na
+ requires 615.27171, found 615.27168; [α]23
D







A solution of oxalylchloride (4.1 mL, 47.68 mmol, 4 equiv) in dry DCM
(40 mL) was cooled to -78 ◦C and stirred for 15 minutes. After drop-
wise addition of DMSO (4.23 mL, 59.6 mmol, 5 equiv) in dry DCM
(20 mL) over 10 minutes, the reaction was stirred for 40 minutes at
-70 ◦C. Subsequently, a dry solution of 183 (6.90 g, 11.92 mmol) in dry DCM (15 mL) was
added dropwise in 15 minutes, while keeping the reaction temperature at -70 ◦C. The re-
action mixture was stirred for 2 h after which Et3N (20 mL, 143 mmol, 12 equiv) was drop-
wise added and the mixture was allowed to warm to -5 ◦C in 1 h. This reaction mixture
was added to a cooled (0 ◦C) solution of NaCNBH3 (2.79 g, 47.68 mmol, 4 equiv), NH4CO3
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(18.84 g, 238.4 mmol, 20 equiv) and Na2SO4 (6.77 g, 47.68 mmol, 4 equiv) in 300 mL MeOH.
The reaction was stirred overnight allowing the mixture to warm to room temperature. Af-
ter TLC-analysis showed full conversion into a lower running product, the reaction mix-
ture was filtered and concentrated under reduced pressure. The oily residue was redis-
solved in EtOAc and washed with NaHCO3, after which the organic layer was dried us-
ing Na2SO4, filtered and concentrated in vacuo. Purification using a short silica column
(EtOAc/PE 15%) gave compound 184 in 63% yield (4.32 g, 7.55 mmol). TLC: EtOAc/PE
30%; 1H NMR (400 MHz, CDCl3) δ 7.83 - 7.70 (m, 3H), 7.64 - 7.59 (s, 1H), 7.48 - 7.40 (m,
2H), 7.39 - 7.16 (m, 17H), 5.06 - 4.93 (d,J = 11.0 Hz, 2H), 4.92 - 4.81 (d,J = 11.0 Hz, 1H),
4.74 - 4.58 (m, 3H), 4.50 - 4.24 (m, 2H), 3.70 - 3.46 (m, 4H), 3.46 - 3.36 (t,J = 9.2 Hz, 1H),
3.30 - 3.17 (dd,J = 12.3, 5.0 Hz, 1H), 2.78 - 2.68 (m, 1H), 2.56 - 2.45 (dd,J = 12.4, 10.3 Hz,
1H) ; 13C NMR (100 MHz, CDCl3) δ 139.0 - 133.0, 128.1 - 127.6, 87.45, 80.73, 80.08, 75.75,
75.27, 73.44, 72.84, 70.27, 59.82, 48.17; IR (neat) ν 2864, 2800, 1770, 1724, 1496, 1454, 1361,
1166, 1093, 1064, 817, 734, 689, 624; HRMS: C38H39NO4 +Na
+ requires 596.27713, found
596.27715; [α]23
D









Compound 184 was dissolved in DCM (35 mL) and Ns-Cl (8.37 g,
37.75 mmol, 5 equiv.) and pyridine (1.21 mL, 15.1 mmol, 2 equiv)
were added. The reaction was stirred overnight after which TLC anal-
ysis showed incomplete conversions. An additional 2 equivalents of
pyridine (1.21 mL) was added and stirring was continued for 5 h. The mixture was diluted
with DCM and washed with H2O and NaHCO3. The DCM layer was dried with MgSO4, fil-
tered and concentrated in vacuo. Purification using a short silica column (EtOAc/PE 40%)
gave compound 185 as a yellow oil in 87% yield (4.98 g, 6.56 mmol). TLC:EtOAc/PE 50% ;
1H NMR (400 MHz, CDCl3) δ 8.12 - 8.05 (m, 1H), 7.81 - 7.75 (m, 1H), 7.73 - 7.60 (m, 2H),
7.57 - 7.53 (d,J = 1.6 Hz, 1H), 7.46 - 7.37 (m, 2H), 7.29 - 7.08 (m, 15H), 7.01 - 6.93 (m, 1H),
6.79 - 6.71 (m, 1H), 4.65 - 4.33 (m, 7H), 4.33 - 4.29 (s, 2H), 4.02 - 3.97 (t,J = 3.4 Hz, 1H),
3.89 - 3.67 (m, 4H), 3.66 - 3.54 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 148.0, 137.9 - 137.6,
135.09, 133.0 - 122.9, 76.19, 75.28, 72.90, 72.87, 72.33, 71.89, 71.03, 68.68, 56.20, 42.29; IR
(neat) ν 2858, 2349, 2310, 1541, 1456, 1354, 1338, 1163, 1089, 1074, 1028, 748, 698; HRMS:
C44H42N2O8S+Na
+ requires 781.25541, found 781.25540; [α]23
D









To a dry solution of 185 (4.98 g, 6.56 mmol) in DCM/MeOH (300/80
mL), DDQ (4.47 g, 19.68 mmol, 3 equiv) was added portion wise. The
reaction mixture turned dark instantly and was stirred for 20 h. Next
the reaction mixture was diluted with DCM and extracted thrice with
NaHCO3 and twice with brine. The organic layer was dried using MgSO4, filtered and con-
centrated in vacuo. Purification using a short silica column (EtOAc/PE 30%) gave com-
pound 177 in 72% yield (2.92 g, 4.72 mmol). TLC: EtOAc/PE 50%; 1H NMR (400 MHz,
CDCl3) δ 8.07 - 8.02 (m, 1H), 7.46 - 7.19 (m, 14H), 7.19 - 7.11 (dd,J = 6.7, 2.8 Hz, 2H), 7.06 -
6.95 (dd,J = 6.6, 3.0 Hz, 2H), 4.81 - 4.74 (d,J = 11.5 Hz, 1H), 4.52 - 4.32 (m, 4H), 4.28 - 4.21
(m, 1H), 4.20 - 4.05 (m, 2H), 3.93 - 3.79 (m, 1H), 3.74 - 3.59 (m, 2H), 3.55 - 3.43 (m, 2H);
13C NMR (100 MHz, CDCl3) δ 147.4, 137.6 - 134.2, 132.9 - 127.4, 123.63, 74.02, 72.82, 72.54,
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72.27, 71.16, 66.99, 66.00, 60.02, 39.43; IR (neat) ν 3522, 3500, 3487, 3086, 2922, 2866, 1541,
1496, 1371, 1357, 1174, 1089, 1076, 972, 852, 744, 698; HRMS: C33H34N2O8S+Na
+ requires
641.19281, found 641.19281; [α]23
D



















Dimer 175 (652 mg, 571 µmol, 1.1 equiv) and
acceptor 177 (298 mg, 519 µmol) were coevap-
orated thrice with toluene and dissolved in dry
DCM (3 mL). Molecular sieves 3Å were added
and the reaction was cooled to 0 ◦C. After 10
minutes NIS (140 mg, 0.623 mmol, 1.2 equiv) was added and the reaction was activated
by addition of TMSOTf (5 µl, cat.). The reaction mixture turned deep purple and was
stirred for 2 h at 0 ◦C. After 2 h TLC-analysis showed complete conversion and the re-
action was quenched by addition of Et3N (0.2 mL). The reaction mixture was diluted with
DCM and washed with Na2S2O3, NaHCO3 and H2O. The organic layer was dried using
MgSO4, filtered and concentrated under reduced pressure. The crude oil was dissolved in
an Ac2O-pyridine cocktail (1 mL/3 mL) to acetylate the unreacted acceptor. After 3 h the
reaction was quenched using a little MeOH and concentrated in vacuo. Purification using
a short silica column (MeOH/DCM 5%) gave 187 in 60% yield as a yellow foam (507 mg,
307 µmol). TLC: MeOH/DCM 7%; 1H NMR (400 MHz, CDCl3) δ 8.07 - 6.49 (m, 61H), 5.31 -
5.25 (d, J = 8.2 Hz, 1H), 5.20 - 5.15 (m, 1H), 4.95 - 2.99 (m, 37H); 13C NMR (100 MHz, CDCl3)
δ 168.4, 168.2, 167.5, 147.8, 138.3 - 137.5, 132.5, 131.7, 131.3, 128.4 - 127.2, 123.0, 74.9, 74.7,
74.5, 73.1, 72.5, 72.3, 71.8, 70.5, 68.2, 67.9, 67.8; IR (neat) ν 1710, 1387, 1357, 1070, 1027,
737, 720, 697, 586; HRMS: C96H90N4O20S+Na
+ requires 1674.57949, found 1674.58146;
[α]23
D



















Fully protected trimer 187 (129 mg, 80 µmol)
was dissolved in DMF (1 mL), followed by ad-
dition of HSPh (17 µL, 160 µmol, 2 equiv) and
K2CO3 (33 mg, 240 µmol, 3 equiv). The reac-
tion mixture was stirred for 20 h at rT after which
TLC-analysis showed conversion into a lower running product. The reaction mixture was
diluted with EtOAc and washed twice with NaHCO3 and once with H2O. The organic layer
was dried using Na2S2O3, filtered and concentrated under reduced pressure. Purification
using a short silica column (EtOAc/PE 80%) gave 189 in 75% yield (88 mg, 60 µmol). TLC:
EtOAc 100%; 1H NMR (400 MHz, CDCl3) δ 7.99 - 7.53 (m, 7H), 7.41 - 7.07 (m, 29H), 7.04 -
6.89 (m, 9H), 6.85 - 6.75 (m, 4H), 5.34 - 5.27 (d, J = 8.1 Hz, 1H), 5.29 - 5.21 (d, J = 8.3 Hz,
1H), 4.98 - 4.87 (m, 2H), 4.85 - 4.80 (d, J = 11.3 Hz, 2H), 4.77 - 4.31 (m, 11H), 4.31 - 4.04 (m,
5H), 3.98 - 3.66 (m, 4H), 3.45 - 3.30 (m, 4H), 3.19 - 2.81 (m, 5H), 2.62 - 2.54 (m, 1H), 2.42 -
2.32 (t, J = 11.2 Hz, 1H).; 13C NMR (100 MHz, CDCl3) δ 168.3, 167.7, 139.7, 138.9, 138.7 -
138.0, 132.0, 131.6, 128.5 - 127.3, 74.91, 74.86, 74.54, 74.06, 73.28, 72.92, 72.67, 72.35, 70.71,






















Trimer 189 (120 mg, 82µmol, 1 equiv),
1-bromobutane (17 mg, 123 µmol, 1.5
equiv) and K2CO3 (34 mg, 246 µmol, 3
equiv) were dissolved in DMF and stirred
overnight at 85 ◦C. TLC analysis showed
incomplete conversion of the starting material, so an additional 3 equivalents of 1-
bromobutane (40 mg) were added and stirring was continued for 18 h. Subsequently,
the mixture was filtered and concentrated in vacuo. The resulting oil was taken up in n-
butanol (2 mL) and ethylenediamine (27µL) was added. The reaction mixture was refluxed
for 4 h, after which it was diluted with toluene, concentrated and coevaporated twice with
toluene. The resulting yellow oil was taken up in an Ac2O-pyridine cocktail (0.5 mL/1.5
mL) and stirred overnight. The reaction was stopped by quenching with a little MeOH and
concentrated in vacuo. The crude oil was dissolved in EtOH:HCl (1:0.1 mL), purged thrice
with argon and charged with Pd/C (20%) and purged thrice again with argon, followed by
purging with H2. The mixture was stirred overnight at rT and under atmospheric pressure.
HPLC-MS showed full deprotection of all the benzyl groups. Purification by HPLC (gradi-
ent H2O-MeOH+ 0.1% TFA) evaporation of MeOH and lyophilizing H2O yielded 174 (2.08
mg, 2.9 µmol, 4%). 1H NMR (600 MHz, D2O) δ 4.50 - 4.40 (m, 1H), 3.92 - 3.87 (d,J = 11.9
Hz, 1H), 3.84 - 2.78 (m, 25H), 1.99 - 1.87 (m, 7H), 1.88 - 1.82 (m, 1H), 1.61 - 1.54 (s, 2H), 1.30



















Trimer 189 (120 mg, 82
µmol, 1 equiv), 5-(adaman-
tan1-yl-methoxy)-1-bromo-
pentane 19 (39 mg, 123µmol,
1.5 equiv) and K2CO3 (34
mg, 246 µmol, 3 equiv) were dissolved in DMF and stirred overnight at 85 ◦C. TLC analysis
showed incomplete conversion of the starting material, so an additional 3 equivalents of
5-(adamantan-1-yl-methoxy)-1-bromo-pentane (80 mg) were added and stirring was con-
tinued for 18 h. Subsequently, the mixture was filtered and concentrated in vacuo. The
resulting oil was taken up in n-butanol (2 mL) and ethylenediamine (36 µL) was added.
The reaction mixture was refluxed for 4 h, after which it was diluted with toluene, concen-
trated and coevaporated twice with toluene. The resulting yellow oil was taken up in an
Ac2O-pyridine cocktail (0.5 mL/1.5 mL) and stirred overnight. The reaction was stopped
by quenching with a little MeOH and concentrated in vacuo. The crude oil was dissolved in
EtOH:HCl (1:0.1 mL) and charged with Pd/C (20%) and purged thrice with argon, followed
by purging with H2. The mixture was stirred over night at rT and under atmospheric pres-
sure. HPLC-MS showed full deprotection of all the benzyl groups. Purification by HPLC
(gradient H2O-MeOH+ 0.1% TFA) evaporation of MeOH and lyophilizing H2O yielded 172
(1.61 mg, 2.0 µmol, 3%). 1H NMR (600 MHz, D2O) δ 4.55 - 4.41 (m, 1H), 4.02 - 3.92 (1H),
3.84 - 3.48 (m, 13H), 3.48 - 3.33 (m, 7H), 3.01 - 2.94 (s, 1H), 2.84 - 2.78 (s, 1H), 2.61 - 2.50
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(1H), 2.33 - 2.13 (m, 1H), 2.10 - 2.01 (m, 2H), 1.99 - 1.89 (3H), 1.86 - 1.71 (s, 7H), 1.64 - 1.56


















Fully protected trimer 188 (153 mg, 99 µmol)
was dissolved in DMF (1 mL), followed by ad-
dition of HSPh (20 µL, 200 µmol, 2 equiv) and
K2CO3 (42 mg, 300 µmol, 3 equiv). The re-
action mixture was stirred for 20 h at rT after
which TLC-analysis showed conversion into a lower running product. The reaction mix-
ture was diluted with EtOAc and washed twice with NaHCO3 and once with H2O and brine.
The organic layer was dried using Na2S2O3, filtered and concentrated under reduced pres-
sure. Purification using a short silica column (EtOAc/PE 80%) gave 190 in 85% yield (114
mg, 83 µmol). TLC: EtOAc 100%; 1H NMR (400 MHz, CDCl3) δ 7.99 - 7.90 (m, 1H), 7.83 -
7.70 (m, 1H), 7.65 - 7.54 (m, 2H), 7.36 - 6.89 (m, 40H), 6.85 - 6.79 (dd, J = 5.3, 1.9 Hz, 3H),
5.33 - 5.22 (d, J = 8.1 Hz, 1H), 5.21 - 5.10 (d, J = 8.3 Hz, 1H), 4.89 - 4.74 (m, 3H), 4.60 - 4.40
(m, 10H), 4.35 - 3.98 (m, 8H), 3.95 - 3.83 (d, J = 11.4 Hz, 1H), 3.56 - 3.46 (m, 2H), 3.44 -
3.24 (m, 5H), 3.14 - 2.89 (m, 4H), 2.87 - 2.79 (m, 1H), 2.55 - 2.47 (d, J = 4.4 Hz, 1H), 2.34 -
2.20 (m, 2H), 1.30 - 1.21 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 168.4, 167.9, 139.7, 138.8,
- 138.0, 134.11, 133.91, 133.87, 133.80, 131.95, 131.77, 129.7 - 126.9, 123.68, 123.33, 123.15,
98.26, 97.10, 85.29, 80.32, 78.87, 75.13, 74.66, 74.31, 74.08, 73.46, 72.87, 72.65, 72.52, 72.28,
72.10, 71.10, 70.73, 70.62, 67.22, 59.00, 57.82, 56.76, 47.92, 34.41; IR (neat) ν 2866, 2355,
1775, 1710, 1453, 1387, 1363, 1068, 1027, 911, 697, 720, 530, 352; HRMS: C83H81N3O15+H
+
requires 1360.57405 , found 1360.57852; [α]23
D



















Compound 190 was coevaporated thrice
with toluene and dissolved in dioxane/A-
cOH (1:0.1 mL). After addition of freshly
prepared 193 26 in 0.2 mL dioxane the mix-
ture was purged with argon. Subsequently, the mixture was charged with Pd/C (20%) and
purged thrice with argon, followed by purging with H2. The mixture was stirred over night
at rT and under atmospheric pressure. HPLC-MS showed full coupling of aldehyde 193
with the starting material and simultaneously cleavage of all the benzyl groups. The mix-
ture was filtered over Celite R© and concentrated in vacuo resulting in a white solid. The
solid was taken up in n-butanol 5 mL and ethylenediamine (23 µL) was added. The re-
action mixture was refluxed for 4 h, after which it was diluted with toluene, concentrated
and coevaporated twice with toluene. The resulting yellow oil was taken up in an Ac2O-
pyridine cocktail (0.5 mL/1.5 mL) and stirred overnight. The reaction was stopped by
quenching with a little MeOH and concentrated in vacuo. The resulting oil was applied to
a Sephadex R© size exclusion column (50 mmD x 1500mmL) and eluted with DCM/MeOH
(1:1) yielding 191 as an amorphous solid in 36% yield over 4 steps. (9 mg, 8.34 µmol). TLC:
EtOAc/Tol 80%; 1H NMR (600 MHz, CDCl3) δ 5.08 - 4.84 (m, 2H), 4.50 - 4.14 (m, 4H), 4.10 -
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3.93 (m, 2H), 3.85 - 3.60 (m, 4H), 3.43 - 3.32 (m, 2H), 3.28 - 3.15 (m, 3H), 3.02 - 2.88 (s, 2H),
2.76 - 2.62 (m, 1H), 2.61 - 2.47 (m, 1H), 2.44 - 2.24 (s, 1H), 2.21 - 1.86 (m, 32H), 1.76 - 1.16
(m, 22H), 1.06 - 0.71 (m, 2H); 13C NMR (150 MHz, CDCl3) δ 172.6, 172.1 - 171.01, 102.7,
102.7, 82.9, 78.5, 76.3, 75.5, 74.1, 73.6, 72.5, 72.4, 71.6, 71.5, 71.5, 71.2, 70.9, 70.6, 66.3, 63.8,
63.3, 60.0, 55.9, 54.5, 53.9, 52.9, 40.8, 38.3, 35.1, 33.8, 32.9, 31.3, 30.7, 30.4, 30.4, 29.3, 24.9,
24.3, 24.2, 23.7, 22.0, 21.9, 21.9, 21.9, 21.8, 21.8, 15.1; IR (neat) ν 2925, 2366, 2184, 2017,
1977, 1958, 1744, 1654, 1368, 1235, 1047, 576, 464, 350, 313; HRMS: C52H79N3O21+H
+ re-
quires 1082.63165, found 1082.63156; [α]23
D


















Protected 191 9 mg (8.34 µmol) was dis-
solved in MeOH (0.5 mL), followed by ad-
dition of a catalytic amount of NaOMe
(30% in MeOH). The reaction mixture was
stirred for 30 minutes after with LCMS
showed conversion towards the deprotected product. The reaction mixture was quenched
with 4 drops of AcOH and diluted with toluene and coevaporated twice with toluene. The
oily residue was loaded as a mixture (in H2O) on a Dowex
TM H+ cation exchange resin
(type 50 WX4-200), which was stored on 2M H2SO4 and flushed with H2O and MeOH prior
to use. The column was flushed thrice with H2O (30 mL) followed by twice 2M NH4OH
in MeOH:H2O (1:1). Concentration in vacuo and lyophilizing H2O yielded the target com-
pound with some small impurities that were removed by HPLC (gradient H2O-MeOH +
0.1% TFA). Evaporation of MeOH and lyophilizing H2O yielded 173 in 30% (1.85 mg, 2.36
µmol). 1H NMR (600 MHz, DMSO d6) δ 7.93 - 7.78, 7.75 - 7.58, 5.76 - 5.44, 4.99 - 4.70, 4.56
- 4.46, 4.29 - 4.24, 3.79 - 3.14, 3.13 - 2.84, 1.95 - 1.40, 1.42 - 0.76; 13C NMR (150 MHz, DMSO
d6) δ 169.0, 116.3, 102.5, 101.1, 81.7, 81.0, 77.9, 74.8, 74.4, 72.8, 72.4, 70.3, 68.1, 65.7, 63.4,
63.3, 60.2, 56.9, 54.6, 36.7, 33.6, 31.3, 27.6, 23.1.
Coupling conditions entry 2, Table 4.1
Dimer 175 (228 mg, 200 µmol, 1.25 equiv) and acceptor 177 (91 mg, 160 µmol) were co-
evaporated thrice with toluene and dissolved in 5 mL dry DCM:Et2O (1:4). Molecular
sieves 3Å were added and the reaction was cooled to -30 ◦C. After 1 h a 1M solution of
Me2S2−TF2O (300 µL, 300 µmol, 1,5 equiv relative to donor). The reaction mixture was
stirred for 10 min at -30 ◦C, subsequently quenched by the addition of excess triethylamine
(0.5 mL, 3.6 mmol) and diluted with DCM (50 mL). The mixture was washed with 2 M
aqueous HCl, saturated aqueous NaHCO3, and water. The organic layer was dried using
MgSO4, filtered and concentrated under reduced pressure. Purification using a short silica
column (EtOAc/PE 30%) gave 187 in 41% yield (108 mg, 65 µmol). For analytical data see
compound 187.
Coupling conditions entry 3-6, Table 4.1
Dimer 175 (228 mg, 200 µmol, 1.25 equiv) and Ph2SO (88 mg, 440 µmol) were coevap-
orated thrice with toluene and dissolved in dry DCM (8 mL). Molecular sieves 3Å were
added and the reaction was cooled to -60 ◦C. Subsequently, Tf2O (47 µL, 280 µmol, 1.4
equiv relative to donor) was added. After 10 minutes at -60 ◦C acceptor 177 (91 mg, 160
µmol) in 4 mL dry DCM was added an the reaction mixture was stirred for 1.5 h allowing
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the mixture to warm to -30 ◦C. The reaction mixture was quenched at -30 ◦C by addition
of excess Et3N (0.5 mL, 3.6 mmol) and concentrated in vacuo. Purification using a short
silica column (EtOAc/PE 30%) gave 187 in 24% yield (62 mg, 38 µmol). For analytical data
see compound 187.
Coupling conditions entry 7, Table 4.1
Dimer 175 (228 mg, 200 µmol) was dissolved in acetone:H2O (6:2 mL) and cooled to -20
◦C. Next NBS (178 mg, 1 mmol) was added and the reaction was stirred for 1 h at -20 ◦C.
After 1 h the reaction mixture was quenched by addition of a little Na2S2O3 and subse-
quently carefully concentrated to remove the acetone. The resulting mixture was taken
up in ethyl acetate and washed twice with H2O. The organic layer was dried and concen-
trated in vacuo. The resulting oil was purified using a short silica column (30% EtOAc/PE)
gaining the hemiacetal in quantitative yield (221 mg, 210 µmol). TLC: 50% EtOAc/PE; 1H
NMR (400 MHz, CDCl3) δ 7.85 - 7.52 (m, 7H), 7.34 - 7.18 (m, 14H), 7.03 - 6.93 (m, 3H), 6.92
- 6.81 (m, 3H), 6.80 - 6.73 (m, 2H), 5.31 - 5.24 (d, J = 8.3 Hz, 1H), 5.21 - 5.14 (d, J = 8.5 Hz,
1H), 4.91 - 4.84 (d, J = 12.7 Hz, 1H), 4.82 - 4.75 (dd, J = 11.4, 4.5 Hz, 2H), 4.70 - 4.62 (d, J
= 10.8 Hz, 1H), 4.59 - 4.33 (m, 7H), 4.26 - 4.14 (m, 2H), 4.06 - 3.99 (m, 1H), 3.91 - 3.62 (m,
3H), 3.54 - 3.32 (m, 3H); 13C NMR (75 MHz, CDCl3) δ 178.14, 168.44, 167.96, 138.63, 138.28,
138.08, 138.05, 138.01, 133.71, 131.57, 131.30, 128.4-127.3, 96.91, 92.74, 79.63, 79.02, 76.49,
75.54, 75.10, 74.87, 74.80, 74.41, 74.36, 73.16, 72.70, 68.29, 67.95, 57.49, 56.59. The dimer
hemiacetal was coevaporated thrice with toluene, dissolved in dry DCM (2mL) and to 0
◦C. Subsequently, DBU (8 µL, 52 µmol, 0.25 equiv) and CCl3CN (0.21 mL, 2.1 mmol, 10
equv.) were added and the mixture was stirred overnight. The reaction was concentrated
in vacuo and purified using a short silica column (EtOAc/PE 30%+ 2.5 % TEA) yielding the
dimer imidate 186 in a low 15% yield (37 mg, 30 µmol). TLC: EtOAc/PE 40%; 1H NMR (400
MHz, CDCl3) δ 7.94 - 7.55 (m, 8H), 7.42 - 7.19 (m, 15H), 7.04 - 6.95 (m, 4H), 6.95 - 6.84 (m,
3H), 6.83 - 6.67 (m, 3H), 6.26 - 6.17 (d, J = 8.9 Hz, 1H), 5.38 - 5.25 (d, J = 8.3 Hz, 1H), 4.93 -
4.85 (d, J = 12.8 Hz, 1H), 4.84 - 4.77 (dd, J = 11.5, 4.1 Hz, 2H), 4.72 - 4.62 (m, 1H), 4.62 - 4.32
(m, 9H), 4.30 - 4.17 (m, 2H), 3.95 - 3.80 (dd, J = 9.9, 8.5 Hz, 1H), 3.77 - 3.36 (m, 6H). Dimer
imidate (37 mg, 30 µmol) and acceptor 177 were coevaporated thrice with toluene and
dissolved in dry DCM (1 mL). Molecular sieves 3Å were added and the reaction was cooled
to 0 ◦C. Next TMSOTf (1 µL, 3 µmol, 0.1 equiv) was added and the mixture was stirred for
2.5 h at 0 ◦C, after which the reaction was quenched using excess Et3N. Purification using a
short silica column (EtOAc/PE 30%) gave 186 in 34% yield (17 mg, 10 µmol). For analytical
data see compound 187.
Coupling conditions Scheme 4.2
Imidate 178 (141 mg, 200 µmol, 1.1 equiv relative to acceptor) and acceptor 177 (105 mg,
180 µmol, 1 equiv) were coevaporated thrice with toluene and dissolved in dry DCM (2
mL). Molecular sieves 3Å were added and the reaction was cooled to -20 ◦C. Subsequently,
TMSOTf (4 µL, 20 µmol) was added. The resulting mixture was stirred for 2 h while the
mixture was allowed to warm to 0 ◦C. Protected DNJ 177 (138mg, 216 µmol, 1.2 equiv rel-
ative to acceptor) and NIS (48 mg, 216µmol, 1.2 equiv relative to acceptor) were coevapo-
rated thrice with toluene and added in 0.3 mL dry DCM. The reaction mixture was stirred
for an additional 2 h at 0 ◦C. Subsequently, the reaction was quenched using excess Et3N.
Purification using a short silica column (EtOAc/PE 30%) gave 187 in 8% yield (24 mg, 14
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µmol). For analytical data see compound 187.
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Iminosugars are naturally occurring carbohydrate analogs in which the endocyclic
oxygen is replaced by a nitrogen atom. Because of their structural similarities they
can act as carbohydrate mimics and are therefore often found to be good inhibi-
tors of glycosidases and glycosyltransferases. 1 The first member of the iminosu-
gar family, nojirimycin (NJ, 1), was isolated from Streptomyces roseochromogenes
R-468 and Streptomyces lavendulae SF-425. This compound showed remarkable
biological activity. 2,3 Because nojirimycin bears a hemiaminal function which ren-
ders it rather unstable under neutral and acidic conditions at room temperature, it
is stored as its bisulphite adduct or reduced to the more stable 1-deoxynojirimycin
(DNJ, 2). 2,4 Later it was found that DNJ could also be isolated from bacterial cul-
tures (Bacillus and Streptomyces) 5,6 and from white mulberry (Morus alba) root
bark. 7 Over the years several N-alkylated derivatives of DNJ have been synthe-
sized such as N-butyl-1-deoxynojirimycin (NB-DNJ, 16) and N-[5-(adamantan-
1-yl-methoxy)-pentyl-1-deoxynojirimycin (AMP-DNJ, 17) 8 which both showed to
be good inhibitors for glucosylceramide synthase (GCS), with the latter being the
more active inhibitor. 9 NB-DNJ is the first orally administered drug, which is active
in the treatment of type 1 Gaucher disease. 10 Gaucher disease is a rare lysosomal
storage disorder in which glucosylceramide (GC) is inefficiently hydrolyzed by mu-
tant glucocerebrosidase (GBA1). This causes accumulation of GC-laden macro-
phages. Inhibition of GCS restores the balance of GC in Gaucher cells.
It is known that some iminosugars and N-alkylated derivatives thereof have a
bitter taste. 11 The daily intake of NB-DNJ, as a drug against Gaucher, will become
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more convenient for the patients when the bitter taste of the drug (NB-DNJ) is
masked. 11–13 To palliate the bitter taste of both NB-DNJ and AMP-DNJ, it was en-
visaged that appendage of a galactose moiety to the 4-position of DNJ would give
an analog of lactose, which is known to have a mild sweet taste. 14 However, alter-
nation of the 4-position of DNJ renders it inactive. 15 It is therefore anticipated that
lactase-phlorizin hydrolase (LPH) would be able to cleave the terminal galactose
moiety, 16 thereby releasing the active drug from prodrugs 199 and 201.
This chapter describes the synthesis of galactosylated NB-DNJ (199) and AMP-
DNJ (201) as potential prodrugs. Both compounds were accessible from octa-O-
acetyl-α/β -D-lactose. The ability of LPH, from rat mucosa, to cleave the glycosidic
bond of 201 is evaluated.
5.2 Results and Discussion
The use of octa-O-acetyl-α/β -D-lactose as starting material for the synthesis of
compounds 199 and 201 has the following advantages; it is cheap and saves a gly-
cosylation step. Lactose octa-acetate was converted into thio lactoside 194 ac-
cording to a published procedure. 17 Subsequent treatment with NBS in aqueous
acetone furnished hemi acetal 195, which was reduced with LiAlH4 in dry THF to
give diol 196. To access the iminosugar, lacitol 196 was first oxidized using the
Swern procedure. 18 Next, the crude di-carbonyl was subjected to a double reduc-
tive amination using an excess of ammonium formate in methanol at 0 ◦C in the
presence of NaBH3CN and Na2SO4 to give 197.
19
Mono-alkylation of the endocyclic nitrogen in 197 with either 5-(adamantan-
1-yl-methanol)-1-bromo-pentane (192) or 1-bromobutane under influence of
K2CO3 and TBAI in hot DMF proved to be difficult. Better results were obtained by
performing a reductive amination, using aldehydes, 5-(adamantan-1-yl-methoxy)-
1-pentanal 19 (193) or butanal in a dioxane:AcOH with H2 and Pd/C (20%) as a cat-
alyst. Because of the partial deprotection of the benzyl groups under the reaction
conditions used, a second reduction was performed. Hydrogenolysis of the crude
product in the presence of Pd/C (20%), HCl and 5 bar H2 pressure gave target com-
pounds 199 and 201, respectively. To facilitate their purification by silica gel chro-
matography both compounds were acetylated in a mixture of Ac2O-pyridine with
a catalytic amount of DMAP. Deacetylation of 198 and 200 under Zemplén con-
ditions and purification by a Dowex
TM
H+ column yielded target compounds 199
and 201 as white solids.
Next, it was examined whether the inactive galactosylated GCS inhibitors (199
and 201) could be processed by LPH to gain access to the active GCS inhibitors.
Because AMP-DNJ (17) was found to be a more active GCS inhibitor than NB-DNJ
(227) the preliminary biological tests were done using prodrug 201. Therefore,
mucosa was isolated by scraping the intestine of freshly sacrificed rats. The in-
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Reagents and conditions: a) NBS, acetone/H2O, -20
◦C, 51%; b) LiAlH4, THF, 0
◦C, 62%; c) (1)
(COCl)2, DMSO, -78
◦C, next Et3N, 0
◦C; (2) NaBH3CN, HCOONH4, Na2SO4, MeOH, 0
◦C, 47% d)
(1) butanal, Pd/C, H2, dioxane, AcOH; (2) Pd/C, 5 bar H2 , dioxane, HCl; (3) Ac2O, pyr., 198 41%;
e) (1) 193, Pd/C, H2, dioxane, AcOH; (2) Pd/C, 5 bar H2 , dioxane, HCl; (3) Ac2O, pyr., 200 34%; f)
NaOMe, MeOH, 199 68%, 201 67%.
testinal mucosa fraction (220 µg total protein per assay) was incubated for 2 h at
37 ◦C in a 0.1 mM potassium phosphate buffer (pH 6.5) with either 1 mM of com-
pound 201, or 1 mM compound of 17 as control. In a second assay the LPH, from
intestinal rat mucosa, was inactivated by boiling for 5 minutes prior to incubation
of the homogenate with 1 mM compound 201.




























Figure 5.1: Detection of 17 by LC-MS/MS, after cleavage of prodrug 201 by LPH (Left);
Recovery of AMP-DNJ (17) after incubation of LPH from in intestinal rats mucosa (Right);
Assay 1: LPH + 1mM 201, Assay 2: Inactive LPH + 1mM 201; Assay 3: LPH + 1mM 17.
During the incubation the concentration of AMP-DNJ (17) was determined by
LC-ESI-MS/MS or by a bio-assay employing the inhibition properties of AMP-DNJ
(but not prodrug 201) to inhibit recombinant glucocerebrosidase (GBA1). Fig-
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ure 5.1 (left) shows an example of AMP-DNM detection by LC-MS/MS. Figure 5.1
(right) shows that AMP-DNJ (17) was nicely recovered (92%) and that approxi-
mately 4% of the prodrug (201) was partially converted during the 2 h incubation,
with LPH, to AMP-DNJ (17).
5.3 Conclusion
A convergent and scalable route of synthesis to prodrugs 199 and 201 was achieved
using octa-O-acetyl-α/β -D-lactose as starting material. In an eight step sequence
lactose was transformed into galactosylated DNJ derivative 197. This intermedi-
ate furnished the target compounds 199 and 201 by reductive amination and hy-
drogenolysis. Biological evaluation of 201 showed the ability of LPH, from intesti-
nal rat mucosa, to cleave the glycosidic bond thereby releasing AMP-DNJ (17).
5.4 Experimental section
All reagent were of commercial grade and used as received (Acros, Fluka, Merck, Schleicher
& Schuell) unless stated otherwise. Diethyl ether (Et2O), light petroleum ether (PE 40-60),
en toluene (Tol) were purchased from Riedel-de Haën. Dichloromethane (DCM), N,N-
dimethylformamide (DMF), methanol (MeOH), pyridine (pyr) and tetrahydrofuran (THF)
were obtained from Biosolve. THF was distilled over LiAlH4 before use. Dichloromethane
was boiled under reflux over P2O5 for 2 h and distilled prior to use. Molecular sieves 3Å
were flame dried under vacuum before use. All reactions sensitive to moisture or oxygen
were performed under an inert atmosphere of argon unless stated otherwise. Solvents
used for flash chromatography were of pro analysis quality. Flash chromatography was
performed on Screening Devices silica gel 60 (0.004 - 0.063 mm). TLC-analysis was con-
ducted on DC-alufolien (Merck, Kieselgel60, F245) with detection by UV-absorption (254
nm) for UV-active compounds and by spraying with 20% H2SO4 in ethanol or with a so-
lution of (NH4)6Mo7O24 ·4 H2O 25 g/L, (NH4)4Ce(SO4)4 ·2 H2O 10 g/L, 10% H2SO4 in H2O
followed by charring at∼150 ◦C. 1H and 13C NMR spectra were recorded on a Bruker DMX-
400 (400/100 MHz), a Bruker AV 400 (400/100 MHz), a Bruker AV 500 (500/125 MHz) or a
Bruker DMX-600 (600/150 MHz) spectrometer. Chemical shifts (δ) are given in ppm rel-
ative to the chloroform residual solvent peak or tetramethylsilane as internal standard.
Coupling constants are given in Hz. All given 13C spectra are proton decoupled. High
resolution mass spectra were recorded on a LTQ-Orbitrap (Thermo Finnigan) Mass spec-
trometer. LC/MS analysis was performed on a Jasco HPLC-system (detection simultane-
ous at 214 nm and 245 nm) equipped with an analytical Alltima C18 column (Alltech, 4.6
mmD x 50 mmL, 3µ particle size) in combination with buffers A: H2O, B: MeCN and C:
0.5% aq. TFA and coupled to a Perkin Almer Sciex API 165 mass spectrometer. Optical
rotations were measured on a Propol automatic polarimeter. IR spectra were recorded on















A solution of 194 (24 g, 22.55 mmol) in acetone:H2O
(350:25 mL) was cooled to -20 ◦C followed by portion
wise addition of NBS (20 g, 112.73 mmol, 5 equiv). The
reaction mixture turned into a yellow suspension which
became clear in 10 minutes. After 15 minutes the reac-
tion turned bright orange and the starting material was completely converted in a polar
spot on TLC. The reaction mixture was quenched by the addition of 50 mL of Na2S2O3
and subsequently carefully concentrated in vacuo to remove the acetone. The resulting
mixture was taken up in EtOAc and washed twice with H2O. The EtOAc layer was dried
and concentrated in vacuo. The resulting oil was purified using a short silica column
(EtOAc/PE 30%) yielding compound 195 in 51 %. (11.1 g, 11.4 mmol). TLC: EtOAc/PE
50%; 1H NMR (400 MHz, CDCl3) δ 7.39 - 7.08 (m, 35H, CHa rom Bn), 5.15 (d, J = 3.6 Hz,
1H, H-1β ), 5.11 - 5.01 (m, 2H), 4.96 (dd, J = 11.4, 7.1 Hz, 2H), 4.90 - 4.79 (m, 1H), 4.79 -
4.43 (m, 17H), 4.40 - 4.17 (m, 8H), 4.02 - 3.81 (m, 7H), 3.79 - 3.70 (m, 3H), 3.66 - 3.61 (m,
1H), 3.57 - 3.47 (m, 5H), 3.41 - 3.29 (m, 7H); 13C NMR (100 MHz, CDCl3) δ 139.3-138.0 (Cq ),
129.0-125.3 (Ca rom ), 102.9 (C-1’β ), 102.8 (C-1’α), 97.3 (C-1α), 91.3 (C-1β ), 82.8, 82.7, 82.5,
82.4, 79.9, 79.1, 77.5, 77.2, 76.7, 75.4, 75.3, 75.2, 74.7, 73.7, 73.6, 73.4, 73.4, 73.1, 73.0, 72.5,
72.5, 70.3, 68.4, 68.2, 68.1; IR (neat) ν 3063, 3028, 2914, 2866, 1497, 1452, 1362, 1090, 1059,
1026, 908, 731, 677, 615; HRMS: C61H64O11+Na













Compound 195 (11.1 g, 11.4 mmol) was coevaporated
thrice with toluene and dissolved in dry THF 60 mL. The
reaction mixture was cooled with an ice-bath and LiAlH4
(1.50 g, 39.9 mmol, 3.5 equiv) was added portion wise.
The mixture was allowed to warm to room temperature
overnight after which the reaction mixture was cooled to 0 ◦C and quenched with MeOH .
Subsequently the mixture was diluted with EtOAc and washed with 1M HCl. The organic
layer was dried with MgSO4, filtered and concentrated in vacuo. Purification using a short
silica column (EtOAc/PE 30%) gave compound 196 in 62% yield.(6.96 g, 7.14 mmol) TLC:
EtOAc/PE 50%; 1H NMR (400 MHz, CDCl3) δ 7.36 - 7.08 (m, 35H, CHa rom Bn), 4.96 - 4.50
(m, 10H), 4.43 - 4.21 (m, 5H), 4.10 - 3.95 (m, 4H), 3.84 - 3.66 (m, 6H), 3.59 - 3.45 (m, 3H),
3.41 - 3.32 (m, 2H), 2.66 (s, OH, 1H) 13C NMR (100 MHz, CDCl3) δ 138.7-137.6 (Cq ), 128.9-
127.3 (Ca rom ), 103.5 (C-1’), 82.2, 79.8, 79.5, 79.2, 77.4, 75.1, 74.7, 74.4, 73.6, 73.3, 73.4, 72.8,
72.7, 70.6, 70.6, 68.7, 62.0; IR (neat) ν 3030, 2920, 2866, 1467, 1454, 1361, 1207, 1062, 1026,
906, 706, 692 ; HRMS: C61H66O11+Na












A solution of oxalylchloride (2.5 mL, 28.56 mmol, 4 equiv)
in dry DCM (30 mL) was cooled to -78 ◦C and stirred for 15
minutes. After the dropwise addition of a solution of DMSO
(2.63 mL, 37 mmol, 5 equiv) in dry DCM (5 mL) over 10 min-
utes, the reaction was stirred for 40 minutes at -70 ◦C. Sub-
sequently a dry solution of 196 (6.96 g, 7.14 mmol) in DCM (10 mL) was added dropwise,
while keeping the reaction temperature at -70 ◦C. The reaction mixture was stirred for 2 h
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after which Et3N (11.91 mL, 85.68 mmol, 12 equiv) was added dropwise. The mixture was
allowed to gradually warm to -5 ◦C. This reaction mixture was then added to a cooled (0 ◦C)
solution of NaBH3CN (1.79 g, 28.56 mmol, 4 equiv), HCOONH4 (11.28 g, 142.8 mmol, 20
equiv) and Na2SO4 (3.04 g, 21.42 mmol, 3 equiv) in 300 mL MeOH. The reaction was stirred
overnight allowing the mixture to warm to room temperature. After TLC-analysis showed
full conversion into a polar product, the reaction mixture was filtered and concentrated in
vacuo. The oily residue was dissolved in EtOAc and washed with NaHCO3, after which the
organic layer was dried with Na2SO4, filtered and concentrated in vacuo. Purification us-
ing a short silica column (EtOAc/PE 20%) yield compound 197 in 47% (3.19 g, 3.33 mmol).
TLC: EtOAc/PE 40%; 1H NMR (400 MHz, CDCl3) δ 7.38 - 7.09 (m, 35H, CHa rom Bn), 5.06
(d, J = 10.7 Hz, 1H), 5.00 - 4.94 (m, 1H), 4.86 - 4.78 (m, 2H), 4.78 - 4.67 (m, 5H), 4.65 - 4.51
(m, 3H), 4.41 - 4.28 (m, 3H), 4.23 (dd, J = 11.7, 7.9 Hz, 2H), 3.93 - 3.87 (m, 1H), 3.77 (dd, J =
12.0, 4.3 Hz, 1H), 3.71 - 3.58 (m, 3H), 3.55 - 3.47 (m, 1H), 3.47 - 3.41 (m, 1H), 3.39 - 3.30 (m,
2H), 3.23 - 3.14 (m, 1H, CH2, DNJ), 2.73 - 2.66 (m, 1H, CH, H-2), 2.50 (dd, J = 12.1, 10.1 Hz,
1H, CH2, DNJ);
13C NMR (100 MHz, CDCl3) δ 139.7-138.2 (Cq ), 128.4-127.0 (C
a rom ), 103.5
(C-1’), 85.47, 82.73, 80.19, 79.97, 79.73, 75.44, 75.34, 74.80, 73.75, 73.49, 73.21, 73.17, 72.98,
72.68, 70.02, 68.29, 60.57 (C-2), 48.4 (CH2, DNJ); IR (neat) ν 3102, 2859, 2360, 1496, 1454,
1362, 1102, 1061, 1027, 730, 694, 458; HRMS: C61H65NO9 +H













Compound 197 (1 g, 1.05 mmol) was dissolved in a
mixture of 10 mL dioxane and 0.1 mL AcOH. Butanal
(0.28 mL, 3.2 mmol, 3 equiv) was added and the mix-
ture was purged trice with argon. Subsequently Pd/C
(20%) was added and the reaction was again purged
(trice) with argon followed by purging with H2. The reaction was stirred overnight. Pres-
ence of starting material was indicated by HPLC-MS. Therefore mixture was filtered, con-
centrated and recharged with Pd/C in a dioxane/AcOH mixture. After overnight HPLC-MS
analysis indicated product formation together with partial cleavage of the benzyl groups.
The mixture was filtered, concentrated and dissolved in a mixture of 10 mL dioxane and
0.2 mL HCl (2M), followed by addition of Pd/C. The mixture was shaken overnight in a
Parr apparatus R© under 5 bar hydrogen pressure. The resulting mixture was filtered over
Whatmann R© filter paper, concentrated in vacuo and taken up in an Ac2O-pyridine mix-
ture (3 mL/9 mL). The reaction was stirred at room temperature for 18 h, after which it
was cooled using an ice-bath and quenched with MeOH. The resulting mixture was con-
centrated in vacuo and purified using a short silica column (EtOAc/PE 60%) yielding com-
pound 198 in 41% yield. (276 mg, 408 µmol) TLC: EtOAc/PE 70%; 1H NMR (400 MHz,
CDCl3) δ 5.36 - 5.29 (m, 1H), 5.10 (dd, J = 10.4, 7.9 Hz, 1H), 5.02 (t, J = 9.2 Hz, 1H), 4.96
- 4.83 (m, 2H), 4.50 (m, 2H), 4.18 - 4.02 (m, 3H), 3.84 (t, J = 6.9 Hz, 1H), 3.76 (t, J = 9.1
Hz, 1H), 3.11 (dd, J = 11.3, 5.1 Hz, 1H), 2.67 (m, 1H), 2.54 (d, J = 9.2 Hz, 1H), 2.46 (m,
1H), 2.29 (t, J = 10.8 Hz, 1H), 2.14 (s, 3H), 2.12 (s, 3H), 2.05 (s, 3H), 2.04 (m, 6H), 2.01 (s,
3H), 1.95 (s, 3H), 1.42 - 1.18 (m, 4H), 0.89 (t, J = 7.2 Hz, 3H).; 13C NMR (100 MHz, CDCl3)
δ 170.49, 170.33, 170.21, 170.15, 170.08, 169.94, 168.99, 101.10, 76.77, 74.10, 71.17, 70.57,
69.58, 69.26, 66.69, 62.54, 60.86, 59.00, 52.65, 51.59, 26.74, 20.97, 20.89, 20.68, 20.64, 20.50,















To a solution of compound 198 (276 mg, 408 µmol)
in MeOH a catalytic amount of NaOMe (30% in
MeOH) was added. The reaction was stirred overnight
after wich HPLC-MS indicated cleavage of all the
acetyl groups. The mixture was quenched with five
drops of AcOH (pH∼ 7) and concentrated in vacuo. Compound 228 was purified by load-
ing the mixture (in H2O) on a Dowex
TM H+ cation exchange resin (type 50 WX4-200), which
was stored on 2 M H2SO4 and flushed with H2O and MeOH prior to use. The column was
flushed trice with H2O (30 mL) followed by twice with 1 M NH4OH in H2O. Concentration
in vacuo and lyophilizing H2O yielded 199 in 68% yield (103 mg, 270µmol) as a white fluffy
solid. 1H NMR (400 MHz, MeOD) δ 4.45 (d, J = 7.6 Hz, 1H), 4.08 - 4.00 (m, 1H), 3.90 - 3.68
(m, 4H), 3.67 - 3.49 (m, 5H), 3.31 (m, 2H), 3.00 (dd, J = 11.2, 4.9 Hz, 1H), 2.87 - 2.75 (m, 1H),
2.69 - 2.57 (m, 1H), 2.30 (d, J = 9.6 Hz, 1H), 2.22 (t, J = 10.9 Hz, 1H), 154 - 1.44 (m, 2H), 1.39
- 1.28 (m, 2H), 0.98 (t, J = 7.3 Hz, 3H).; 13C NMR (151 MHz, (D4) MeOD) δ 103.90, 80.58,
77.38, 75.69, 73.49, 71.39, 69.08, 68.86, 64.90, 61.00, 56.65, 55.92, 51.73, 26.01, 20.34, 12.98.;
HRMS: C16H31NO9+H













Compound 197 (1 g, 1.05 mmol) was dis-
solved in a mixture of 10 mL dioxane and
0.1 mL AcOH. Aldehyde 229 19 was freshly
oxidized and added to the mixture and
purged trice with argon. Subsequently
Pd/C was added and the reaction mixture
was again purge trice with argon followed by purging with H2 (trice). The reaction was
stirred overnight. Presence of starting material was indicated by HPLC-MS. Therefore mix-
ture was filtered, concentrated and recharged with Pd/C in a dioxane/AcOH mixture. After
overnight HPLC-MS analysis indicated product formation together with partial cleavage of
the benzyl groups. The mixture was filtered, concentrated and dissolved in 10 mL dioxane
and 0.2 mL HCl (2 M), followed by the addition of Pd/C. The mixture was shaken overnight
on a Parr apparatus R© under 5 bar hydrogen pressure. The resulting mixture was filtered
over Whatmann R© filter paper, concentrated in vacuo and taken up in an Ac2O-pyridine
mixture (3 mL/9 mL). The reaction was stirred at room temperature for 18 h, after which
it was cooled using an ice-bath and quenched wiotyh MeOH. The resulting mixture was
concentrated in vacuo and purified using a short silica column (EtOAc/PE 70%) yielding
compound 200 in 35% yield. (300 mg, 351 µmol) TLC: EtOAc/PE 80%; 1H NMR (400 MHz,
CDCl3) δ 5.25 (d, J = 3.4 Hz, 1H), 5.00 (dd, J = 10.3, 7.9 Hz, 1H), 4.93 (t, J = 9.2 Hz, 1H),
4.88 - 4.74 (m, 2H), 4.40 (d, J = 7.9 Hz, 2H), 4.02 (m, 3H), 3.77 (t, J = 6.8 Hz, 1H), 3.67 (t, J =
9.1 Hz, 1H), 3.25 (t, J = 6.4 Hz, 2H), 3.02 (dd, J = 11.3, 5.0 Hz, 1H), 2.84 (s, 2H), 2.66 - 2.32
(m, 3H), 2.21 (t, J = 10.7 Hz, 1H), 2.05 (s, 2H), 2.03 (s, 2H), 1.96 (s, 3H), 1.95 (s, 4H), 1.92 (s,
2H), 1.86 (s, 3H), 1.57 (dd, J = 27.9, 12.0 Hz, 7H), 1.46 - 1.13 (m, 13H); 13C NMR (100 MHz,
CDCl3) δ 170.39, 170.23, 170.06, 169.97, 169.86, 168.93, 101.03, 81.83, 76.75, 74.06, 71.28,
71.10, 70.50, 69.48, 69.20, 66.65, 62.45, 60.83, 58.99, 52.58, 51.76, 39.66, 37.15, 33.99, 29.32,
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28.18, 24.45, 23.81, 20.91, 20.81, 20.61, 20.57, 20.43.; IR (neat) ν 3021, 2902, 2848, 1739,
1367,1217, 116, 1045, 908, 727, 648; HRMS: C42H63NO17 +H














To a solution of compound 200 (300
mg, 351 µmol) in MeOH a catalytic
amount of NaOMe (30% in MeOH)
was added. The reaction mixture was
stirred overnight after wich HPLC-MS
indicated cleavage of all the acetyl
groups. The mixture was quenched with five drops of AcOH (pH ∼ 7)and concentrated
in vacuo. Compound 230 was purified by loading the mixture (in H2O) on a Dowex
TM H+
cation exchange resin (type 50 WX4-200), which was stored on 2M H2SO4 and flushed with
H2O and MeOH prior to use. The column was flushed trice with H2O (30 mL) followed
by twice 2M NH4OH in MeOH:H2O (1:1). Concentration in vacuo and lyophilizing H2O
yielded 201 in 67% yield (133 mg, 237 µmol) as a white fluffy solid. 1H NMR (600 MHz,
D2O) δ 4.54 (d, J = 7.4 Hz, 1H, H-1), 4.18 (d, J = 12.5 Hz, 1H), 4.01 (d, J = 12.6 Hz, 1H), 3.91
(m, 2H), 3.85 (s, 1H), 3.80 - 3.71 (m, 4H), 3.69 - 3.64 (m, 2H), 3.56 (m, 2H), 3.50 (t, J = 6.4
Hz, 2H), 3.38 (m, 2H), 3.24 (s, 1H), 3.14 - 3.06 (m, 4H), 1.92 (s, 4H), 1.83 - 1.74 (m, 2H), 1.71
(m, 4H), 1.61 (m, 6H), 1.49 (s, 8H), 1.46 - 1.38 (m, 2H); 13C NMR (151 MHz, D2O) δ 103.9
(C-1), 82.6 (OCH2 Ada), 76.81, 76.47, 75.34, 73.41, 72.02, 71.89, 69.42, 65.14 (CH2 C-6’/5’-
pentyl), 61.95 (CH2 C-6’), 47.6 (CH2, DNJ), 40.0 (3x CH2 Ada), 37.5 (3x CH2 Ada), 34.4 (Cq
Ada), 28.8 (CH Ada), 28.7 (CH2 4’-pentyl), 23.4 (CH2 3’/2’-pentyl); IR (neat) ν 3366, 2904,




Detection of AMP-DNJ (17) in homogenate of intestinal Mucosa: The homogenate was sub-
jected to butanol extraction. The organic phase was desiccated in a heat block set at (37
◦C) using a mild N2 flow. The dried samples were dissolved in 100 µL MeOH, of which 10
µL was analyzed by LC-ESI-MS/MS (Waters Corp., Milford, MA, USA). Chromatographic
elution of glucosylsphingosine was achieved on a BEH C18 Column, 1.0 x 50 mm., 1.7 µm
(Waters Corp., Milford, MA, USA) using the following eluent. Eluent A: 1 mM ammonium
formate in 37% MeOH, 62.5% MQ-H2O, with 0.1% formic acid. Eluent B: 1 mM ammo-
nium formate in 99.5% MeOH, with 0.5% formic acid. On an Acquity UPLC system, gluco-
sylsphingosine was resolved at a flow rate of 0.25 mL/min. For this the following gradient
was used: 0 -> 2.5 min. from 100% A to 100% eluent B, 2.5 -> 4 min. 100% eluent B, 4
-> 5 min. from 100% B to 100% eluent A, and from 5 -> 5.5 min. 100% eluent A to equi-
librate the column. Subsequent detection was achieved on a tandem quadrupole mass
spectrometer (TQD, Waters corp., Milford, MA, USA) using electrospray ionisation in pos-
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itive mode. For optimization of ion source parameters and ionization conditions, direct
infusion of standard (D-glucosyl-β -1-1’-D-erythro-sphingosine;) at a 1 µM concentration
in MeOH (+ 0.5% formic acid (vol/vol)) was performed. Optimized ion source parameters:
capillair voltage, 3.5 kV; cone voltage, 30 V; source and desolvation temperatures were 120
◦C and 450 ◦C, respectively. Nitrogen gas flow in the cone was 50 L/h and desolvation gas
was 500 L/h. Argon gas was used for collision-induced dissociation. Single reaction mon-
itoring of precursor, fragment ions (m/z 398 > X) was used for quantification and data
were analyzed using MassLynx software (version 4.1, Waters, Manchester, UK). Limit of
detection was defined as a signal to noise ratio S/N higher than 5.
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Synthesis of α- and β -Cholesteryl
Glucosides
6.1 Introduction
Steryl glycosides are abundant in nature. 1 For example the gram-negative bac-
terium Helicobacter pylori, a common human pathogens which is known to cause
ulcers contains several steryl glycosides, such as cholesteryl-6-O-acyl-α-D-gluco-
pyranoside, cholesteryl-α-D-glucopyranoside and cholesteryl-6-O-phosphatidyl-
α-D-glucopyranoside. 2 Additionally various steryl-β -glucosides are synthesized
by plants, including sitosteryl-β -glucoside which can serve as primer in the biosyn-
thesis of cellulose. 3 Studies reporting on the occurrence of endogenous cholesterol-
β -glucoside in mammals are surprisingly scarce. Only Murakami-Murofushi and
co-workers have reported on the formation of cholesterol-β -glucoside in cultured
fibroblasts as a rapid response to heat stress. 4 Very recently they presented evi-
dence that glucosylceramide (GC) and not UDP-glucose acts as a sugar donor in
the biosynthesis of cholesteryl glucoside. 5 The enzyme responsible for the synthe-
sis of cholesterol-β -glucoside in man has not yet been identified.
The limited knowledge on endogenous cholesterol-β -glucosides in mammals
is surprising since there are numerous speculations that steryl glucosides may act
as (neuro)toxins. An example thereof is the neurological disorder amyotrophic
lateral sclerosis-parkinsomism dementia complex (ALS-PDC) in which features of
parkinsomism are presented and which is linked to the consumption of flour made
from cycad fruits (Cycas micronesica) that is known to contain a high concentra-
tion of steryl glycosides. 6–9
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Parkinsonism and glucosylceramide metabolism also appear to be linked
given, the high incidence of neurodegenerative conditions in Gaucher disease pa-
tients. 10 Gaucher disease is a rare lysosomal storage disorder, which is caused
by the inefficient catabolism of GC by mutant glucocerebrosidase (GBA1). 11 This
causes accumulation of GC-laden macrophages which leads to the enlargement of
organs (spleen and liver) and inflammation. It may be speculated that GC acts as
a donor in the biosynthesis of the potentially neurotoxic steryl-β -glucosides, im-
plying that cholesteryl-β -glucoside is a missing link between parkinsonism and
Gaucher.
To further investigate this hypothesis pure samples of α- and β -glucosylated
cholesterol are needed. This chapter describes the synthesis of α-cholesteryl glu-
coside 204 and β -cholesteryl glucoside 207 (Scheme 6.1).
6.2 Results and Discussion
In carbohydrate chemistry the glycosylation of naturally occurring terpenes and
steroids present a special challenge. Besides controlling the stereoselectivity, the
reactivity of the functional groups in the steroids is an important issue. The sec-
ondary 3-OH function in cholesterol is moderately nucleophilic and the alkene
function is sensitive to hydrogenation. 12
The synthesis of α-cholesteryl glucoside 204 and β -cholesteryl glucoside 207
is shown in Scheme 6.1. For the synthesis of α-cholesteryl glucoside 204, 13 donor
2,3,4,6-tetra-O-benzyl-α/β -D-glucopyranose 202 14 was used bearing benzyl
groups which were cleaved by transfer hydrogenation leaving the alkene in cho-
lesterol intact. In situ tosylation of the anomeric alcohol in 202 and coupling
with an excess of cholesterol, to prevent self condensation gave steryl glycoside
203. In almost complete anomeric selectivity (β<5%) and 90% overall yield. 15
Careful deprotection of the benzyl groups using Pearlman’s catalyst in EtOH:cyclo-
hexene to prevent the reduction of the endocyclic unsaturated bond in cholesterol,
gave 204 which was purified by HPLC. 16
β -Cholesteryl glycoside 207 was synthesized according to literature. 17 Activa-
tion of imidate 205 using TMSOTf followed by addition of cholesterol gave 206
(Scheme 6.1). Saponification of 206 under Zemplén conditions and purification
by HPLC gave target compound 207 as a white solid.
6.3 Conclusion
The syntheses ofα-cholesteryl glycoside 204 andβ -cholesteryl glycoside 207 were
successfully executed. The use of Pearlman’s catalyst and cyclohexene, as hydro-
gen source, for the hydrogenation of the benzyl ethers in 203 prevented saturation
of the double bond in cholestrol. Both 204 and 207 are currently used as internal
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Reagents and conditions: a) TosCl, TEBA, DCM, NaOHaq 3M, 90%; b) Pd(OH)2, H2,
EtOH:cyclohexene, 30%; c) TMSOTf, DCM, -40◦C, 83%; d) NaOMe, MeOH ,89%.
standards for the investigation of cholesterol glucosides as common denominator
for parkinsonism and Gaucher disease.
6.4 Experimental section
All reagent were of commercial grade and used as received (Acros, Fluka, Merck, Schleicher
& Schuell) unless stated otherwise. Diethyl ether (Et2O), light petroleum ether (PE 40-60),
en toluene (Tol) were purchased from Riedel-de Haën. Dichloromethane (DCM), N,N-
dimethylformamide (DMF), methanol (MeOH), pyridine (pyr) and tetrahydrofuran (THF)
were obtained from Biosolve. THF was distilled over LiAlH4 before use. Dichloromethane
was boiled under reflux over P2O5 for 2 h and distilled prior to use. Molecular sieves 3Å
were flame dried under vacuum before use. All reactions sensitive to moisture or oxygen
were performed under an inert atmosphere of argon unless stated otherwise. Solvents
used for flash chromatography were of pro analysis quality. Flash chromatography was
performed on Screening Devices silica gel 60 (0.004 - 0.063 mm). TLC-analysis was con-
ducted on DC-alufolien (Merck, Kieselgel60, F245) with detection by UV-absorption (254
nm) for UV-active compounds and by spraying with 20% H2SO4 in ethanol or with a so-
lution of (NH4)6Mo7O24 ·4 H2O 25 g/L, (NH4)4Ce(SO4)4 ·2 H2O 10 g/L, 10% H2SO4 in H2O
followed by charring at∼150 ◦C. 1H and 13C NMR spectra were recorded on a Bruker DMX-
400 (400/100 MHz), a Bruker AV 400 (400/100 MHz), a Bruker AV 500 (500/125 MHz) or a
Bruker DMX-600 (600/150 MHz) spectrometer. Chemical shifts (δ) are given in ppm rel-
ative to the chloroform residual solvent peak or tetramethylsilane as internal standard.
Coupling constants are given in Hz. All given 13C spectra are proton decoupled. High
resolution mass spectra were recorded on a LTQ-Orbitrap (Thermo Finnigan) Mass spec-
trometer. LC/MS analysis was performed on a Jasco HPLC-system (detection simultane-
ous at 214 nm and 245 nm) equipped with an analytical Alltima C18 column (Alltech, 4.6
mmD x 50 mmL, 3µ particle size) in combination with buffers A: H2O, B: MeCN and C:
0.5% aq. TFA and coupled to a Perkin Almer Sciex API 165 mass spectrometer. Optical
rotations were measured on a Propol automatic polarimeter. IR spectra were recorded on













A solutions of known 202 14 (0.54 g, 1
mmol), TosCl (0.21 g, 1.1 mmol, 1.1
quiv.), benzyltriethyl ammonium chloride
(TEBA) (70 mg, 0.3 mmol, 0.3 equiv) and
cholesterol (1.54 g, 4 mmol, 4 equiv) in dry
DCM (10 mL) was stirred with 40% aque-
ous NaOH (5 mL) at room temperature.
After 10 minutes an addition 5 mL of DCM
was added to dilute the mixture. The re-
action mixture was stirred overnight after
which TLC analysis showed full conversion of the starting material. The mixture was di-
luted with DCM and H2O, followed by seperation of the layers. The organic layer was
washed thrice with H2O and dried using MgSO4. After filtration the mixture was concen-
trated in vacuo and purified using a short silica column (EtOAc/Tol 2.5%) gave 203 in 90%
yield as a colourless oil (0.28 g, 0.31 mmol).The recorded data agree with those of Vankay-
alapati et al. 18 However, 1H and 13C NMR are given. TLC: 10% EtOAc/Tol; 1H NMR (200
MHz, CDCl3): δ = 7.33 - 7.11 (m, 20H), 5.38 - 5.35 (m, 1H), 5.03 - 4.41 (m, 9H), 4.00 - 3.44
(m, 7H), 2.37 - 2.10 (m, 2H), 1.99 - 1.68 (m, 5H), 1.55 - 0.85 (m, 33H), 0.68 (s, 3H); 13C NMR
(50 MHz, CDCl3): δ = 140.8, 138.9, 138.2, 128.3 - 121.7, 102.2, 94.6, 93.4, 84.7, 82.0, 79.9,
79.7, 77.9, 76.6, 75.6, 75.1, 73.4, 72.9, 70.0, 69.1, 68.6, 56.7, 56.1, 42.3, 39.7, 39.4, 36.7, 36.2,











Compound 203 was dissolved in a mix-
ture of ethanol (8 mL) and cyclohexene
(4 mL). The reaction mixture was purged
thrice with argon followed by addition of a
catalytic amount of Pd(OH)2 (20% on car-
bon). The suspension was stirred under
reflux on till TLC analysis showed com-
plete deprotection of the benzyl groups.
The mixture was filtered over Whatman R©
filter paper and concentrated in vacuo.
Purification by HPLC (gradient H2O-MeOH+ 0.1% TFA) followed by evaporation of MeOH
and lyophilizing H2O yielded 207 (0.131 mg, 0.24 mmol, 30%) as white fluffy solid. The
recorded data agree with those of Nagarajan et al. 13 However, 1H and 13C NMR are given.
1H NMR (400 MHz, (D6) DMSO): δ = 5.36 - 5.26 (d, J = 4.5 Hz, 1H), 4.90 - 4.82 (d, J = 5.3
Hz, 1H), 4.82 - 4.76 (d, J = 3.7 Hz, 1H), 4.75 - 4.66 (d, J = 4.7 Hz, 1H), 4.52 - 4.40 (m, 2H),
3.66 - 3.55 (d, J = 9.4 Hz, 1H), 3.50 - 3.41 (m, 3H), 3.19 - 3.11 (m, 1H), 3.09 - 3.00 (m, 1H),
2.41 - 2.18 (m, 2H), 2.02 - 1.77 (m, 5H), 1.61 - 0.80 (m, 34H), 0.69 - 0.64 (s, 3H); 13C NMR
(100 MHz, (D6) DMSO): δ = 140.7, 121.1, 96.9, 76.4, 73.2, 72.8, 71.8, 70.4, 61.0, 56.2, 55.6,
49.5, 41.8, 40.2, 39.9, 39.8, 36.6, 36.2, 35.6, 35.2, 31.4, 31.3, 27.7, 27.4, 27.4, 23.9, 23.2, 22.6,













Known imidate 205 17 (0.74 g, 1 mmol) and
cholesterol (0.32 g, 0.83 mmol, 0.83 equiv)
were coevapporated thrice with toluene
and dissolved in dry DCM (5 mL). To this
mixture 3Å molsieves were added and the
mixture was cooled to -40◦C. After 10 min-
utes the mixture was activated by addition
of TMSOTf (9 µL, 0.05 mmol) and stirring
was continued for 1 hour at -40◦C. After
complete consumption of the donor the
mixture was quenched using 2 mL Et3N, diluted with DCM and washed twice with H2O
and once with brine. The organic layer was dried (MgSO4), filtered and concentrated in
vacuo. Purification by column chromatography (EtOAc/Tol 2%) gave 206 in 83% yield
(0.67 g, 0.69 mmol). The recorded data agree with those of Deng et al. 17 However, 1H
and 13C NMR are given. TLC: 10% EtOAc/Tol;1H NMR (400 MHz, CDCl3): δ = 8.08 - 7.80
(m, 9H), 7.58 - 7.17 (m, 11H), 6.01 - 5.87 (t, J = 9.6 Hz, 1H), 5.72 - 5.61 (t, J = 9.7 Hz, 1H),
5.61 - 5.47 (dd, J = 9.8, 7.9 Hz, 1H), 5.28 - 5.18 (m, 1H), 5.02 - 4.93 (d, J = 7.9 Hz, 1H), 4.68
- 4.46 (m, 2H), 4.22 - 4.13 (m, 1H), 3.60 - 3.52 (m, 1H), 2.26 - 2.12 (m, 2H), 2.07 - 0.80 (m,
38H), 0.73 - 0.60 (s, 3H); 13C NMR (100 MHz, CDCl3): δ = 166.1 - 165.1, 140.3, 133.5 - 122.0,
100.2, 80.5, 73.2, 72.2, 72.1, 70.2, 63.4, 56.8, 56.2, 50.2, 42.4, 39.8, 39.6, 38.9, 37.2, 36.7, 36.3,











Compound 206 (0.31 g, 0.33 mmol) was
dissolved in a mixture of MeOH:dioxane
(10:1 mL). To this mixture a catalytic
amount of NaOMe (30% in MeOH) was
added and the mixture was stirred for 1.5
hours. After TLC analysis showed com-
plete deprotection of all acetyl groups,
the mixture was neutralized using Amber-
lite R© H+ till ∼ pH 7, filtered and con-
centrated in vacuo. Purification by HPLC
(gradient H2O-MeOH+ 0.1% TFA) followed by evaporation of MeOH and lyophilizing H2O
yielded 207 (145 mg, 0.26 mmol, 81%) as white fluffy solid. The recorded data agree with
those of Nagarajan et al. 13 However, 1H and 13C NMR are given. 1H NMR (400 MHz,
CDCl3): δ = 5.44 - 5.25 (d, J = 4.2 Hz, 1H), 4.99 - 4.77 (m, 3H), 4.47 - 4.38 (t, J = 5.7 Hz,
1H), 4.30 - 4.20 (d, J = 7.3 Hz, 1H), 3.73 - 3.60 (m, 1H), 3.53 - 3.40 (m, 2H), 3.19 - 2.98 (m,
3H), 3.00 - 2.86 (m, 1H), 2.46 - 2.31 (m, 1H), 2.24 - 2.05 (t, J = 12.1 Hz, 1H), 2.06 - 1.89 (m,
2H), 1.87 - 1.73 (m, 3H), 1.56 - 0.83 (m, 34H), 0.80 - 0.58 (s, 3H); 13C NMR (100 MHz, CDCl3):
δ = 140.4, 129.2, 128.5, 121.2, 100.8, 76.9, 76.8, 73.5, 70.1, 61.1, 56.2, 55.6, 49.6, 41.8, 38.3,
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Summary and Future Prospects
7.1 Summary
Iminosugars are carbohydrate analogs in which the endocyclic oxygen is replaced
by a nitrogen. This class of polyhydroxylated alkaloids have interesting inhibitory
properties towards glycosidases and glycotransferases, due to their close resem-
blance of natural carbohydrates. These iminosugars are wildly distributed
throughout nature. A great variety of iminosugars can be found in all parts of
the Mullberry tree (Morus spp.) including 1-deoxynojirimycin 2 (DNJ, 2). DNJ
was earlier synthesized as stable analog of nojirimycin 1 (NJ, 1), which in turn
was the first iminosugar isolated from natural sources. Over the years several N-
alkylated DNJ derivatives were synthesized. Two examples being; N-butyl- and
a N-5-(adamantan-1-yl-methoxy)-pentyl (AMP)-DNJ (16 and 17, Figure 7.1) were
found to inhibit glycosylceramide synthase (GCS). NB-DNJ 16 is currently used in
SRT of patients suffering from Gaucher disease. Gaucher disease is a rare lysoso-
mal storage disorder in which glucosylceramide (GC) is inefficiently hydrolyzed
by mutant glucocerebrosidase (GBA1). This causes accumulation of GC-laden
macrophages which results in enlargement of organs (spleen and liver) and in-
flammation. Inhibition of GCS restores the influx/efflux balance of GC in Gaucher
cells and thereby reduces its effects. The research in this thesis describes the syn-
thesis of several prodrugs based on NB-DNJ 16 and AMP-DNJ 17. Furthermore
several new chitotriosidase substrates are synthesized which were designed to with-
stand stepwise degradation of other enzymes.
By glycosylating iminosugars one can gain more selective glycosidase inhibi-





































Figure 7.1: Compounds described in section 7.1.
substrate of the enzyme. The first section of Chapter 1 summarises the synthesis
of all O-glycosylated iminosugars from the piperidine class, reported in literature.
Several syntheses are described in which iminosugars are glycosylated on various
positions using a variety of chemical and enzymatic synthetic strategies. In the
second part of Chapter 1 an overview is given of glycosylated iminosugars which
bear a different linkage between the carbohydrate and the iminosugar.
Chitotriosidase (CHIT1) is the first identified human chitinase and is strongly
expressed and secreted by lipid-laden tissue macrophages that are found in pa-
tients suffering from Gaucher disease. CHIT1 is correlated to the progression of
the disease and the effect of therapeutic intervention. Originally 4-methylumbelliferyl
chitobioside 126 was used as a fluorogenic substrate in biological assays to give a
fluorescent read-out. However, it was found that human CHIT1 possesses intrin-
sic transglycosylase activity, resulting in a suboptimal fluorescent read-out. Trans-
glycosylase activity can be circumvented by the use of 125 in which the 4’-OH is
removed. This 4’-deoxychitobiosyl methylumbelliferone 125 indeed showed to be
a superior CHIT1 substrate as compared to 126. Previously 125 was synthesized
via a nine-step low-yielding sequence. Therefore, Chapter 2 presents a reliable
and scalable route for the synthesis of 4’-deoxychitobiosyl umbelliferone 125. In
the synthetic route one partially protected thiophenyl glucosamine is used as main
building block. This building block was readily transformed into both the reducing
and non-reducing end building blocks which were condensed to form the carbo-
hydrate core. This disaccharide was in turn coupled with the fluorophore (4-MU)
under phase transfer conditions.
In Chapter 3, three novel human CHIT1 substrates are designed, synthesized
and biologically evaluated. All compounds (136, 137 and 138) bear an anomeric
4-MU fluorophore for fluorometric read-out and have a different modification on
the 4-hydroxyl of the non-reducing end sugar. This modification goes from the rel-
ative small O-methyl group (OMe) to the more sterically demanding O-isopropyl
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(iOPr) and O-methyl cyclohexane group (OMCH). These substrates were synthe-
sized using a 1,6-anhydro glucosamine derivative as the key building block in the
synthesis of the donor and acceptor glycosides. Biological evaluation of the sub-
strates showed that all compounds follow Michaelis-Menten kinetics like the par-
ent 4’-deoxy substrate 125, but proved to be more stable towards stepwise degra-








































R1 = OH, R2 = AMP
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Figure 7.2: Overview of the chapters described in this thesis.
∗ AMP = N-5-(adamantan-1-yl-methoxy)-pentyl
Due to the direct correlation of CHIT1 to the progression of Gaucher disease,
the locally elevated CHIT1 activity in Gaucher cells is a potential target for site-
specific drug delivery. In Chapter 4 4’-deoxychitobiose and chitobiose are linked
to 16 and 17 to form potential prodrugs for Gaucher disease (172, 174 and 173).
By linkage of the CHIT1 substrates to the 4-position of 16 and 17 both inhibitors
become less active. Further research is needed to see if through cleavage of the
substrates, by CHIT1, the free N-alkylated DNJ derivatives will be liberated, with
restored activity. Synthesis of the chitobiose core is based on the work described
in Chapter 2. The DNJ part of the prodrug was based on a reported synthesis in
which glucose is converted into an iminosugar by an initial reduction and oxida-
tion under Swern conditions, followed by a double reductive amination to yield a
protected DNJ derivative. By orthogonal protection of the 4-position of DNJ this
position could be selectively liberated, after which the DNJ derivative was used
as acceptor in the glycosylation. After coupling, the endocyclic nitrogen was de-




It is known that some alkaloids and derivatives thereof have a bitter taste. The
human primeval aversion against bitterness is a defense mechanism to preclude
digestion of potential toxic substances. Therefore, Chapter 5 describes the syn-
thesis of two different prodrugs (199 and 201, Figure 7.2) in which 16 and 17 bear
a galactose moiety on the 4-position of the iminosugar, thereby gaining a lactose
derivatives with a potential sweeter taste. Upon arrival of the prodrugs in the in-
testine the galactose moiety will be cleaved by lactase and the activity of the GCS
inhibitors will be restored. For the synthesis of the prodrugs (199 and 201) octa-O-
acetyl-α/β -D-lactose was used as starting material because it is cheap and saves
a glycosylation step. Transformation into the iminosugar derivative was done by
reduction of the reducing end sugar, followed by a oxidation under Swern condi-
tions and a double reductive amination. Next the endocyclic nitrogen was dec-
orated with butyl or AMP chain. Biological assays showed that lactase-phlorizin
hydrolase (LPH) found in intestinal rat muscosa was able to cleave prodrug 201
and thereby liberate GCS inhibitor 17.
During the ongoing research to find the common denominator for parkinson-
ism and glucosylceramide metabolism, it was shown that high levels of steryl gly-
cosides are found in people suffering from parkinsonism. Very recently evidence
was reported that not UDP-glucose but GC acts of sugar donor for the biosynthesis
of glycosylated cholesterol. Chapter 6 describes the synthesis of α- and β -chol-
esteryl glycoside (204 and 207) which can be used as internal standard.
7.2 Future Prospects
As shown in Chapter 1 there are several synthetic strategies that can be used for
the synthesis of O-glycosylated iminosugars. One can tackle this synthetic chal-
lenge of synthesizing O-glycosylated iminosugars by two different routes. The first
strategy employs a carbohydrate that acts as a donor and a suitably protected im-
inosugar that acts as the acceptor in the key glycosylation step. This strategy was
used for the synthesis of the prodrugs described in Chapter 4, where the chito-
biose donor was first synthesized using two suitable protected glucosamine moi-
eties. This chitobiose core was than condensed with a DNJ acceptor, in the next
glycosylation event.
The second route towards glycosylated iminosugars is pursued by the synthe-
sis of the carbohydrate core, followed by transformation of the reducing end car-
bohydrate into an iminosugar. This approach is used by Stütz et al. 1,2 as reviewed
in Chapter 1. The synthesis of galactosylated DNJ derivatives described in Chap-
ter 5 is also based on this strategy, in which the use of octa-O-acetyl-α/β -D-lactose
circumvents a glycosylation step.
The strategy used in Chapter 5 can be applied for synthesis of compounds 172,
173 and 174 described in Chapter 4 and vice versa. For example, by using benzy-
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lated allyl glucopyranoside 181 as acceptor in a glycosylation with chitobiose cores
175 or 176, trimers 208 and 209 will be produced (Scheme 7.1). Transformation
of the reducing end carbohydrate into the corresponding iminosugar gives pro-
drugs 172, 173 and 174. This can be achieved by deallylation, followed by LiAlH4
mediated reduction to give glucitols 210 and 211. Formation of the respective im-
inosugar derivatives can be achieved via oxidation of lacitols 210 and 211 using
the Swern reaction followed by subsequent double reductive amination of the di-
carbonyl yielding compounds 189 and 190. The endocyclic nitrogen could in turn
be decorated with a butyl or AMP chain to gain prodrugs 172, 173 and 174, after
deprotection.


























































































































Reagents and conditions: a) NIS, TMSOTf, DCM, 0◦C, b) (1) KOtBu, DMSO, 100◦C, (2) I2, THF/H2O,
(3) LiAlH4, THF; c) (1) DMSO, (COCl)2, DCM, -75
◦C, (2) Et3N, -75
◦C to rT, (3) NaCNBH3, HCOONH4,
Na2SO4, MeOH, 0
◦C.
A different strategy for the synthesis of the prodrugs from Chapter 5 is repre-
sented by the condensation of galactose donor 212 with DNJ acceptor 177
(Scheme 7.2). Galactose thio donor 212 was synthesized using a literature pro-
cedure 3 and used in the coupling with DNJ acceptor 177 (Chapter 4) under in-
fluence of NIS and TMSOTf in DCM at -20◦C to give dimer 213 in 68% yield. Lib-
eration of the endocyclic nitrogen was achieved under similar conditions used in
Chapter 4 (HSPh and K2CO3) giving 214 in 80% yield. The free secondary amine
97
CHAPTER 7
can be linked to the desired alkyl chain (butyl or AMP), to gain prodrugs 199 and
200, after deprotection.



























































Reagents and conditions: a) NIS, TMSOTf, DCM, -20◦C, 68%; b) HSPh, K2CO3, DMF, 80%.
The prodrug strategy presented in Chapter 4 can fail, when CHIT1 is unable
to hydrolyze the substrate-drug bond due to the steric hindrance. 4,5 Hence, a so-
called tripartite produg may be a useful alternative (Figure 7.3 B). The linker group
of a tripartite prodrug creates a distance between the drug part and the enzyme
substrate. In this way, the enzyme cleaves the substrate-linker bond in 217 rather
than the substrate-drug bond as in 215. However, the linker portion must be cho-
sen wisely so that the linker-drug bond (218) hydrolyses under physiological con-
ditions after hydrolysis of the substrate-linker bond, resulting in the release of the








Figure 7.3: Schematic representation of enzymatic prodrug cleavage of bipartite and tri-
partite prodrugs. ◦: inactive drug ; •: active drug.
In a preliminary study tripartite prodrug 226 was synthesized based on the
work of Monneret and co-workers, who used a two-part spacer system, linked to-
gether by carbamate functions, in the synthesis of a novel anti-cancer prodrug. 7,8
In this study GlcNAc was chosen as the enzyme substrate-part to optimize the cou-
pling conditions with 4-hydroxy-3-nitro benzyl alcohol. Changing the substrate-
part to chitobiose or 4’-deoxy chitobiose would result in more usable prodrug
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model. Overdijk et al. found a local elevation of CHIT1 activity during inflam-
mation. 9 Therefore, the drug-part of this tripartite prodrug is prednisone, which is
a well known anti-inflammatory drug (Figure 7.4).
The chloride donor 221 used in the coupling with the phenol, could be pre-
pared in a two-step procedure, via first regioselective introduction of the acetyl-
group at the nitrogen of D-glucosamine 219 to give 220 which in turn was treated
with anhydrous AcCl resulting in the formation of chloride donor 221
(Scheme 7.3). 10 Using a optimized phase transfer conditions (PTC), α-chloride in
221 was substituted, via a SN 2 displacement, with 4-hydroxy-3-nitro benzyl alco-
hol to give 222.







































































Reagents and conditions: a) NaOMe (30% in MeOH), MeOH, Ac2O, 0
◦C; b) AcCl, rT, 65% over two
steps; c) NaHCO3, TBABr, 4-hydroxy-3-nitrobenzyl alcohol, DCM, rT, 3.5h, 46%; d) (1) 4-nitrophenyl
chloroformate, TEA, DCM, 0◦C to rT, (2) 223, DCM, 0◦C, 87% over two steps; e) (1) 4M HCl in dioxane,
rT, (2) 225, DIPEA, DCM, 21% two steps.
Product 222 was used as starting material for the synthesis of the second part
of the self-immolative linker. The free hydroxyl function in 222 was activated as
a para-nitrophenylcarbamate and condensed with the mono-Boc-protected di-
amine 223 11 affording benzyl carbamate 224. A higher yield was achieved by us-
ing a one-pot procedure, thereby avoiding isolation of the intermediate carbonate.
Anhydrous 4M HCl in dioxane was used to remove the Boc-group in 224 giving the
corresponding free amine as a HCl salt. No attempts were made to isolate the
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free amine, which would obviously cyclize very rapidly resulting in liberation of
the starting benzylic alcohol. Treatment of prednisone with 4-nitrophenyl chloro-
formate and pyridine in anhydrous chloroform produced para-nitrophenylcarbo-
nate 225. Activated carbonate 225 was dissolved in DCM and added to a cooled
solution of 224. Dropwise addition of DIPEA gave the desired tripartite produg of








































Figure 7.4: Release of prednisone upon cleavage of the substrate by chitinase.
7.3 Experimental section
All reagent were of commercial grade and used as received (Acros, Fluka, Merck, Schleicher
& Schuell) unless stated otherwise. Diethyl ether (Et2O), light petroleum ether (PE 40-60),
en toluene (Tol) were purchased from Riedel-de Haën. Dichloromethane (DCM), N,N-
dimethylformamide (DMF), methanol (MeOH), pyridine (pyr) and tetrahydrofuran (THF)
were obtained from Biosolve. THF was distilled over LiAlH4 before use. Dichloromethane
was boiled under reflux over P2O5 for 2 h and distilled prior to use. Molecular sieves 3Å
were flame dried under vacuum before use. All reactions sensitive to moisture or oxygen
were performed under an inert atmosphere of argon unless stated otherwise. Solvents
used for flash chromatography were of pro analysis quality. Flash chromatography was
performed on Screening Devices silica gel 60 (0.004 - 0.063 mm). TLC-analysis was con-
ducted on DC-alufolien (Merck, Kieselgel60, F245) with detection by UV-absorption (254
nm) for UV-active compounds and by spraying with 20% H2SO4 in ethanol or with a so-
lution of (NH4)6Mo7O24 ·4 H2O 25 g/L, (NH4)4Ce(SO4)4 ·2 H2O 10 g/L, 10% H2SO4 in H2O
followed by charring at∼150 ◦C. 1H and 13C NMR spectra were recorded on a Bruker DMX-
400 (400/100 MHz), a Bruker AV 400 (400/100 MHz), a Bruker AV 500 (500/125 MHz) or a
Bruker DMX-600 (600/150 MHz) spectrometer. Chemical shifts (δ) are given in ppm rel-
ative to the chloroform residual solvent peak or tetramethylsilane as internal standard.
Coupling constants are given in Hz. All given 13C spectra are proton decoupled. High
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resolution mass spectra were recorded on a LTQ-Orbitrap (Thermo Finnigan) Mass spec-
trometer. LC/MS analysis was performed on a Jasco HPLC-system (detection simultane-
ous at 214 nm and 245 nm) equipped with an analytical Alltima C18 column (Alltech, 4.6
mmD x 50 mmL, 3µ particle size) in combination with buffers A: H2O, B: MeCN and C:
0.5% aq. TFA and coupled to a Perkin Almer Sciex API 165 mass spectrometer. Optical
rotations were measured on a Propol automatic polarimeter. IR spectra were recorded on
a Shimadzu FTIR-8300 and are reported in cm−1.














Donor 212 3 1 g (1.76 mmol, 1.1 equiv) and DNJ acceptor 177
0.92 g (1.60 mmol) were coevaporated thrice with toluene
and dissolved in 10 mL dry DCM. Molecular sieves 3Å were
added and the reaction was cooled to -20◦C. NIS 0.43 g (1.92
mmol, 1.2 equiv) was added and the mixture was stirred for
15 minutes. Next, a catalytic amount of TMSOTf (25 µL)
was added and the reaction mixture was stirred for 45 minutes, after which the reaction
was quenched using Et3N (0.6 mL). The mixture was diluted with DCM and washed with
NaS2O4 and brine. The organic layer was dried using MgSO4 and concentrated in vacuo.
Purification using a short silica column (EtOAc/PE 10%) gave 213 in 68% yield. (1.177 g,
1.09 mmol) TLC: EtOAc/Tol 20%; 1H NMR (400 MHz, CDCl3) δ 8.09 - 7.95 (m, 3H), 7.84 -
7.71 (m, 2H), 7.56 - 7.04 (m), 6.96 - 6.85 (m, 1H), 5.82 - 5.72 (dd, J = 10.3, 7.9 Hz, 1H), 5.56 -
5.50 (s, 1H), 5.28 - 5.19 (dd, J = 10.3, 3.4 Hz, 1H), 4.86 - 4.75 (d, J = 8.1 Hz, 1H), 4.68 - 3.99
(m, 12H), 3.95 - 3.83 (t, J = 9.5 Hz, 1H), 3.71 - 3.63 (m, 2H), 3.59 - 3.52 (d, J = 2.8 Hz, 1H),
3.53 - 3.43 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 166.3, 165.5, 148.0, 138.6, 138.2, 137.9,
137.8, 137.6, 133.5 - 126.3, 123.03, 102.4, 100.8, 73.6, 73.7, 73.2, 73.1, 72.5, 70.9, 69.4, 69.0,














Compound 213 0.92 g (0.85 mmol) was dissolved in DMF (5
mL), followed by addition of HSPh 0.44 mL (4.26 mmol, 5
equiv) and DIPEA 0.6 mL (3.41 mmol, 4 equiv). The mixture
was stirred for 18 h after which it was taken up in EtOAc and
washed with NaHCO3. The organic layer was dried and con-
centrated under reduced pressure. Purification using a short
silica column (EtOAc/PE 80%) gave 214 in 80% yield. (0.58 g, 0.68 mmol) TLC: EtOAc/Tol
60%; 1H NMR (400 MHz, CDCl3) δ 8.01 - 7.89 (t, J = 6.8 Hz, 4H), 7.56 - 7.11 (m, 27H), 5.87
- 5.74 (dd, J = 10.4, 7.9 Hz, 1H), 5.46 - 5.41 (s, 1H), 5.19 - 4.99 (m, 3H), 4.93 - 4.84 (d, J = 7.9
Hz, 1H), 4.71 - 4.52 (m, 2H), 4.47 - 4.37 (d, J = 3.7 Hz, 1H), 4.31 - 4.22 (d, J = 11.6 Hz, 1H),
4.18 - 4.09 (d, J = 12.5 Hz, 1H), 4.05 - 3.94 (d, J = 11.4 Hz, 1H), 3.86 - 3.73 (d, J = 12.3 Hz,
1H), 3.68 - 3.46 (m, 4H), 3.41 - 3.31 (dd, J = 9.0, 6.1 Hz, 1H), 3.22 - 3.08 (m, 2H), 2.69 - 2.61
(m, 1H), 2.51 - 2.37 (t, J = 11.2 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 166.3, 165.2, 139.6,
138.5, 138.0, 137.7, 133.4, 133.4, 130.0 - 126.4, 101.8, 100.9, 85.5, 80.6, 80.3, 73.5, 73.3, 73.2,
72.8, 70.3, 70.2, 68.8, 66.6, 59.8, 47.8.
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A mixture of 172 mL MeOH and 28 mL NaOMe (30% in MeOH) was
added to 43.6 g (200 mmol) D-glucosamine hydrochloride 219. The
mixture was stirred at ambient temperature for 10 minutes, after
which it was gently heated and filtrated. The filtrate was cooled to
0◦C. Subsequently 250mL Ac2O was added and the solution was left overnight at room
temperature to crystallize. The crystals were filtered affording 30 g of 220 as an off-white








Crude compound 220 (7.5 g, 33.9 mmol) was dissolved in 25 mL dis-
tilled AcCl. The reaction mixture starts to boil spontaneously after
1 h. The reaction is left overnight yielding an amber colored clear
liquid. The solution is diluted with 20 mL DCM and rapidly washed
with 2x 20 mL of cold water, 2x 30 mL of Na2CO3 and brine. The organic layer is dried and
concentrated under reduced pressure. Crystallization in EtOAc/PE afforded 8.10 g (22.20
mmol, 65%) of the title compound 221 as a beige solid. Proton and carbon NMR were











In a two phase-system of 50 mL DCM and 25 mL 1M
NaHCO3 were 4-hydroxy-3-nitrobenzyl alcohol (2.53 g,
15 mmol, 1.5 equiv) and tetra-butylammonium bro-
mide (3.32 g, 10 mmol) dissolved. The mixture was vig-
orously stirred for 15 minutes. After which 3.7 g (10
mmol) of 221 in 5 mL DCM was added dropwise. Vigorous stirring was continued for
3.5 hours after which the organic layer was washed with 1x 35 mL H2O and 1x 35 mL brine.
The DCM layer was dried, filtered and concentrated in vacuo. The yellow oil was purified
by silica gel chromatography. Evaporation of the eluent afforded a yellow solid which was
re-crystalized (EtOAc/PE) yielding title compound 222 in 46% yied (2.3 g, 4.6 mmol) as yel-
low crystals. TLC: EtOAc/PE 40%; 1H NMR (600 MHz, CDCl3) δ 1.94 (s, 3H, CH3, NAc); 2.01
(s, 3H, CH3, Ac); 2.02 (s, 3H, CH3, Ac); 2.04 (s, 3H, CH3, Ac); 3.89 (d, J = 8.4 Hz, 1H, CH); 4.23
(dd, J = 12.28, 5.17 Hz, 2H, CH2, C’-6); 5.05-5.12 (m, 4H, CH, CH2, C’-4, C’-5, CH2); 5.51 (t,
J = 8.4 Hz, 1H, CH, C’-3); 5.58 (d, J = 8.04 Hz, 1H, CH, C’-1β ); 7.41-7.75 (m, 3H, CH, arom);
13C NMR (101 MHz, CDCl3) δ 20.54, 20.59, 20.64 (CH3, 3x Ac); 23.10 (CH3, NAc); 55.03 (CH,
C’-2); 61.86 (CH2, C’-6); 67.82 (CH2); 68.55, 71.17, 72.06 (CH, C’-3, C’-4, C’-5); 99.46 (CH,
C’-1); 120.44, 126.02, 133.54 (CH, arom); 148.24, 149.52, 154.43 (Cq, arom); 169.23, 170.27,
170.47, 171.20 (Cq, 3x Ac, NAc); IR (neat) ν 373.8, 463.9, 600.1, 762.1, 791.9, 822.7, 1032.1,

















Compound 222 (0.848 g, 1.70 mmol)
was dissolved in 15 mL DCM. The so-
lution was cooled to ice bath temper-
ature followed by dropwise addition
of 0.71 mL Et3N (5.1 mmol, 3 equiv).
A solution of 0.50 g (2.55 mmol, 1.5 equiv) 4-nitrophenyl chloroformate in 2 mL DCM was
added, over 15 minutes. The reaction mixture was stirred overnight at room temperature,
after which is was re-cooled to icebath temperature and 0.47 g (2.55mmol, 1.5 equiv) of
compound 223 in 2 mL DCM was added drop by drop. After 18 hours the reaction mixture
was washed with 1x10 mL H2O and 1x 15 mL brine. The organic layer was dried, filtrated
and concentrated in vacuo. Silica gel purification (1% MeOH in DCM) afforded compound
224 in 87% yield. (1.05 g, 1.48 mmol) 1H NMR (400 MHz, CDCl3) δ 1.44 (s, 9H, CH3, t-Bu);
1.95, 2.05, 2.06, 2.09 (s, 12H, CH3, Ac); 2.85 (d, J = 22.26 Hz, 3H, CH3, NMe); 2.96 (s, 3H,
CH3, NMe); 3.38 (d, J = 15.64 Hz, 4H, CH2, Et); 3.93 (td, J = 10.30, 8.24, 8.24 Hz, 1H, CH,
C’-2); 4.21 (d, J = 12.12 Hz, 1H, CH2, C’-6); 4.29 (dd, J = 12.28, 5.13 Hz, 1H, CH2, C’-6);
5.17-5.07 (m, 1H, CH, CH2, C’-4, C’-5, CH2); 5.57 (d, J = 8.55 Hz, 1H, C’-1β ); 5.64-5.58 (m,
1H, CH, C’-3); 6.31 (s, 1H, NH); 7.80-7.34 (m, 3H, CH, arom); 13C NMR (150 MHz, CDCl3) δ
21.05-20.22 (CH3, 3x Ac); 23.13 (CH3, NAc); 28.31 (CH3, t-Bu); 34.60 (d, J = 30.80 Hz, CH3,
NMe); 35.28 (CH3, NMe); 46.44 (CH2, Et); 46.73 (CH2, Et); 55.11 (CH, C’-2); 61.90 (CH2,
C’-6); 65.25 (dd, J = 17.72, 4.17 Hz, CH2, CH2); 68.54 (CH, C’-4, C’-5); 71.20 (CH, C’-4, C’-
5); 72.11 (CH, C’-3); 99.34 (CH, C’-1); 120.47 (CH, arom); 124.35 (CH, arom); 132.86 (Cq,
arom, Cq, Boc); 133.29 (CH, arom); 141.22 (Cq, arom); 148.96 (Cq, arom); 155.57 (Cq, Boc);
169.38 (Cq, NAc); 170.33 (Cq, Ac); 170.44 (Cq, Ac); 171.13 (Cq, Ac); IR (neat) ν 332.0, 356.3,
374.0, 430.0, 597.7, 1038.0, 1224.2, 1366.0, 1537.8, 1699.8, 1747.1; ESI-MS: 713.4 (M+H+)








Anhydrous prednisone (1.8 g, 5 mmol) was dissolved
in 25 mL CHCl3. The solution was cooled to ice bath
temperature, after which a solution of 1.5 g (6 mmol,
1.2 equiv) 4-nitrophenyl chloroformate in 4 mL CHCl3
was slowly added. The suspension was stirred for 1 h,
followed by addition of pyridine (1.2 mL, 15 mmol, 3
equiv). When the reaction turned clear the mixture was
coevaporated thrice with 20 mL toluene, yielding a off

























Compound 224 (0.98 g, 1.4 mmol)
was dissolved in cooled 4M HCl in di-
oxane (7 mL). After 45 minutes, TLC-
analysis showed tcomplete deprotec-
tion of the starting material. The re-
action mixture was was coevaporated
twice with toluene yielding a white
foam. This foam was dissolved in dry
DCM 5 mL and cooled with a ice bath.
A slurry of prednisone derivative 225
in 8 mL of dry DCM was added dropwise, followed by addition of DIPEA (0.2 mL, 1.38
mmol, 1 equiv). The suspension was stirred for 3 h, allowing the mixture to warm to room
temperature. The clear oker colored solution was concentrated in vacuo and applied to a
Sephadex R© size exclusion column (50 mmD x 1500 mmL) and eluted with MeOH yielding
a off-white solid. Silica gel purification (2.5% EtOH in CHCl3) afforded title compound 226
as off-white solid in 21% yield (292 mg, 0.29 mmol). 1H NMR (400 MHz, CDCl3) δ 0.66 (s,
3H, CH3, C’-18); 1.43 (s, 3H, CH3, C’-19); 1.93, 2.04, 2.08 (s, 12H, CH3, 4x Ac); 2.25-2.70 (m,
5H); 2.86-2.95 (m, 6H, CH3, 2x Me); 3.44 (s, 4H, 2x CH2); 3.94 (s, 1H, CH, C-2); 4.18-4.29 (m,
2H, CH2, C-6); 4.57 (m, 3H); 4.91-4.96 (m, 1H); 5.04-5.17 (m, 2H, CH, C-5, C-4, CH); 5.57-
5.59 (m, 2H, CH, C-3, C-1); 6.06 (s, 1H); 6.18 (d, J = 10.4 Hz, 1H); 6.80 (s, 1H, NH); 7.32-7.83
(m, 4H) IR (neat) ν 312.1, 326.0, 340.0, 376.1, 435.8, 507.9, 602.0, 668.1, 765.6, 822.9, 889.9,
1040.2, 1218.0, 1366.7, 1537.8, 1660.9, 1699.8, 2360.2, 2945.7
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Iminosuikers zijn suiker (koolhydraat) derivaten waarin de ring-zuurstof is ver-
vangen door een stikstof. Deze groep van gehydroxyleerde alkaloïden heeft inte-
ressante biologische eigenschappen. Ze blijken uitstekende remmers te zijn voor
verscheidene glycosidases en glycotransferases. Iminosuikers zijn in grote ver-
scheidenheid te vinden in bladeren, vruchten en de stam van de moerbeiplant
(Morus spp.). Eén van de iminosuikers die uit deze plant kan worden geïsoleerd is
1-deoxynojirimycin (DNJ) 2, waarvan door de jaren heen verschillende derivaten
zijn gesynthetiseerd. Twee van deze derivaten, NB-DNJ 16 en AMP-DNM 17
(Figuur 2), zijn uitstekende remmers voor het enzym glycosylceramide synthase
(GCS). NB-DNJ wordt tegenwoordig gegeven aan patiënten met de ziekte van
Gaucher, een lysosomale stapelingsziekte die wordt veroorzaakt door een verstoor-
de activiteit van het enzym glucocerebrosidase (GBA1) (Figuur 1). Hierdoor ont-
staat een overschot aan glucosylceramide (GC) in de lysosomen, met als gevolg dat
organen opzwellen (lever en nieren) en ontstekingen ontstaan. Door het remmen
van GCS wordt er minder GC aangemaakt en zal de balans tussen anabolisme en
katabolisme van GC worden hersteld.
Het in dit proefschrift beschreven onderzoek behelst de synthese van NB-DNJ en
AMP-DNJ prodrugs. Voorts zijn er verschillende nieuwe substraten voor het men-
selijke chitinase enzym chitotriosidase gesynthetiseerd waarbij ook rekening is ge-























Figuur 1: Anabolisme en katabolisme van glucosylceramide.
De inleiding van dit proefschrift (Hoodstuk 1) geeft een overzicht van alle in de
literatuur beschreven O-geglycosyleerde iminosuikers. Er worden verschillende
voorbeelden gegeven van chemische en enzymatische synthese strategieën waar-
bij iminosuikers van één of meerdere "gewone" suikers worden voorzien. Ook
wordt een kort overzicht gegeven van geglycosyleerde iminosuikers die op een an-































Figuur 2: Moleculen beschreven in de samenvatting.
Chitine is de op een na meest voorkomende bio-polymeer en kan worden
gevonden in het exoskelet van geleedpotigen, zoals insecten, kreeftachtigen en
spinnen, waar het zorgt voor stevigheid. Tot het einde van de vorige eeuw werd er
gedacht dat het menselijk lichaam niet in staat was om chitine of derivaten daar-
van af te breken. De eerste menselijke chitinase werd bij toeval gevonden tijdens
onderzoek naar een verhoogde glycosidase-activiteit in het serum van Gaucher-
patiënten. Dit enzym werd geïdentificeerd als chitotriosidase (CHIT1) en wordt
tegenwoordig gebruikt als indicator om de ernst van de ziekte en de werking van
de medicatie van Gaucher patiënten te visualiseren. Lange tijd werd umbellif-
eryl chitobiose 126 (Figuur 2) gebruikt als fluorescent substraat, maar dit sub-
straat bleek bij verhoogde concentraties een onjuist beeld te geven. De oorzaak
hiervan bleek de transglycosylase activiteit van CHIT1 te zijn, waarbij chitotriose
of chitobiose aan het substraat wordt gekoppeld. Door de alcoholfunctie op de
4-plaats van het niet reducerende suiker te verwijderen, kon transglycosylering
worden voorkomen. Het verbeterde 4’-deoxychitobyosyl umbelliferone 125 bleek
een beter substraat voor CHIT1. Eerder beschreven syntheseroutes leidden echter
slechts tot milligrammen van dit substraat (125, Figuur 3).
Hoofdstuk 2 behelst een verbeterde en op te schalen synthese route naar het flu-
orescente substraat 125. De route is gebaseerd op het gebruik van een centrale
bouwsteen die kan worden gebruikt voor de synthese van zowel de donor als de
acceptor. De cruciale koppeling tussen het chitobiose deel en de fluorofoor vind
plaats onder geoptimaliseerde “phase transfer conditions“.
Daarna wordt in Hoofdstuk 3 het ontwerp, de synthese en de biologische eva-
luatie van drie nieuwe CHIT1 substraten beschreven (136, 137 en 138, Figuur 3).
Deze chitobiosederivaten zijn voorzien van een fluorofoor op het anomere cen-
trum en hebben een verschillende ether functies op de 4-positie van de niet-redu-
cerende suiker. Deze modificaties omvatten de relatief kleine methylgroep (OMe),











































R1 = OH, R2 = AMP
*










































Figuur 3: Een overzicht van de stoffen beschreven in dit proefschrift.
∗ AMP = N-5-(adamantan-1-yl-methoxy)-pentyl.
Voor de synthese van substraten 136, 137 en 138 werd gebruik gemaakt van
een 1,6-anhydro glucosamine derivaat, dat dienst deed als uitgangsstof voor de
synthese van zowel de donoren als de acceptoren. Uit biologische testen bleek
dat alle nieuwe substraten de Michaelis-Menten kinetiek volgen, maar ook dat de
nieuwe substraten stabieler zijn voor de ongewenste stapsgewijze degradatie door
β -hexosaminidase.
De lokaal verhoogde activiteit van CHIT1 en de directe correlatie met de ernst
van de ziekte van Gaucher, biedt de mogelijkheid voor het lokaal activeren van
medicatie door gebruik te maken van een zo genoemde “prodrug”. Hoofdstuk 4
behandelt het ontwerp en de synthese van mogelijke prodrugs voor de ziekte van
Gaucher, waarbij chitobiose of 4’-deoxychitobiose wordt gebruikt als enzym sub-
straat en NB-DNJ (16) of AMP-DNJ (17) als medicatie. Door deze moleculen via
een glycosidische binding aan elkaar te koppelen ontstaan er inactieve prodrugs
(172, 174 en 173, Figuur 3). De actieve verbinding 16 of 17 komt vrij wanneer het
enzym, CHIT1, het chitobiose deel er weer afknipt. Hierdoor is de medicatie alleen
lokaal actief waardoor de kans op mogelijke bijwerkingen wordt verminderd.
Het is bekend dat sommige iminosuikers een bittere smaak hebben. De af-
keer van de mens tegen stoffen met een bittere smaak is een oerinstinct dat ons
waarschuwt voor potentieel gevaarlijke stoffen. Met als doel de bittere smaak van
NB-DNJ en AMP-DNJ te maskeren wordt in Hoofdstuk 5 de synthese van twee ver-
schillende prodrugs (201 en 199) uiteengezet, waarbij galactose is gekoppeld aan
een iminosuiker (Figuur 3). De aldus verkregen prodrugs zijn lactose derivaten
die bekend staan om hun mild zoete smaak. Door lactose te gebruiken als uit-
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gangsstof kon een glycosyleringsstap worden vermeden. Uit de biologische resul-
taten bleek dat de AMP-DNJ prodrug (201) kan worden geknipt door het enzym
lactase-phlorizin hydrolase (LPH), dat wordt gevonden in het darmslijm van rat-
ten.
Uit onderzoek om een eenduidige oorzaak voor de ziekte van Parkinson en
het metabolisme van glycosylceramide te vinden, is gebleken dat patiënten met
de ziekte van Parkinson een hoge dosis geglucosyleerd cholesterol hebben. Re-
cent onderzoek toont aan dat tijdens de biosynthese van deze geglucosyleerde
cholesterol niet de verwachte UDP-glucose als glucosedonor wordt gebruikt, maar
glycosylceramide. Met de synthese van α (204) en β geglucosyleerde cholesterol
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